Health Economics, Outcomes & Epidemiology
PUBLISHED RESEARCH AND PRESENTATIONS
Health Economics, Outcomes & Epidemiology
PUBLISHED RESEARCH AND PRESENTATIONS

A COMPENDIUM OF OUR RESEARCH
Health outcomes research is playing an increasingly important role in pharmaceutical development as new products enter competitive markets and face demands for economic evidence, safety, and efficacy. A clear and early understanding of value is critical to commercial success, and requires companies to have capabilities in health economics and associated disciplines of epidemiology, biostatistics, outcomes research, and pharmacoconomics in place for ready use across their customers and therapeutic areas.

For nearly three decades, Analysis Group has been distinguished by a unique combination of expertise in health economics, outcomes research, epidemiology, biostatistics, and health policy. Our outcomes research has resulted in thought leadership and a robust record of publications and presentations across the leading medical, outcomes, and health economics journals and conferences, covering a range of clinical and methodological areas. This compendium includes published manuscripts as well as abstracts through October 2018.

For more information on our research activities and health care consulting practice, please visit our website, www.analysisgroup.com.
CONTENTS

Autoimmune/Inflammatory 4
Cardiovascular 20
Dermatology 41
Endocrine/Metabolic/Diabetes 57
Gastrointestinal 75
Hematology 89
Infectious Diseases 104
Neurology 112
Oncology 150
Renal 214
Respiratory 218
Substance Abuse 230
Other Diseases & Conditions 235
Other (Health Policy, Market Access, and other topics) 247
Autoimmune/Inflammatory

**Short-term costs associated with non-medical switching in autoimmune conditions.**
*Authors:* Gibofsky A, Skup M, Yang M, Mittal M, Macaulay D, Ganguli A.

**Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population.**

**Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population.**

**Burden of Work Instability in Patients with Rheumatoid Arthritis in US and Its Association with Work Productivity and Transitions.**
*Abstract:* Academy of Managed Care & Specialty Pharmacy Annual Meeting, Boston, MA April 23-26, 2018.
*Authors:* Tundia N, Zhou J, Yang M, Macaulay D, JR C.

**Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.**
*Authors:* Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.

**Economic burden of illness among commercially-insured patients with systemic sclerosis in the United States.**
*Abstract:* Systemic Sclerosis World Congress, 5th Annual, Bordeaux, France February 15-17, 2018.

**Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis.**
*Authors:* Strand V, Elaine Husni M, Betts KA, Song Y, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A.

**Burden of illness of systemic sclerosis among commercially insured patients.**
*Abstract:* Steering Committee of the 5th Systemic Sclerosis World Congress, Bordeaux, France February 15-17, 2018.

**Burden of Illness of Systemic Sclerosis with Interstitial Lung Disease among Commercially Insured Patients.**

**Estimating the economic value of a patient support program in rheumatoid arthritis in the United Kingdom.**
*Authors:* Ostor A, Garg V, Yang M, Chamberlain C, Skup M.

**Estimating the short-term costs associated with non-medical switching in rheumatic diseases.**
*Authors:* Gibofsky A, Garg V, Yang M, Qi CZ, Skup M.
Patient reported outcomes of upadacitinib: Results from biologic inadequate responders (select beyond phase iii trial).

Authors: Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J.

Patterns of Immunosuppressive Therapy among Patients with Newly Diagnosed Systemic Sclerosis (SSc) and SSc-Associated Interstitial Lung Disease (SSc-ILD).


Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs: Results from selectnext.

Authors: Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M.

Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population.

Authors: Wang SX, Ganguli AX, Bodhani A, Medema JK, Reichmann WM, Macaulay D.


Authors: Rice JB, White A, Lopez A, Nelson WW.

Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review.

Authors: Rice JB, White AG, Scarpati LM, Wan G, Nelson WW.

Economic burden of sarcoidosis in a commercially-insured population in the United States.


Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.

Authors: Li N, Betts KA, Messali AJ, Skup M, Garg V.

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.

Publication: Rheumatology Therapeutics 2017 07. e-pub ahead of print 2017/08/02; doi: 10.1007/s40744-017-0070-6.
Authors: Strand V, Betts KA, Mittal M, Song J, Skup M, Joshi A.
Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis.
Authors: Wells AF, Curtis JR, Betts KA, Douglas K, Du EX, Ganguli A.

Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective.
Authors: Husni ME, Betts KA, Griffith J, Song Y, Ganguli A.

Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons.
Authors: Wolf D, Skup M, Yang H, Fang AP, Kageleiry A, Chao J, Mittal M, Lebwohl M.

Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
Authors: Yang M, Galebach PJ, Signorovitch JE, Garg V.

Association between disease activity level improvement and reduction in healthcare resource utilization in patients with rheumatoid arthritis receiving targeted therapy.
Authors: Lopez A, Priest J, Duh MS, McDonnell E, Bobbili PJ, Haider BA, Sundaresan D, Yood RA, Reed JI.

Association of corticosteroid exposure with ophthalmologic complications and systemic adverse events in non-infectious uveitis patients using administrative claims in the United States.
Authors: Acharya N, Betts KA, Patterson-Lomba O, Ganguli A, Schonfeld S, Griffith J.

Burden of high disease activity in systemic lupus erythematosus (SLE): Results of a targeted literature review.
Abstract: ISPOR 20th Annual European Congress, Glasgow, UK.
Authors: Tan R, Adamski K, Tuttle E, Güenther O, Henke C.

Drug Cost per Responder for the Treatment of Moderate-to-Severe Psoriasis and Active Psoriatic Arthritis.
Authors: Armstrong A, Merola J, Yang M, Li J, Zhao J, Sundaram M, A G.

HPR predicting the future development of spondyloarthritis among patients with idiopathic acute anterior uveitis using real-world data.
Abstract: Annual European Congress of Rheumatology, Madrid, Spain June 14-17, 2017.
Authors: Haroon M, Betts KA, Mu F, Skup M, Anderson JK, Joshi AD.

Network meta-analysis of targeted immunomodulators in the treatment of biologic-naive psoriatic arthritis.
Authors: Strand V, Husni ME, Singh R, Betts K, Song Y, Griffith J, Ganguli A.

Quantifying clinical and economic outcomes associated with chronic corticosteroid exposure in a US population.
Economic Evaluation of Timely versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.
Authors: Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.

Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn’s disease in Argentina, Brazil, Colombia and Mexico.

Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.

Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor-alpha and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis.
Authors: Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A.

Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Authors: Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ.

Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Authors: Zhou ZY, Griffith J, Du EX, Chin D, Betts KA, Ganguli A.

An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naive patients with psoriatic arthritis.
Authors: Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A.

ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.
Authors: van der Heijde D, Joshi A, Pangan AL, Chen N, Betts K, Mittal M, Bao Y.

Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons in psoriatic disease patients.
Authors: Lewwohl M, Skup M, Sundaram M, Yang H, Faust E, Kageleiry A, Chao J, Wolf D.
Comparison of Annual Treatment Costs for Patients Treated with Infusion versus Injectable Biologics.

Authors: Skup M, Macaulay D, Wei J, Terasawa E, Chao J.

The economic burden of dermatomyositis and polymyositis in the US.


Economic burden of non-responders to biologic DMARD treatments in rheumatoid arthritis.

Authors: Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.

Effects of Adalimumab on Health-related Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Value of Reducing PASI Scores and Systemic Inflammation.

Authors: Okun M, Yang M, Koo V, Sundaram M, Signorovitch J.

Evaluation of timely versus delayed use of tumor necrosis factor inhibitors in the treatment of psoriatic arthritis: Economic and clinical results from a modeling study.

Authors: Strand V, Husni ME, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.

Incremental benefit of radiographic inhibition on long-term outcomes in patients with rheumatoid arthritis.

Authors: Keystone EC, Betts KA, Schlacher CA, Song Y, Ganguli A, Griffith J.

Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor, Interleukin, and Phosphodiesterase Inhibitors in the Treatment of Psoriatic Arthritis.

Authors: Strand V HM, Betts K, Griffith J, Song Y, Beppu M, Ganguli A.

Prediction of flaring in rheumatoid arthritis patients upon biologics dose tapering: a chart review study in Taiwan.


Real-world Impact of Taiwan Health Policy on Dose Tapering and Withdrawing Biologics in Rheumatoid Arthritis Patients: A Retrospective Chart Review Study.


Relative efficacy of adalimumab versus secukinumab in active ankylosing spondylitis: A matching-adjusted indirect comparison.

Authors: Betts KA, Mittal M, Song J, Skup M, Joshi A.

Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison.

Authors: Betts K, Mittal M, Joshi A, Song J, Bao Y.
Thresholds of benefit-risk trade-offs from the patient perspective for treatment decisions in moderate-to-severe rheumatoid arthritis.

*Authors:* Husni ME, Griffith J, Betts K, Song Y, Ganguli A.

Assessment of salary growth in patients with ankylosing spondylitis treated with and without anti-tumor necrosis factor therapy.

*Abstract:* European League Against Rheumatism Congress, Rome, Italy   Jun 10-13, 2015.
*Authors:* Deodhar A, Mittal M, Joshi A, Signorovitch J, Yang M, Bao Y.

Comorbid psoriatic arthritis significantly impairs health-related quality of life in patients with moderate to severe psoriasis.

*Authors:* Kimball AB, Sundaram M, Signorovitch J, Yang M, Taska B.

Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured population in the US.


Projected economic impact of increased use of biologic treatments for rheumatoid arthritis in Argentina, Colombia, and Mexico over 10 years.

*Abstract:* ISPOR 5th Latin America Conference, Santiago, Chile   Sep 6-8, 2015.

Short-term clinical outcomes and healthcare resource utilization in patients with rheumatoid arthritis tapering anti-TNF agents in Taiwan.

*Abstract:* 17th Asia Pacific League of Associations for Rheumatology Congress, Chennai, India   Sep 6-9, 2015.

Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons.

*Authors:* Wolf D, Skup M, Yang H, Faust E, Kageleiry A, Chao J, Lebwoh M.

Comorbidity burden and medication use among patients with psoriatic arthritis in the US.

*Abstract:* American College of Rheumatology Annual Scientific Meeting San Francisco, CA   Nov 6-11, 2015.
*Authors:* Merola J, Han S, Xie J, Song H, Herrera V, Wei J, Wu EQ, Palmer JB.

Impact of Taiwan health policy for dose tapering and withdrawing biologics in rheumatoid arthritis patients: A real-world chart review study.

*Abstract:* 17th Congress of the Asia Pacific League of Associations for Rheumatology in Conjunction with IRA Annual Congress, Chennai, India   Sep 6-9, 2015.

Economic Impact of Expanded Use of Biologic Therapy for Crohn’s Disease In Latin American Countries.

*Abstract:* ISPOR 5th Latin America Conference, Santiago, Chile   Sept 6-8, 2015.
*Authors:* Kotze PG, Tundia N, Gumen A, Macaulay D, Chaves L, Bao Y.
Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study.

Authors: Shiozawa A, Cloutier M, Heroux J, Guerin A, Wu EQ, Jackson R.

Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.

Authors: Feldman SR, Zhao Y, Shi L, Tran MH, Lu J.

Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.

Authors: Bergman M, De G, Ganguli A, Signorovitch J, Bao Y.

Comparison of Annual Treatment Costs for Patients Treated with Infusion versus Injectable Biologics.

Authors: Macaulay D, Wei J, Terasawa E.

Economic Burden and Treatment Patterns of Cycling between Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) among Patients with Rheumatoid Arthritis (RA).

Authors: Li N, Betts KA, Griffith J, Ristovska L, Douglas K, Ganguli A.

Economic evaluation of timely versus delayed use of anti-tumor necrosis factor (TNF) biologics in the treatment of psoriatic arthritis (PSA) in the US.

Authors: Zhou Z, Signorovitch JE, Griffith JM, Zhong Y, Ganguli A.

Indirect Treatment Comparison of Adalimumab, Etanercept, Certolizumab, Golimumab, and Infliximab for the Treatment of Ankylosing Spondylitis.
San Diego, CA Apr 7-10, 2015.
Authors: Betts KA, K. H.

Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor and Phosphodiesterase Inhibitors in the Treatment of Psoriatic Arthritis.

Authors: Betts K, Reichmann W, Guo J.


Authors: Strand V, Husni ME, Reichmann W, Betts K, Griffith J, Song Y, Beppu M, Ganguli A.

Rates and risk factors of PsA disease progression amongst newly diagnosed PsA patients.

Authors: Meroloa J, Guerin A, Sundaram M, Jarvis J, Cummings AK, Ghorayeb E.

Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison.

Authors: Betts KA, Mittal M, Joshi A, Song J, Bao Y.
Real-world persistence with single versus multiple tablet regimens for HIV-1 treatment.
*Authors:* Sweet DE, Kim Y, Song J, Zhong Y, Signorovitch J.

Real-world treatment patterns during and after an emergency room or acute care facility visit for gout.
*Authors:* Krishnan E, Cloutier M, Guérin A, Héroux J.

ASAS40 and ASDAS responses are associated with improved physical function, HRQOL, and work productivity in patients with non-radiographic axial spondyloarthritis.
*Authors:* Van Der Heijde D, Joshi A, Mittal M, Pangan A, Chen N, Betts K, Qi C, Bao Y.

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.
*Authors:* Zhang HF, Gauthier G, Hiscock R, Curtis JR.

Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
*Authors:* Oglesby A, Korves C, Laliberte F, Dennis G, Rao S, Suthoff ED, Wei R, Duh MS.

Claims database analysis of adherence to adalimumab therapy and health care costs for patients with rheumatoid arthritis.
*Authors:* Liu Y, Tundia N, Skup M, Ayyagari R, Du EX, Chao J, Mulani P, Bao Y.

The economic burden of osteoarthritis in Americans: Analysis from a privately insured population.
*Authors:* Wang SX, Ganguli AX, Macaulay D, Reichmann W, Medema JK, Cifaldi MA.

Economic implications of flares among patients with early rheumatoid arthritis (ra).
*Authors:* Signorovitch J, Betts K, Garg V, Bao Y.

Incremental burden of psoriatic arthritis is substantial among patients with mild and moderate to severe psoriasis.
*Authors:* Merola J, Guerin A, Jarvis JL, Wang K, Sundaram M.

An indirect comparison and cost per responder analysis of adalimumab, methotrexate (MTX) and apremilast in the treatment of MTX-naive psoriatic arthritis (PSA) patients.
*Authors:* Strand V, Griffith J, Betts K, Friedman A, Signorovitch J, Ganguli A.

A prediction model that identifies patients most likely to benefit from first-line therapy with adalimumab plus methotrexate in early rheumatoid arthritis.
*Authors:* Van Vollenhoven RF, Betts K, Signorovitch J, Bao C, Shaw JW, Ganguli A.
Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.


*Authors:* Sweet D, Song J, Zhong Y, Signorovitch J.

Real-world risk of fall-related injuries among rheumatoid arthritis (RA) patients treated with tumor necrosis factor inhibitors (anti-TNFs) or methotrexate (MTX).


*Authors:* Bao Y, Ganguli A, De G, Kelkar S, Curtis JR.

Effect of adalimumab on physical function, health-related quality of life, and work productivity in patients with peripheral spondyloarthritis: Results from the ability-2 clinical trial.


*Authors:* Mease PJ, Rao S, Betts KA, Lu M, Fan L, Pangan AL, Van Der Heijde D, Cifaldi MA.

The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials.


*Authors:* Burmester G, Emery P, Signorovitch J, Williams D, Valdes J, Bao Y, Mulani PM.

Health care resource utilization (HRU) and costs associated with disease activity in systemic lupus erythematosus (SLE): A retrospective observational cohort analysis.


*Authors:* Kan H, Guerin A, Kaminsky M, Yu AP, Wu EQ, Denio AE, Jhingran PM, Narayanan S, Molta CT.

Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naive HIV-1 patients treated with atazanavir/ritonavir versus darunavir/ritonavir.


*Authors:* Xie J, Juday TR, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on oral disease-modifying anti-rheumatic drugs (DMARDs).


*Authors:* Zhang F, Guerin A, Gauthier G, Curtis J.

Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.


*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

Serum urate and incidence of kidney disease among veterans with gout.


*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu E, Tawk RH, Liu J, Shi L.

A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus.


Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.

Assessment of wage and salary growth in patients with rheumatoid arthritis (RA).

Clinical outcomes and healthcare utilization following early versus late diagnosis of systemic lupus.

Cost-effectiveness of different treatment sequences including adalimumab in the treat-to-target framework for early rheumatoid arthritis in Germany.

Cost-per-responders analysis of biological agents for the treatment of active ankylosing spondylitis in Germany.

The economic burden of osteoarthritis in Americans: Analysis from a privately insured population.

Indirect comparison of joint damage prevention with adalimumab v. Abatacept, each in combination with methotrexate, in early rheumatoid arthritis.

Progression from undifferentiated spondyloarthritis to ankylosing spondylitis: Is USPA a proxy for non-radiographic axial SPA?

Spondyloarthritis epidemiology and burden phase 2 [speed 2] study: Disease progression in axial spondyloarthropathy (SpA).

Switching from adalimumab to other disease-modifying antirheumatic drugs without apparent medical reasons in rheumatoid arthritis: Impact on health care service use.
Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis.

**Abstract:** Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

**Authors:** Nurmohamed MT, Bao Y, Signorovitch J, Mulani PM, Furst DE.

Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE.

**Abstract:** 7th Congress of ECCO European Crohn’s and Colitis Organization, Barcelona, Spain Feb 16-18, 2012.


**Abstract:** Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

**Authors:** Bergman MJ, Shaw JW, Cifaldi MA, Guerin A, Chopra P, Signorovitch J.

Comparison of rheumatoid arthritis-related health care resource use and comorbidities among patients with rheumatoid arthritis treated with adalimumab vs etanercept.

**Abstract:** Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

**Authors:** Xie J, Ganguli A, Yang H, Parikh K, Wu EQ, Cifaldi M.

Health care costs in psoriatic arthritis (PSA) patients newly initiated on a biologic disease-modifying anti-rheumatic drug (DMARDS) or methotrexate (MTX).

**Abstract:** ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

**Authors:** Zhang F, Hiscock R, Curtis J.

Healthcare costs in psoriatic arthritis patients newly initiated on a biologic disease-modifying anti-rheumatic drug or methotrexate.

**Abstract:** Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

**Authors:** Zhang F, Hiscock R, Curtis J.

Patient-reported outcomes associated with achieving and maintaining low disease activity in rheumatoid arthritis.

**Abstract:** Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14 2012.

**Authors:** Bergman MJ, Shaw JW, Cifaldi M, De G, He T, Ayyagari R, Signorovitch J.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.

**Abstract:** ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

**Authors:** Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.

**Abstract:** 70th Annual Meeting of the American Academy of Dermatology, San Diego, CA Mar 16-20, 2012.

**Authors:** Guerin A, Zhang F, Gauthier G, Day R, Khan Z.

Risk differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.


**Authors:** Van Vollenhoven R, Shaw JW, Cifaldi MA, Signorovitch JE, Wu EQ, Samuelson TM, Faust E, Emery P.
Impact of early versus late systemic lupus erythematosus (SLE) diagnosis on clinical and economic outcomes.
Authors: Oglesby AK, Dennis GL, Korves C, Laliberte F, Suthoff ED, Wei R, Duh MS.

Comorbidty burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
Authors: Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M.

Comorbidty burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
Authors: Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M.

Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).
Authors: Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, M TA.

Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.
Authors: Kavanagh S, Kwong W, Hammond G, Nelson W, Upmalis D, Yang M.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.
Authors: Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.
Authors: Birnbaum HG, Pike C, Banerjee R, Waldman T, Cifaldi M.

Glucocorticoid-induced tumor necrosis factor receptor family-related protein exacerbates collagen-induced arthritis by enhancing the expansion of Th17 cells.

Adherence to subcutaneous vs. Oral disease-modifying antirheumatic drugs in rheumatoid arthritis.
Abstract: Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 22012.
Authors: Bergman M, Bao Y, Ayyagari R, Mulani PM.

Differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.
Authors: Van Vollenhoven RF, Shaw JW, Cifaldi MA, Signorovitch J, Wu EQ, Samuelson T, Faust E, Emery P.

Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on non-biologic disease modifying anti-rheumatic drugs (DMARDS).
Authors: Curtis J, Gauthier G, Hiscock R, Zhang F.
Treatment patterns in psoriatic arthritis patients newly initiated on non-biologic disease-modifying antirheumatic drugs.

Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

Authors: Curtis J, Gauthier G, Hiscock R, Zhang F.

Use of anti-tumor necrosis factor therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis.

Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

Authors: Nurmohamed MT, Bao Y, Signorovitch J, Mulani PM, Furst DE.

Variation in the use of biologics in the management of rheumatoid arthritis across the United Kingdom.

Abstract: British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meeting, Glasgow, UK May 1-3, 2012.

Authors: Choy E, McAuliffe S, Roberts K, Sargeant I.

Economic burden of psoriatic arthritis and diabetes in patients with psoriatic arthritis in the United States.

Abstract: ACR/ARHP Annual Scientific Meeting, Chicago, IL Nov 4-9, 2011.

Authors: Guérin A, Gauthier G, Day R, Khan Z, Zhang F.

Indirect comparison of adalimumab versus etanercept for the treatment of psoriatic arthritis.


Authors: Kirson NR, S.; Birnbaum, H. G.; Kantor, E.; Wei, R.; Cifaldi, M.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriatic arthritis in the united states.

Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

Authors: Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

Uncontrolled serum uric acid in veteran gout patients is associated with a higher risk of diabetes.

Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.


Uncontrolled serum uric acid is associated with an increased risk of developing renal disease in veterans with gout.

Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

Authors: Krishnan E, Sharma H, Pandya BJ, Marynchenko M, Yu A, Wu E, Liu J.

Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.


Refractory gout brings economic pain.

Publication: PharmacoEconomics & Outcomes News 2011 03; 623: 5.

Authors: Wu E.
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors.
Publication: Arthritis Research & Therapy 2011 02; 13(1); R25. doi: 10.1186/ar3249.
Authors: Rendas-Baum R, Wallenstein GV, Koncz T, Kosinski M, Yang M, Bradley J, Zwillich SH.

Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (Compairs).
Authors: Sussman DA, Kubiliun N, Chao J, Mulani PM, Gillis CA, Yang M, Lu M, Abreu MT.

Economic burden of psoriatic arthritis and obesity in patients with psoriatic arthritis in the United States.
Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.
Authors: Zhang F, Guerin A, Latremouille-Viau D, Day RR, Khan Z.

Economic model of workplace impacts of anti-TNF therapy for rheumatoid arthritis in Brazil.
Abstract: ISPOR 3rd Latin America Conference Mexico City, Mexico Sep 8-10, 2011.
Authors: Teich V, Chaves L, Birnbaum H, Pike C, Waryas C, Cifaldi M.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.
Abstract: 30th Annual Scientific Meeting of the American Pain Society, Austin, TX May 19-21, 2011.
Authors: Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman R, Mullen R, Reed C.

Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (compairs).
Authors: Sussman D, Kubiliun N, Chao J, Mulani P, Gillis C, Yang M, Lu M, Abreu M.

Diagnostic and resource use profiles before and after diagnosis of spondyloarthritis.
Authors: Kirson N, Birnbaum H, Rao S, Swallow K, Waldman T, Dayoub E, Cifaldi M.

Evaluation of cardiovascular diseases (CVDs) risk for patients with fibromyalgia syndrome in the United States.
Authors: Mease PJ, Duh MS, Vekeman F, Lefebvre P, Laliberte F, Boerstoel-Streefland M, Jiang W, Zimetbaum PJ.

Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.
Publication: Dermatology 2010 11; 220(1); 1-7. doi: 10.1159/000260371.
Authors: Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Societal cost of rheumatoid arthritis patients in the US.
Publication: Current Medical Research and Opinion 2010 01; 26(1); 77-90. doi: 10.1185/03007990903422307.
Authors: Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

Direct and indirect costs of spondyloarthritis patients pre-and post-diagnosis.
Authors: Kirson N, Birnbaum H, Rao S, Swallow E, Waldman T, Dayoub E, Cifaldi M.
Longer psoriasis duration is independently associated with greater persistent functional impairment in patients with psoriatic arthritis.
*Authors:* Kimball A, Signorovitch J, Mulani P, Bao Y.

**Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis.**
*Authors:* Birnbaum H, Pike C, Kaufman R, Cifaldi M.

**Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?**
*Authors:* Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E.

**Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature.**
*Authors:* Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M.

**Adalimumab reduces symptoms of depression in patients with moderate to severe psoriasis.**
*Authors:* Menter A, Signorovitch J, Mulani P, Gupta S.

**Adalimumab reduces symptoms of psoriatic arthritis among psoriasis patients with comorbid psoriatic arthritis.**
*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

**Changes in health care utilization and costs for employed patients with rheumatoid arthritis from 1997 to 2006.**
*Abstract:* American College of Rheumatology Annual Scientific Meeting Atlanta, GA  Nov 6-11, 2010.
*Authors:* Birnbaum H, Pike C, Banerjee R, Waldman T, Cifaldi M.

**The costs of treatment failure gout: A claims-based analysis.**
*Abstract:* American College of Rheumatology Annual Scientific Meeting Atlanta, GA  Nov 6-11, 2010.
*Authors:* Wu EQ, Yu AP, Guerin A, Latremouille-Viau D, Tsaneva M, Forsythe A.

**The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis.**
*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

**Impact of adalimumab treatment in the workplace in patients with rheumatoid arthritis.**
*Abstract:* British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meeting, Glasgow, UK  Apr 28 - May 1, 2009.
*Authors:* Cifaldi MA, Birnbaum H, Pike C, Kaufman R, Schiller M, Shi L, Sun P, Ray S.

**Societal cost of rheumatoid arthritis (RA) in the United States: Methodology for incorporating intangible costs.**
*Authors:* Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.
Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States.
Authors: White AG, Birnbaum HG, Janagap C, Buteau S, Schein J.

Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Authors: Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

Disease-related and all-cause health care costs of elderly patients with gout.
Publication: Journal of Managed Care Pharmacy 2008 03; 14(2): 164-175.
Authors: Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E.

Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
Authors: Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

Cost and Risk of Gout Flares among the Elderly: Does Serum Uric Acid Level Matter?
Authors: Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R.

Authors: Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R.

Authors: Wu EQ, Patel P, Krishnan E, Yu AP.

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.

Book Section: Linking administrative claims data with archival productivity measures to inform employer decision making.
Authors: Greenberg PE, Birnbaum HG.

Tighter control of serum uric acid in gout is associated with lower morbidity and health care costs.
Authors: Wu EQ, Mody RR, Krishnan E, Yu AP, Cahill KE, Tang J, Patel PA.

Direct and indirect costs of rheumatoid arthritis to an employer.
Authors: Birnbaum HG, Barton M, Greenberg PE, Sisitsky T, Auerbach R, Wanke LA, Buatti MC.
Cardiovascular

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).
Publication: Circulation 2018 10; 138(14): 1387-1398. doi: http://dx.doi.org/10.1161/CIRCULATIONAHA.117.033200.

The Association of Severe Diabetic Retinopathy With Cardiovascular Outcomes in Long-standing Type 1 Diabetes: A Longitudinal Follow-up.
Authors: Pongrac Barlovic D, Harjutsalo V, Gordin D, Kallio M, Forsblom C, King G, Groop P-H.

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.
Authors: Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH.

The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: An observational cohort study.

A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment.
Authors: Ayyagari R, Xie J, Cheng D, Wu EQ, Huang XY, Chen S.

Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.
Authors: Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberte F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P.

Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function.

Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation.
Publication: Journal of Cardiac Failure. 2018 05.
Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.
*Authors:* McHorney CA, Crivera C, Laliberte F, Germain G, Wynant W, Lefebvre P.

Community health workers improve disease control and medication adherence among patients with diabetes and/or hypertension in Chiapas, Mexico: an observational stepped-wedge study.

An answer to “Anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution”.

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism.
*Authors:* Berger JS, Seheult R, Laliberte F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S.

Adherence to heart failure medications pre-and post-cardiac resynchronization therapy.
*Authors:* Shah B, DerSarkissian M, Xiao Y, Davis E, Kinrich D, Lefebvre P, Duh MS, May D, Tsintzos S, Dasta J.

Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.

Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.
*Authors:* Kaatz S, Coleman CI, Bookhart B, Laliberte F, Nelson WW, Brown K, Martin S, Schein J, Lefebvre P.

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.

Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation.
Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.


Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests.


**Authors:** Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ.

Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis.


**Authors:** Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Yannicelli D, Schein J.

Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.

**Publication:** Clinical Therapeutics 2017 07; 39(7): 1396-1408. doi: http://dx.doi.org/10.1016/j.clinthera.2017.05.357.


Importance of balancing follow-up time and impact of oral-anticoagulant users’ selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.


**Authors:** Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberte F, Lefebvre P, Peterson ED.

A single-center experience with low-dose warfarin in patients undergoing total hip or knee replacement surgery.

**Publication:** Current Orthopaedic Practice 2017 05; 23(3): 221-228.

**Authors:** Balcom WB, Mishol DN, Eapen S, Bookhart BK, Nutescu EA, Schein JR, Duh MS.

Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.


**Authors:** Nelson WW, Laliberte F, Patil AA, Germain G, Pilon D, McCormick N, Lefebvre P.

Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate.


**Authors:** Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P.

Adherence to rivaroxaban versus apixaban among patients with atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.

**Abstract:** American Heart Association's Quality of Care and Outcomes Research, Arlington, VA  Apri 2-3, 2017.

**Authors:** McHorney CA, Crivera C, Laliberte F, Germain G, Wynant W, Lefebvre P.
Anticoagulant treatment patterns for cancer-associated thrombosis in a commercial insurance population.


**Authors:** Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

Elevated b-type natriuretic peptide levels and cardiovascular outcomes in patients with heart failure across different ejection fraction levels.


**Authors:** Greenberg B, Berger JS, Peterson ED, Laliberte F, Zhao Q, Germain G, Lejeune D, Wu JW, Lefebvre P, Fonarow GC.

Healthcare costs associated with venous thromboembolism in cancer patients treated with anticoagulants.

**Abstract:** 59th Annual Meeting of the American Society of Hematology, Washington, DC  Dec 9-12, 2017.

**Authors:** Streiff MB, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Khorana AA.

Healthcare resource utilization associated with venous thromboembolism in cancer patients treated with anticoagulants in a commercial insurance population.


**Authors:** Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

Impact of differences in once-vs twice-daily medications adherence on the risk of bleed and stroke in non-valvular atrial fibrillation: Analysis of randomized trials and claims data sources.

**Abstract:** American Heart Association’s Quality of Care and Outcomes Research, Arlington, VA  Apr 2-3, 2017.

**Authors:** McHorney CA, Peterson ED, Durkin M, Ashton V, Laliberte F, Crivera C, Sheikh N, Germain G, Schein JR, Xiao Y, Lefebvre P.

Impact of renal function on clinical outcomes among nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban.

**Abstract:** ISPOR 22nd Annual International Meeting, Boston, MA  May 20-24, 2017.

**Authors:** Weir MR, Haskell L, Berger JS, Ashton V, Laliberte F, Crivera C, Brown K, Lefebvre P, Schein JR.

Importance of balanced follow-up time and other study design considerations when evaluating adherence using two novel oral anticoagulants.

**Abstract:** American Heart Association’s Quality of Care and Outcomes Research, Arlington, VA  Apr 2-3, 2017.

**Authors:** Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberte F, Lefebvre P, Peterson E.

Incremental risk of ischemic stroke over time in newly diagnosed heart failure patients without atrial fibrillation.


**Authors:** Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

Myocardial fibrosis and the effect of defibrillator implantation in patients with non-ischemic systolic heart failure - DANISH-MRI.

**Abstract:** European Society of Cardiology, Barcelona, Spain  Aug 26-30, 2017.

**Authors:** Elming MB, Hammer-Hansen S, Nyktari E, Voges I, Raja AA, Signorovitch J, Koeber L, Prasad S, Thune JJ.

Rivaroxaban users have significantly less treatment discontinuation compared with users of other oral anticoagulants in non-valvular atrial fibrillation.


**Authors:** McHorney C, Ashton V, Laliberte F, Germain G, Wynnant W, Crivera C, Schein J, Lefebvre P, Peterson E.
Stroke and myocardial infarction risk among newly diagnosed heart failure patients with reduced, borderline, and preserved left ventricle ejection fraction.

Abstract: 21st Annual Scientific Meeting of the Heart Failure Society of America, Gravevine, TX   Sept 16-19, 2017.
Authors: Fonarow GC, Peterson ED, Greenberg B, Berger JS, Laliberte F, Zhao Q, Germain G, Lejeune D, Lefebvre P.

VTE recurrence and safety of anticoagulants among patients with cancer treated for venous thromboembolism.

Authors: Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB.

Comparison of Adherence to Rivaroxaban versus Apixaban Among Patients with Atrial Fibrillation Treated with Rivaroxaban versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.

Authors: McHorney CA, Peterson ED, Laliberte F, Germain G, Nelson WW, Crivera C, Schein J, Lefebvre P.

The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older.

Authors: Agus DB, Gaudette E, Goldman DP, Messali A.

Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.

Authors: Deitelzweig S, Laliberte F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

Impact of a Telehealth and Care Management Program on All-Cause Mortality and Healthcare Utilization in Patients with Heart Failure.


Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.

Publication: Menopause 2016 06; 23(6): 600-610. doi: http://dx.doi.org/10.1097/GME.0000000000000590.
Authors: Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

Cost impact of switching from metoprolol to nebivolol for hypertension.

Authors: Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu E.

Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.


Adherence to QD vs. BID medications in naf patients is associated with reduced risk of ischemic stroke: A modeling study using rct and claims data.


Cardiac resynchronization therapy and adherence to heart failure management regimens.

Abstract: 20th Annual Scientific Meeting of the Heart Failure Society of America, Orlando, FL   Sep 17-20, 2016.
Authors: Der Sarkissian M, Xiao Y, Shen Y, May D, Tsintzos SI, Lefebvre P, Duh MS.
Clinical and economic outcomes of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.

Clinical and economic outcomes of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.

Cost of hyperkalemia among patients with heart failure.
Authors: Woolley JM, Betts K, Mu F, Xiang C, Tang W, Wu E.

The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.
Authors: Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhania A, Wu E.

Healthcare costs among patients diagnosed with deep vein thrombosis in the outpatient setting and treated with Rivaroxaban versus low-molecular-weight Heparin and Warfarin.
Authors: Laliberte F, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

Patient characteristics and treatment patterns of venous thromboembolism (VTE) among hospitalized patients in China: an analysis of electronic medical record data.

Patient characteristics and treatment patterns of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.

Risk of ischemic stroke in newly diagnosed heart failure patients.
Authors: Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

Risk of venous thromboembolism recurrences in patients who continued versus discontinued rivaroxaban therapy after an initial six-month therapy.
Authors: Berger JS, Seheult R, Laliberte F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S.

Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.
Abstract: 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany   Sep 12-16, 2016.
Authors: Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.
Development of a shared decision-making tool to assist patients and clinicians with assessing the individualized risks and benefits of oral anticoagulation therapy for atrial fibrillation.

**Abstract:** ISPE’s 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA  August 22-26, 2015.


Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy.


**Authors:** Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberte F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis.


**Authors:** Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE.

The Relationship between Local Economic Conditions and Acute Myocardial Infarction Hospital Utilization by Adults and Seniors in the United States, 1995-2011.


**Authors:** Carls GS, Henke RM, Karaca Z, Marder WD, Wong HS.

Glycemic and Cholesterol Control versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.


**Authors:** Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Zhang M, Wang Y, Fonseca VA.

Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.


**Authors:** Olson WH, Ma YW, Crivera C, Schein J, Lefebvre P, Laliberte F, Dea K, Germain G, Lynch SM.

Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.


The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.


**Authors:** Penn MS, Yenikomshian MA, Cummings AK, Kleemes A, Damron JM, Purvis S, Beidelschies M, Birnbaum HG.

Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.


**Authors:** Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P.
Response to comment on “is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients? Real-world evidence from a retrospective analysis of a large United States hospital database”.

Publication: Journal of Cardiac Failure 2015 05; 21(5): 435. doi: 10.1016/j.cardfail.2015.03.003.
Authors: Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Duh MS, Ong SH.

Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.
Authors: Merli GJ, Hollander JE, Lefebvre P, Laliberte F, Raut MK, Olson WH, Pollack CV, Jr.

Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.

Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.

Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.
Authors: Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberte F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysis.
Authors: Chen S, Swallow E, Li N, Faust E, Kelley C, Xie J, Wu E.

Anticoagulant options and inpatient costs for patients with non-valvular atrial fibrillation.
Authors: Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Costs of venous thromboembolism (VTE) among hospitalized patients in China.
Authors: Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.
Authors: Penn MS, Yenikomshian MA, Cummings AKG, Damron JM, Purvis S, Birnbaum HG.

Economic impact of switching from metoprolol to nebivolol for the treatment of hypertension.
Authors: Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu EQ.

Effect of prasugrel vs clopidogrel on hospital readmission among acute coronary syndrome patients treated with prasugrel.
Authors: Olson WH, Ma Y, Lefebvre P, Laliberte F, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM.
Effects of rivaroxaban vs warfarin on hospitalization days, healthcare resource utilization, and costs in nonvalvular atrial fibrillation patients using rivaroxaban.


Hospital length of stay: Does rivaroxaban reduce impatient stay compared to warfarin among patients with non-valvular atrial fibrillation.

Authors: Laliberté F, Pilon D, Raut M, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China.

Authors: Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

Pulse pressure and stroke risk: development and validation of a new stroke risk model
Authors: Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients?
Real-world evidence from a retrospective analysis of a large United States hospital database.
Authors: Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS.

Gastrointestinal comorbidities associated with atrial fibrillation.
Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Schein JR, Lefebvre P.

Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel.
Authors: Olson WH, Ma YW, Laliberte F, Lefebvre P, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM.

Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.
Authors: Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Authors: Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.
Authors: Laliberte F, Coleman CI, Bookhart B, Lefebvre P, Cloutier M, Damaraju CV, Schein JR, Kaatz S.

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
Authors: Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P.

Specialized adult congenital heart disease care: the impact of policy on mortality.
Publication: Circulation 2014 05; 129(18): 1804-1812. doi: 10.1161/CIRCULATIONAHA.113.005817.
Authors: Mylotte D, Pilote L, Ionescu-Ittu R, Abrahamowicz M, Khairy P, Therrien J, Mackie AS, Marelli A.
Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension.
Authors: Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ.

Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.
Authors: Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China.
Authors: Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Authors: Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA.

Risk factors associated with myocardial infarction in venous thromboembolism patients.
Authors: Laliberte F, Nutescu EA, Lefebvre P, Rondeau-Leclaire J, Bookhart BK, LaMori JC, Damaraju CV, Schein J, Kaatz S.

Economic benefits associated with medication persistence in the treatment of hypertension: a retrospective analysis in patients who received beta-blockers.
Authors: Chen Y, Swallow E, Li N, Faust E, Kelly C, Xie J, Wu EQ.

Pulse pressure and stroke risk: Development and validation of a new stroke risk model.
Authors: Vekeman F, Ayyagari R, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Real-World Comparative Effectiveness and Safety of Rivaroxaban and Warfarin in Nonvalvular Atrial Fibrillation Patients.
Authors: Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, P. L.

Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China.
Authors: Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

All-cause and disease-related costs associated with recurrent venous thromboembolism.
Authors: Lefebvre P, Laliberte F, Nutescu E, Duh MS, LaMori JC, Bookhart B, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.
The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials.


*Authors:* Burmester G, Emery P, Signorovitch J, Williams D, Valdes J, Bao Y, Mulani PM.

Hospital length of stay: Does rivaroxaban reduce inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?


*Authors:* Laliberte F, Pilon D, Raut M, Nelson WW, Duh MS, Schein JR, Lefebvre P.

Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.


*Authors:* Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

Treating acute heart failure in the elderly: A comparison of three inpatient treatment alternatives in the united states.


*Authors:* Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Lacomte P, Ong SH, Duh MS.

Venous thromboembolism and cardiovascular disease complications in women using transdermal versus oral menopausal estrogen therapy.


*Authors:* Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

All-cause and disease-related health care costs associated with recurrent venous thromboembolism.


*Authors:* Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein J, Kaatz S.

Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.


*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA.

Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors.


*Authors:* Rushani D, Kaufman JS, Ionescu-Ittu R, Mackie AS, Pilote L, Therrien J, Marelli AJ.

Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism.


*Authors:* Laliberte F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS.

Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy.


Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study.
Authors: Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS.

Association of patient characteristics with the initiation of dabigatran versus warfarin among anticoagulant naive patients with non-valvular atrial fibrillation.
Abstract: American Heart Association's Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2013 Scientific Sessions, Baltimore, MD May 15-17, 2013.
Authors: Walker DR, Ivanova J, Betts KA, Rao S, Wu EQ.

Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Authors: Lefebvre P, Coleman CI, Bookhart B, Wang ST, Mody SH, Tran K, Zhuo D, Huynh L, Nutescu EA.

Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?
Publication: Current Medical Research and Opinion 2013 30(4): 645-653.
Authors: Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

Pulse pressure and stroke risk: Development and validation of a stroke risk equation.
Authors: Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
Authors: Laliberte F, Cloutier M, Nelson WW, Coleman CI, Sheng Duh M, Pilon D, Damaraju CV, Schein JR, Lefebvre P.

Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.
Authors: Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

Associations of hypertension with risk of cardiovascular events among chinese stroke patients in the US.
Authors: Fung G, Kahler K, Xie J, Marynchenko M, Wu E, Kam I, Yang W.

Comparisons of costs and clinical outcomes in hypertensive patients treated with angiotensin receptor blockers plus chlorthalidone or hydrochlorothiazide.
Authors: Leahy MJ, Sun SX, Yu AP, Chen KS, Wu EQ, Mattson M, Tang J.

Comparisons of costs and clinical outcomes in hypertensive patients treated with chlorthalidone or hydrochlorothiazide.
Authors: Sun SX, Leahy MJ, Dabbous O, Yu AP, Lu M, Chen KS, Wu EQ.
Compliance and persistence with nebivolol vs. Diuretics as first add-on hypertension treatment.
Authors: Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu E.

Risk of cardiovascular events associated with hypertension among Chinese and Caucasian stroke patients in the US.
Authors: Fung G, Kahler K, Xie J, Liu N, Wu E, Kam I, Yang W.

Acute heart failure patients with and without renal impairment: A study of heart failure-related resource utilization and costs in the United States.
Authors: Eldar-lissai A, Eapen S, Ong SH, Rodermund D, Duh M.

All-cause and disease-specific health care utilization and costs associated with venous thromboembolism in commercial, Medicare and Medicaid beneficiaries.
Authors: Lefebvre P, Laliberte F, Nutescu EA, Duh MS, Lamori JC, Bookhart B, Olson W, Dea K, Schein J, Kaatz S.

Are vasodilators of any value in the care of hospitalized acute heart failure patients?
Authors: Gradman A, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh M.

Are vasodilators of value in the care of patients hospitalized for acute heart failure?
Authors: Duh MS, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Gradman AH.

Are vasodilators of value in the care of patients hospitalized for acute heart failure?
Authors: Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS.

Chronic heart failure in the elderly: Costs and resource utilization following initial hospitalization.
Authors: Eldar-lissai A, Korves C, Wei R, Sharma H, Chen K, Ong SH, Duh MS.

Risk of gastrointestinal conditions among patients with atrial fibrillation.
Authors: Laliberte F, Dea K, Lamori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients.
Authors: Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS.

All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
Publication: Journal of Managed Care Pharmacy 2012 06; 18(5): 363-374.
Authors: Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S.
Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.
Authors: Korves C, Eldar-Lissai A, McHale J, Lafeuille MH, Hwa Ong S, Sheng Duh M.

Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis.
Authors: Signorovitch JE, Samuelson TM, Ramakrishnan K, Marynchenko M, Wu EQ, Blum SI, Ramasamy A, Chen S.

In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty.
Authors: Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

Chronic heart failure in the elderly: Clinical characteristics and resource utilization following initial hospitalization.
Authors: Korves C, Eldar-Lissai A, Wei R, Sharma H, Chen K, Ong SH, Duh MS.

Gastrointestinal conditions among patients with atrial fibrillation.
Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge M, Damaraju CV, Duh MS, Schein J, Lefebvre P.

Impact of once-daily vs. Twice-daily dosing frequency on adherence in chronic medications among patients with non-valvular atrial fibrillation.
Abstract: Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2012 Scientific Sessions, Atlanta, GA May 9-11, 2012.
Authors: Laliberte F, Nelson WW, Schein JR, Rondeau-Leclerc J, Lefebvre P, Duh MS.

Integrated telehealth and care management program reduces all cause mortality in Medicare beneficiaries with heart failure.
Authors: Page RL, Kao DP, Macaulay D, Birnbaum HG, Jarvis J, Desai U, Lindenfeld J.

Risk of gastrointestinal conditions among patients with atrial fibrillation.
Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.
Authors: Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

Tolerability and effectiveness of nebivolol compared to other add-on therapies for hypertension: A retrospective chart review.
Authors: Ayyagari R, Cheng D, Xie J, Huang XY, Wu EQ, Chen S.
Comparison of bleeding rates between statin and statin-free patients on warfarin: A claims database approach.
Abstract: ISPOR 14th Annual European Congress, Madrid, Spain   Nov 5-8, 2011.
Authors: Guerin A, Hylek EM, Frois C, Ponce De Leon Barido D, Marrone C, Bae JP, Zhao Z.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system versus oral estrogen-only hormone therapy.
Authors: Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Evaluation of international normalized ratio monitoring and anticoagulation control in atrial fibrillation/flutter patients using warfarin and antiarrhythmic drug therapy.
Authors: Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ.

Hospitalization due to heart failure is associated with significant medical resource utilization and costs.
Authors: Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS.

Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the United States.
Authors: Korves C, Eldad-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

Real-world clinical outcomes and costs in atrial fibrillation/flutter patients on combined warfarin and antiarrhythmic drug therapy.
Abstract: 23rd Annual Meeting and Showcase of the AMCP, Minneapolis, MN   Apr 27-29, 2011.
Authors: Guerin A, Lin J, Jhaveri M, Wu E, Alpert J.

Treatment persistence among atrial fibrillation/flutter patients on combination warfarin and antiarrhythmic drug therapy in the real-world setting.
Authors: Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ.

Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the US.
Abstract: 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) (ICPE), Chicago, IL   Aug 14-17, 2011.
Authors: Korves C, Eldad-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

Antithrombotic treatment patterns, hospitalizations, and associated costs in acute coronary syndrome (ACS) patients.
Authors: Lefebvre P, Laliberte F, Dea K, Nelson W, Crivera C, Ellis L, Schein JR, Damaraju CV, Mody S, Duh MS.

Clinical characteristics, blood pressure (BP) control, and antihypertensive treatment (TRX) patterns among elderly patients (PTS) with hypertension (HTN).
Does route of administration for estrogen hormone therapy and estradiol transdermal system dosage strength impact risk of venous thromboembolism.

Authors: Kahler KH, Nyirady J, Beresford E, Laliberte F, Dea K, Sheng Duh M, Lefebvre P.

Impact of initial antihypertensive treatment with a single-pill combination on blood pressure (BP) goal attainment: A matched cohort study.

Authors: Gradman AH, Parish H, Lafeuille MH, Falvey H, Lefebvre P, Duh MS.

Impact of initial combination therapy vs monotherapy on major cardiovascular (CV) events: A matched cohort study.

Authors: Gradman AH, Parish H, Lafeuille MH, Falvey H, Lefebvre P, Duh MS.

Long-term consequences and costs associated with venous thromboembolism.

Abstract: 23rd Annual Meeting and Showcase of the AMCP, Minneapolis, MN Apr 27-29, 2011.
Authors: Mody S, Lefebvre P, Laliberte F, Nutescu E, Duh MS, LaMori J, Bookhart BK, Olson W, Dea K, Schein J, Kaatz S.

Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the United States.

Authors: Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.

Authors: Signorovitch J, Brainsky A, Grotzinger KM.

Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.

Authors: Simpson RJ, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A.

Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism?

Estradiol transdermal system versus oral estrogen-only hormone therapy.

Authors: Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.

Authors: Kirson NY, Birnbaum HG, Ivanova JL, Waldman T, Joish V, Williamson T.

Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.

Authors: Kirson NY, Birnbaum HG, Ivanova JL, Waldman T, Joish V, Williamson T.
Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
Authors: Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy.
Authors: Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP.

Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data (February).
Authors: Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guerin A, Boerstoel-Streefland M, Jiang W, Lefebvre P.

Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.

Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.
Authors: Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.
Authors: Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Factors associated with failing to achieve low density lipoprotein cholesterol goal with existing statin therapy: A chart extraction-based approach.
Abstract: ISPOR 14th Annual European Congress, Madrid, Spain  Nov 5-8, 2011.
Authors: Zhao Z, Ivanova J, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Frois C.

Low lipoprotein cholesterol goal attainment in dyslipidemic patients with existing statin therapy: A chart extraction-based approach.
Abstract: ISPOR 14th Annual European Congress, Madrid, Spain  Nov 5-8, 2011.
Authors: Ivanova J, Frois C, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Zhao Z.

Risk of gastrointestinal conditions among patients with atrial fibrillation.
Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

A single-center experience with low-dose warfarin in patients undergoing total hip or total knee replacement surgery.
Authors: Balcom WB, Bookhart BK, Mishol DN, Eapen S, Nutescu EA, Schein JR, Duh MS.
Alikiren combined with angiotensin II-receptor blockers (ARB) resulted in better outcomes compared to ARB combined with angiotensin-converting enzyme inhibitors (ACEI): Results from a claims database analysis.
Authors: Chang JR, Yang W, Kahler KH, Fellers TS, Orloff J, Bensimon AG, Yu AP, Fan CPS, Wu EQ.

Blood pressure goal achievement among hypertension patients treated with valsartan-based single pill combination vs. ARB-based free combination in South Central region.
Authors: Chang JR, Yang W, Fellers TS, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ.

Cardiovascular and economic outcomes following initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.

Compliance and health care utilization among patients with hypertension treated with single pill vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis.
Authors: Yang W, Chang JR, Kahler KH, Fellers TS, Orloff J, Wu EQ, Bensimon AG, Fan CPS, Yu AP.

Economic impact of switching from valsartan to other angiotensin II receptor blockers (ARBS) in patients with hypertension.
Authors: Signorovitch J, Zhang J, Wu EQ, Latremouille-Vlau D, Yu AP, Dastani H, Kahler KH.

The epidemiology, treatment and care patterns, and medical resource utilization following hospitalization for heart failure.
Authors: Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS.

Persistence with nebivolol compared to other beta-blockers in the treatment of hypertension: A retrospective claims analysis.
Authors: Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum SI, Ramasamy A, Wu EQ.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.
Authors: Laliberte F, Dea K, Dub MS, Kahler KH, Rolli M, Lefebvre P.

Incidence rate of venous thromboembolism and hemorrhage in patients undergoing total hip or knee arthroplasty: A managed care perspective.
Authors: Lefebvre P, Vekeman F, Nutescu E, Duh M, Bookhart B, Schein J, Dea K.

Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement
Authors: Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ.
Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives.
Authors: Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG.

Clinical outcomes and medical care costs among Medicare beneficiaries receiving therapy for peripheral arterial disease.
Authors: Jaff MR, Cahill KE, Yu AP, Birnbaum HG, Engelhart LM.

Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.
Authors: Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.
Authors: Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH.

Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.
Abstract: Chest 2010 Meeting
Authors: Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

Cost trend associated with cardiovascular (CV) events in patients (pts) with hypertension (HTN) in US managed care settings.
Authors: Jayawant SS, Fulcher N, Ramamurthy P, Moynere E, Ong SH, Duh MS.

Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
Authors: Simpson RJ, Jr., Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A.

Authors: Duh MS, Fulcher NM, White LA, Jayawant SS, Ramamurthy P, Moynere E, Ong SH.

Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.
Authors: Tian L, Cai T, Pfeffer MA, Piankov N, Cremieux PY, Wei LJ.

The association of aspirin use on risk of hospitalization in CHF patients taking ace inhibitors: A retrospective analysis of a national cohort of veterans.
Authors: Parikh NM, Shah DH, Deswal A, Ashton CM, Agarwal SJ, Chen H, Johnson M.

Economic impact of switching from valsartan to other angiotensin II receptor blockers for nonmedical reasons in patients with hypertension.
Authors: Wu EQ, Signorovitch J, Yu AP, Latremouille-Viau D, Dastani HB, Kahler K.
Healthcare costs and resource utilization of patients receiving combination treatments of angiotensin receptor blocker with chlorthalidone or with hydrochlorothiazide.

Authors: Sun S, Yu A, Chen K, Mattson M, Xu Y, Dabbous O.

Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.

Authors: Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

The risk of coronary heart disease and stroke among psoriasis patients.

Authors: Kimball A, Guerin A, Mulani P, Gupta S.

Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences.
Authors: Xie J, Wu EQ, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR.

An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).
Publication: Journal of Clinical Hypertension (Greenwich, Conn.) 2008 06; 10(6): 436-442.
Authors: Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, Julius S, Investigators TS.

Authors: Shaya FT, Gu A, Yan X.

Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.
Authors: Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD.

Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence.
Authors: Yu AP, Yu YF, Nichol MB, Gwadry-Sridhar F.

Productivity costs associated with cardiometabolic risk factor clusters in the United States.
Authors: Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

Prevalence, referral patterns, testing, and surgery in aortic valve disease: leaving women and elderly patients behind?
Authors: Bach DS, Radeva JI, Birnbaum HG, Fournier AA, Tuttle EG.

The economic impact of a partnership-measurement model of disease management: Improving Cardiovascular Outcomes in Nova Scotia (ICONS).
Publication: Healthc Q 2007 05; 10(2): 38-46.
Authors: Cremieux PY, Fortin P, Meilleur MC, Montague T, Royer J.
Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.
Authors: Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

The value of antihypertensive drugs: a perspective on medical innovation.

Antihypertensive drugs: a perspective on the value of improved blood pressure control in the USA.
Authors: Long G, Cutler DM, Berndt ER.

Impact of Single-Photon Emission Computed Tomography (SPECT) Use after Acute Myocardial Infarction (AMI) on Cardiac Procedures Rates and Hospital Length of Stay.
Authors: Wu EQ, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ.

Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States.
Authors: Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR.

Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to The Netherlands.
Publication: Journal of Medical Economics 2006 9(131): 121.
Authors: Boersma C, Ivanova J, Koopmanschap MA, Voors AA, Postma MJ.

Economic burden and co-morbidities of atrial fibrillation in a privately insured population.
Authors: Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J.

Assessing the economic impact of chronic conditions in postmenopausal women.
Authors: Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M.

Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
Authors: Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfefeer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Calif RM, Schulman KA, Valiant-Investigators.

Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.
Authors: Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation.
Authors: Radeva JI, Reed SD, Kalo Z, Kauf TL, Cantu E, 3rd, Cretin N, Schulman KA.

Comparison of Alternative Strategies for the Diagnosis of Acute Cardiac Ischemia in Emergency Departments: Standard of Care versus BMIPP.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Birnbaum H, Cremieux P, Carpenter S, Borys N, Babich J.


*Authors:* Patel MR, Meine TJ, Radeva J, Curtis L, Rao SV, Schulman KA, Jollis JG.

Cost and Comorbidities Associated with Atrial Fibrillation.

*Abstract:* NASPE - Heart Rhythm Society.

*Authors:* Wu EQ, Howard BG, Mareva MN.

PCV22 Cost and comorbidities associated with atrial fibrillation in different age groups.


*Authors:* Wu E, Birnbaum H, Milena M.

Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.


*Authors:* Birnbaum H, Leong S, Kabra A.

Clinical and Economic Value of Cardiovascular Nuclear Medicine.

*Publication:* Meniscus Health Care Communications 1996.

*Authors:* Mulhern C, Neels K.

**Dermatology**


*Authors:* Kimball AB, Sundaram M, Gauthier G, Guerin A, Pivneva I, Singh R, Ganguli A.

Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.


Impact of Hidradenitis Suppurativa on Work Loss, Indirect Costs and Income.


*Authors:* Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J.

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.


*Authors:* Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: An observational cohort study.


Reliability of the hidradenitis suppurativa clinical response (HiSCR) in the assessment of patients with hidradenitis suppurativa.


**Authors:** Kimball AB, Ganguli A, Fleischer A.

Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States.

**Publication:** Allergy and Asthma Proceedings 2018 05; 39(3): 201-211.

**Authors:** Williams P, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V.

Real-world use of omalizumab in patients with chronic Idiopathic/Spontaneous urticaria in the United States.


**Authors:** Eghrari-Sabet J, Sher E, Kavati A, Pilon D, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Bernstein JA.


**Authors:** Williams PV, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V.

Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis.


**Authors:** Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Ganguli A.


**Authors:** Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guerin A, Ganguli A.

Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.


**Authors:** Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE.

Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis.


**Authors:** Strand V, Elaine Husni M, Betts KA, Song Y, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A.

Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.


**Authors:** Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, Guerin A.

Adverse Medical Conditions across Treatment Options in Patients with Psoriasis: A Claims-Based Analysis.

**Abstract:** Annual Meeting of the American Academy of Dermatology, San Diego, CA   Feb 16-20, 2018.

**Authors:** Wu JJ, Armstrong A, Singh R, Ganguli A, Arikan D, Fleishcher A, CLoutier M, Gauthier-Loiselle M.
Comparison of the efficacy of dupilumab vs. ciclosporin using Eczema Area and Severity Index thresholds in adult patients with moderate-to-severe atopic dermatitis.


Incremental benefits on patient-reported outcomes for achieving PASI90 or PASI100 over PASI75 in patients with moderate to severe psoriasis.

Authors: Ryan C, Puig L, Zema C, Thompson E, Yang M, Wu EQ, Huang X, Skup M, Elewski B.

Indirect economic burden associated with multiple and more complex surgical procedures for hidradenitis suppurativa (HS).


Patient-Reported Outcomes from the IMMVent Trial: Comparison of Risankizumab with Adalimumab in Moderate to Severe Psoriasis Patients.

Authors: Crowley J, Skup M, Huang X, Yang M, Wu EQ, Thompson E, Zema C, Reich K.

Risankizumab Significantly Improves Patient-Reported Outcomes in Moderate to Severe Psoriasis in Two Phase III UltIMMa Trials.

Authors: Augustin M, Lambert J, Zema C, Thompson E, Yang M, Wu EQ, Geng Z, Valdes J, Skup M, Gordon M.

Authors: Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM.

Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014.
Authors: Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB.

Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study.
Authors: Wu JJ, Guerin A, Gauthier G, Sundaram M.

Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate.
Authors: Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P.

Drug Cost per Responder for the Treatment of Moderate-to-Severe Psoriasis and Active Psoriatic Arthritis.
Authors: Armstrong A, Merola J, Yang M, Li J, Zhao J, Sundaram M, A G.
Health-related quality of life and work productivity associated with HiSCR and NRS30 response among patients with moderate to severe hidradenitis suppurativa.

Authors: Kimball A, Yang M, Song Y, Valdecantos W, Ganguli.

High-Value Subpopulation for Skin Pain Improvement in Adalimumab-Treated Patients with Moderate to Severe Hidradenitis Suppurativa.

Authors: Qureshi A, Yang M, Song Y, Zhang A, Sundaram M, Ganguli A.

Comparison of Outcomes between Psoriasis Patients who Switched from Etanercept to Adalimumab versus to Ustekinumab.

Authors: Jashin J, Wu J, Sundaram M, Guérin A, Gauthier G, Thompson-Leduc P.

Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naive patients with psoriasis.
Authors: Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE.

Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.

What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis.
Authors: Jemec GB, Guerin A, Kaminsky M, Okun M, Sundaram M.

Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review.
Authors: Brown J, Su Y, Nelerson D, Shankar P, Mayo C.

Adalimumab Is Associated with Reduced Risk of Joint-related Signs and Symptoms Compared with Methotrexate in Patients with Moderate to Severe Psoriasis.
Authors: Merola J, Sundaram M, Yang M, Li J, Galebach P, Okun M.

Cardiovascular (CV) event risk assessment in psoriasis (PS) patients treated with tumor necrosis factor-alpha inhibitors (TNFi) versus phototherapy.
Authors: Wu J, Cloutier M, Gauthier-Loiselle M, Guerin A, Sundaram M.

How is the severity of hidradenitis suppurativa measured in clinical practice?
Authors: Sundaram M, Lin P, Thomason D, Signorovitch J.
Numbers needed to treat and costs per responder for novel treatments of moderate to severe psoriasis.
Authors: Armstrong A, Betts K, Li J, Sundaram M, Wu E, Signorovitch J.

Patients’ Willingness to Pay for a Subcutaneous Injection Device That Reduces Injection Site Pain in the Treatment of Psoriasis.
Authors: Cividino A, Mittal M, Yang M, Signorovitch JE, M. S.

Predicting PASI90 Response Among Adalimumab-Treated Patients with Moderate to Severe Psoriasis.
Authors: Ryan C, Sundaram M, Yang M, Goyal R, Zhou Z, Signorovitch J.

Progression from a Milder to a More Severe Form of Hidradenitis Suppurativa is Associated with a Substantial Economic Burden.
Authors: Kimball A, Sundaram M, Gauthier G, Nitulescu R, Pivneva I, Guerin A.

Progression from mild hidradenitis suppurativa (m<sup>2</sup>s) to moderate-to-severe (m<sup>2</sup>s) HS is associated with a substantial economic burden.
Authors: Kimball A, Sundaram M, Gauthier G, Nitulescu R, Pivneva I, Guerin A.

Psoriasis Plaque Resolution by Body Region and Plaque Signs with Adalimumab and Etanercept: an Indirect Comparison.
Authors: Papp K, Sundaram M, Yang M, Jarvis J, Signorovitch J.

Relative efficacy and costs per responder for adalimumab versus secukinumab in the treatment of moderate to severe psoriasis.
Authors: Armstrong A, Betts K, Sundaram M, Li J, Wu E.

Risk and economic burden of antibiotic failure in patients with moderate to severe hidradenitis suppurativa.
Authors: Kimball A, Sundaram M, Gauthier G, Pivneva I, Nitulescu R, Guerin A.

Comorbid psoriatic arthritis significantly impairs health-related quality of life in patients with moderate to severe psoriasis.
Authors: Kimball AB, Sundaram M, Signorovitch J, Yang M, Taska B.

Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured population in the US.

Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.
Authors: Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Ittu R, Mulani P.
Psoriasis Treatment Patterns: Phototherapy, Oral Nonbiologic, and Biologic Therapies.
Authors: Kimball AB GG, Hiscock R, Zhang HF.

Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.
Authors: Feldman SR, Zhao Y, Shi L, Tran MH, Lu J.

Authors: Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

Comparative efficacy of methotrexate versus apremilast for methotrexatenaive psoriasis patients: An indirect comparison.
Authors: Armstrong AW, Betts K, Sundaram M, Thomason D, Signorovitch J.

Cost per Responder Associated with Biologic Therapies for Psoriasis.
Authors: Liu Y, Reichmann W, Macaulay D.

Health care resource utilization, health care costs, and dose escalation in biologic-naive psoriasis patients initiated on ustekinumab versus adalimumab.
Authors: Guerin A, Sundaram M, Gauthier G.

Long-term Effect of Achieving PASI90 Compared with PASI75 Response on Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis.
Authors: Ryan C, Sundaram M, Yang M, Goyal R, Signorovitch J.

A practical model for early identification of response with methotrexate for moderate to severe psoriasis.
Authors: Gordon K, Sundaram M, Arunajadai S, Xie M, Signorovitch J, Betts K, Okun M.

Rates and risk factors of PsA disease progression amongst newly diagnosed PsA patients.
Authors: Meroloa J, Guerin A, Sundaram M, Jarvis J, Cummings AK, Ghorayeb E.

Starting-dose trends over time in biologic-naive and biologic-experienced psoriasis patients initiated on ustekinumab or adalimumab.
Authors: Guerin A, Sundaram M, Gauthier G.

Economic and comorbidity burden of moderate-to-severe psoriasis.
Authors: Feldman S, Zhao Y, Tran MH, Shi L.

Health care costs in psoriasis patients newly initiated on a biologic therapy or methotrexate.
Authors: Zhang F, Hiscock R.
Number needed to treat and cost per responder for biologic therapies for the treatment of moderate to severe psoriasis.

Authors: Langley RG, Signorovitch J, Wang K, KA. B, Sundaram M, Mulani P, Yan S.

**Early identification of response with methotrexate for moderate-to-severe psoriasis.**

Authors: Gordon K, Sundaram M, Arunajadai S, Xie M, Signorovitch J, Betts K, Okun M.

**Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.**

Authors: Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M.

**Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.**

Authors: Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM.

**Higher health care costs and dose escalation rates in psoriasis patients treated with ustekinumab compared to adalimumab.**

Authors: Guerin A, Wang K, Sundaram M.

**Incremental burden of psoriatic arthritis is substantial among patients with mild and moderate to severe psoriasis.**

Authors: Merola J, Guerin A, Jarvis JL, Wang K, Sundaram M.

**Nail psoriasis significantly impairs health-related quality of life among patients with chronic plaque psoriasis.**

Authors: Okun M, Kageleiry A, Signorovitch J, Yang M, Sundaram M.

**Patient preferences and willingness to pay for enhancements to subcutaneous injection devices used to treat psoriasis.**

Authors: Cividino A, Signorovitch JE, Skup M, Tundia N, Mulani P, Arulmani U, Bao Y.

**Severity, Healthcare Resource Use, and Costs of Patients Diagnosed with Hidradenitis Suppurativa in the United States: Evidence from a Large Administrative Claims Database.**

*Abstract:* AMCP’s 26th Annual Meeting & Expo, Tampa, FL  Apr 1-4, 2014.
Authors: Sundaram M, Guérin A, Styles A, M K.

**Validation of the hidradenitis suppurativa clinical response as a clinical endpoint for hidradenitis suppurativa treatment evaluation.**

Authors: Okun M, Yang M, Sundaram M, Gu Y.

**Validation of the physician’s global assessment of psoriasis of the hands and/or feet as a clinical endpoint.**

*Abstract:* American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL  Mar 1-5, 2013.
Authors: Goldblum O, Sundaram M, Yang M, Thomason D.
Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease.

Authors: Kimball AB, Signorovitch JE, Sundaram M, Samuelson T.


Authors: Betts KA, Sundaram M, Mughal F, Yan SY, Signorovitch J, Wang K, Wu EQ.


Authors: Cather JC, Sundaram M, Horn EJ, Yang M, Signorovitch JE.

Economic burden of hidradenitis suppurativa after a single surgical intervention: Assessment of unmet needs using a retrospective claims-based analysis.

Authors: Jemec G, Guérin A, Okun M, Kaminsky M, Sundaram M.

Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases.

Authors: Sundaram M, Styles A, Guerin A, Aberki C, Okun M, Hayes O, Mulani P.

Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease.

Authors: Kimball AB, Sundaram M, Samuelson TM, Signorovitch JE.

Cost-effectiveness of biologic therapies for the treatment of moderate to severe psoriasis in Germany.

Authors: Betts K, Yan Y, Sundaram M, Hengst N, Wolff M, Bensimon AG.

Economic burden associated with workplace productivity losses (WPL) in patients with psoriasis in a population in the United States.


Economic burden of hidradenitis suppurativa following a single surgical intervention: Assessment of unmet need using a retrospective claims-based analysis.

Authors: Jemec G, Guérin A, Sundaram M, Kaminsky MS, Okun MM.

Economic burden of psoriasis (PSO) and obesity in patients with psoriasis in the United States.

Authors: Zhang F, Guerin A, Gauthier G, Day R, Khan Z.


Authors: Zhang F, Guerin A, Latremouille-Viau D, Day R, Khan Z.
Indirect comparison suggests that adalimumab is associated with significantly more days of adverse event-free response versus etanercept.


Authors: Reich K, Signorovitch JE, Sundaram M, Mulani PM.

Outcomes of switching to adalimumab vs. continuing methotrexate in patients with moderate to severe psoriasis stratified by initial response to methotrexate.


Authors: Reich K, Sundaram M, Signorovitch JE, Samuelson TM, Goldblum O, Fan L, Wu EQ, Mulani PM.

Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases.


Authors: Sundaram M, Okun MM, Guérin A, Styles A, Hayes OA, Aberki C, Mulani PM.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.


Authors: Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.


Authors: Guerin A, Zhang F, Gauthier G, Day R, Khan Z.

Psoriasis is significantly associated with lower rates of pregnancy and live births.


Authors: Cather JC, Horn EJ, Sundaram M, Latremouille-Viau D, Guérin A.

Risk of developing micro- and macrovascular complications in diabetes patients with psoriasis.


Authors: Armstrong AW, Guérin A, Sundaram M, Faust E, Mulani PM.

Quality-of-life effects of psoriasis skin symptoms affecting different body regions.


Authors: Kimball AB, Sundaram M, Signorovitch J, Yang M, Mulani PM.

Sex differences in health-related quality of life in patients with moderate to severe psoriasis.


Authors: Cather JC, Horn EJ, Sundaram M, Yang M, Farooqui S, Mulani PM.

Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIIB trial.


Authors: Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, Goldblum O, Okun MM, Mulani PM.
Risks of developing psychiatric disorders in pediatric patients with psoriasis.
Authors: Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
Authors: Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

Psoriasis is significantly associated with lower rates of pregnancy and live births.
Authors: Cather JC, Latremouille-Viau D, Horn EJ, Bao Y.

Treatment Patterns in Psoriasis Patients Newly Initiated on an Oral Conventional Systemic Therapy or on Phototherapy.
Authors: Zhang F, Guérin A, Hiscock R, Kimball A.

Fatigue outcomes following withdrawal from and retreatment with adalimumab among patients maintained on adalimumab for moderate to severe psoriasis.
Authors: Papp K, Wu E, Goldblum O, Gupta S.

Health care outcomes associated with continuous use of adalimumab versus continuous and intermittent use of etanercept in patients with psoriasis.
Authors: Papp K, Latremouille-Viau D, Mulani P, Gupta S.

Resource utilization and costs associated with switching from etanercept to adalimumab versus dose escalating with etanercept in patients with psoriasis.
Authors: Papp K, Guérin A, Mulani P, Gupta S.

Treatment patterns of psoriasis patients and trends over time.
Abstract: ISPOR 14th Annual European Congress, Madrid, Spain  Nov 5-8, 2011.
Authors: Zhang F, Guérin A, Gauthier G, Day R, Khan Z.

Economic burden of comorbidities in patients with psoriasis is substantial.
Authors: Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Authors: Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.


*Authors:* Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM.

**ABT-874 versus methotrexate in moderate to severe psoriasis: Effects on health-related quality-of-life outcomes.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Reich K, Tsaneva M, Sundaram M, Bao Y.

**Achieving long-term sustained response is associated with improvements in patient-reported outcomes in patients with psoriasis treated with ABT-874.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Yu A, Sundaram M, Bao Y.

**Adalimumab provides health-related quality of life benefits for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Duffin K, Menter A, Yang H, Gupta S.

**Comparison of psoriasis sign and symptom reduction and complete clearance with adalimumab versus etanercept.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Signorovitch J, Mulani P, Bao Y.

**Effects of ABT-874 treatment on health-related quality of life and Work Productivity and Activity Impairment in patients with psoriasis.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Signorovitch J, Sundaram M, Bao Y.

**Health-related quality of life in patients with moderate to severe psoriasis: Effects of treatment with ABT-874 versus etanercept or placebo.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Crowley J, Yang H, Sundaram M, Mulani P.

**Health-related quality of life outcomes in patients with moderate to severe psoriasis treated with ABT-874 versus etanercept or placebo.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Menter A, Signorovitch J, Sundaram M, Bao Y.

**Persistent impairment of work productivity and activity in patients with longer disease duration of psoriasis with hand/foot involvement.**


*Authors:* Kimball A, Mulani P, Gupta S, Signorovitch J.

**Resource utilization and costs associated with adalimumab or etanercept for moderate to severe psoriasis in a real-world setting.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Guerin A, Gupta S, Bao Y.
ABT-874 versus etanercept or placebo treatment for moderate to severe psoriasis: Health-related quality of life.

Adalimumab improves sleep symptoms in patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.

Adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol combination therapy: Effects on patient-reported outcomes in patients with psoriasis.
Authors: Thaçi D, Xie J, Gupta S, Mulani P.

Adalimumab provides health-related quality-of life benefits for patients with psoriasis with suboptimal response to etanercept methotrexate, or phototherapy.
Authors: Menter A, Guérin A, Yang H, Wu EQ, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM.

Adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety and cost per responder.
Authors: Wu EQ, Signorovitch JE, Bao Y, Mulani PM.

Benefit-risk analysis of adalimumab for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.

Comparative effectiveness of adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety, and cost per responder.
Authors: Wu E, Signorovitch J, Mulani P, Bao Y.

Cost per responder for biologic treatment of psoriasis: Matching-adjusted comparison of adalimumab with etanercept, infliximab, and ustekinumab.
Authors: Signorovitch J, Mulani P, Gupta S, Bao Y.

Effects of ABT-874 versus etanercept or placebo on health-related quality of life in patients with moderate to severe psoriasis.
Authors: Crowley J, Signorovitch J, Tsaneva M, Ramakrishnan K, Yu AP, Yoo S, Valdes J, Sundaram M, Bao Y, Mulani P.
Longer disease duration of psoriasis with hand/foot involvement is independently associated with persistent impairment of work productivity and activity.


Authors: Kimball AB, Signorovitch J, Farooqui S, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Psoriasis treatment with ABT-874: Effects on health-related quality of life and work productivity and activity impairment.


Resource utilization and costs in patients with moderate to severe psoriasis treated with adalimumab or etanercept in a real-world setting.


Authors: Wu EQ, Guérin A, Latremouille-Viau D, Yu AP, Cloutier M, Gupta SR, Bao Y, Mulani PM.

Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.


Authors: Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.


Authors: Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.


Authors: Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM.

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.


Authors: Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.

Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.


Authors: Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice.

Publication: Dermatology 2010 02; 220(2): 128-137. doi: 10.1159/000275198.

Authors: Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM.
Associated Resource Utilization and Costs of Patients with Psoriasis Switching from Etanercept to Adalimumab versus Dose Escalating with Etanercept.  
*Authors:* Wu EQ GA, Lyon-Caen S, Latremouille-Viau D, Yu AP, Gupta SR, Bao Y.

Burden of illness in patients with hidradenitis suppurativa.  
*Authors:* Guerin A, Mulani P, Gupta S.

Comorbidity prevalence in psoriasis patients: A meta-analysis.  
*Authors:* Mrowietz U, Guerin A, Mulani P, Gupta S.

Comorbidity risks increase over time in patients with psoriasis.  
*Authors:* Kimball A, Yu A, Mulani P, Bao Y.

Comparison of benefit-risk profiles for adalimumab, methotrexate, and placebo in the treatment of moderate to severe psoriasis.  
*Authors:* Papp K, Signorovitch J, Mulani P, Bao Y.

Comparison of response rates and drug costs during maintenance therapy with adalimumab versus ustekinumab in patients with moderate to severe psoriasis.  
*Authors:* Signorovitch J, Kantor E, Mulani P, Bao Y.

Cost-effectiveness of continuous adalimumab vs. continuous or intermittent etanercept for the treatment of psoriasis.  
*Authors:* Signorovitch J, Gupta SR, Bao Y, Mulan PM.

Direct and indirect economic burden of employees with moderate to severe psoriasis.  
*Authors:* Reich K, Wu E, Mulani P, Gupta S.

Economic burden of comorbidities in patients with psoriasis.  
*Authors:* Kimball A, Wu E, Mulani P, Bao Y.

Effects of adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol combination therapy on patient-reported outcomes in psoriasis patients.  
*Authors:* Thaci D, Xie J, Mulani P, Gupta S.

Effects of adalimumab monotherapy versus adalimumab plus betametha-sone/calcipotriol on patient-reported outcomes in patients with palmo-plantar, nail, or scalp psoriasis.  
*Authors:* Thaci D, Xie J, Mulani P, Gupta S.
Healthcare Outcomes Associated with the Continuous Use of Adalimumab versus the Continuous and Intermittent Use of Etanercept in Patients with Psoriasis.

Authors: Wu EQ, Latremouille-Viau D, Guérin A, Cloutier M, Yu AP, Gupta SR, Bao Y.

Increased cancer risks among patients with psoriasis.

Authors: Kimball A, Guerin A, Mulani P, Bao Y.

Increased economic burden associated with moderate to severe psoriasis compared with mild psoriasis.

Authors: Kimball A, Yu A, Mulani P, Bao Y.

Increased risk of psychiatric disorders in a pediatric population with psoriasis.

Authors: Kimball A, Yu A, Mulani P, Gupta S.

Longer psoriasis duration is independently associated with greater persistent functional impairment in patients with psoriatic arthritis.

Authors: Kimball A, Signorovitch J, Mulani P, Bao Y.

Potential drugdrug interactions of oral systemic therapies for psoriasis have adverse outcomes in a real-world setting.

Authors: Saurat JH, Guerin A, Mulani P, Gupta S.

Psoriasis is associated with increased mortality risk.

Authors: Kimball A, Guerin A, Mulani P, Bao Y.

Economic burden of psoriasis compared to the general population and stratified by disease severity.
Authors: Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM.

Adalimumab reduces symptoms of depression in patients with moderate to severe psoriasis.

Authors: Menter A, Signorovitch J, Mulani P, Gupta S.

Adalimumab reduces symptoms of psoriatic arthritis among psoriasis patients with comorbid psoriatic arthritis.

Authors: Mease P, Signorovitch J, Mulani P, Gupta S.

Adalimumab treatment for moderate psoriasis reduces the risk of transitioning to severe psoriasis.

Authors: Papp K, Signorovitch J, Mulani P, Gupta S.

Adalimumab’s benefits for patient-reported outcomes in psoriasis patients are consistent across subgroups with different disease histories.

Authors: Kimball AB, Wu EQ, Mulani P, Gupta S.
The benefits of adalimumab on clinical and patient-reported outcomes among moderate to severe psoriasis patients with comorbidities.

Authors: Kimball A, Chen L, Mulani P, Gupta S.

Comorbidities of psoriasis have an independent effect on impairing patient health-related quality of life and work productivity.

Authors: Strober B, Guerin A, Mulani P, Gupta S.

Discontinuation of adalimumab treatment for psoriasis following sustained response: Effects on health-related quality of life.

Authors: Menter A, Wu EQ, Mulani P.

The effect of adalimumab on improving work productivity among moderate to severe psoriasis patients.

Authors: Kimball AB, Yu AP, Mulani P, Gupta S.

The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis.

Authors: Mease P, Signorovitch J, Mulani P, Gupta S.

Health-related quality of life and work productivity among psoriasis patients by disease severity.

Authors: Kimball A, Chen L, Mulani P, Gupta S.

Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free remission days in the CHAMPION trial.

Authors: Reich K, Yu AP, Mulani P, Gupta S.

Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free response days in the CHAMPION trial.

Authors: Reich K, Signorovitch J, Ramakrishnan K, Gupta S, Mulani P.

Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.
Authors: Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK.

The impact of psoriasis on health care costs and patient work loss.
Authors: Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.

The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective.
Publication: Managed Care Interface 2007 10; 20(10): 26-32.
Authors: Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.
Impact of Adalimumab (HUMIRA (R)) on Patient-Reported Outcomes.

Authors: Loftus EV, Wu EQ, Yu AP.

A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization.
Publication: Cutis 2006 06; 77(6): 385-392.
Authors: Fowler JF, Duh MS, Chang J, Person J, Thorn D, Raut M, Ghosh A, Den E, Emani S.

Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs.
Authors: Fowler JF, Ghosh A, Sung J, Emani S, Chang J, Den E, Thorn D, Person J, Duh MS.

Endocrine/Metabolic/Diabetes

The Association of Severe Diabetic Retinopathy With Cardiovascular Outcomes in Long-standing Type 1 Diabetes: A Longitudinal Follow-up.
Authors: Pongrac Barlovic D, Harjutsalo V, Gordin D, Kallio M, Forsblom C, King G, Groop P-H.

Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study.
Authors: Riddle MC, Nahra R, Han J, Castle J, Hanavan K, Hompesch M, Huffman D, Strange P, Öhman P.

Initiation of Basal Insulin Analog Treatment for Type 2 Diabetes and Reasons Behind Patients' Treatment Persistence Behavior: Real-World Data from Germany.
Authors: Moennig E, Perez-Nieves M, Hadjiyianni I, Cao D, Ivanova J, Klask R.

A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States.
Authors: Cloutier M, Greene M, Touya M, Gagnon-Sanschagrin P, Guerin A.

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.
Authors: Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH.

Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes.
Authors: Desai U, Kirson NY, Kim J, Khunti K, King S, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.
Characteristics, Treatment Patterns, and Economic Outcomes of Patients Initiating Injectable Medications for Management of Type 2 Diabetes Mellitus in Japan: Results from a Retrospective Claims Database Analysis.


Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis.


**Authors:** Jiang R, Law E, Zhou Z, Yang H, Wu EQ, Seifeldin R.

Association between biochemical control and comorbidities and symptoms among patients with acromegaly in Italy: Stratified analyses by age and gender.

**Publication:** Value in Health 2018 05; 21 (Supplement 1): S69-S70.

**Authors:** Colao A, Grasso L, Di Cera M, Cheng WY, Thompson-Leduc P, Cheung HC, Duh MS, Neary MP, Pedroncelli AM, Maamari R, Pivonello R.

The Cost of Hyperkalemia in the United States.


**Authors:** Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ.

Insulin non-persistence among people with type 2 diabetes: how to get your patients to stay on insulin therapy.


**Authors:** Garnero TL, Davis NJ, Perez-Nieves M, Hadjijyanni I, Cao D, Ivanova JI, Peyrot M.

Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.


**Authors:** Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P.

Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida.


**Authors:** Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanava M, Emond B, Inman D, Bailey RA.

Reduced Risk of Hyperprolactinemia Among Patients Treated With Atypical Antipsychotics that are Associated With Low or No Prolactin Elevation.

**Abstract:** ISPOR 2018 Annual International Meeting, Baltimore, MD May 19-23, 2018.

**Authors:** Cloutier M, Greene M, Guerin A, Touya M, Gagnon-Sanschagrin P, Wu E.

Comparison of 3-year estimated glomerular filtration rates between recombinant human parathyroid hormone (1-84) (RHPTH[1-84])-treated patients with chronic hypoparathyroidism and a historical control cohort.

**Publication:** Endocrine Practice 2018 04; 24 (Supplement 1): 111. doi: http://dx.doi.org/10.4158/1530-891X-24.s1.1.

**Authors:** Chen K, Mu F, Swallow E, Zhao J, Wang J, Krasner A, Sherry N, Signorovitch J.
Community health workers improve disease control and medication adherence among patients with diabetes and/or hypertension in Chiapas, Mexico: an observational stepped-wedge study.


Hba1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting.


*Authors:* Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P.

The prevalence of hyperkalemia in the United States.


*Authors:* Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ.

Accepting insulin treatment for reluctant people with Type 2 diabetes: A global study to identify effective strategies (EMOTION): Results from the UK cohort.


Attitudes among adults with type 2 diabetes affecting insulin initiation and discontinuation.


Healthcare costs associated with hyperprolactinemia in the United States.

*Abstract:* ISPOR 23rd Annual International Meeting United States.

*Authors:* Cloutier M, Greene M, Guerin A, Touya M, Gagnon-Sanschagrin P, Wu EQ.

Patient-level predictors of delay in insulin initiation and periods of insulin discontinuation among adults with type 2 diabetes.


*Authors:* Fisher L, Polonsky W, Hessler D, Ivanova JI, Desai U, Cao D, Snoek FJ, Perez-Nieves M.

Reduced risk of hyperprolactinemia among patients treated with atypical antipsychotics that are associated with low or no prolactin elevation.


*Authors:* Cloutier M, Greene M, Guerin A, Touya M, Gagnon-Sanschagrin P, Wu EQ.

Trends of insulin-like growth factor 1, growth hormone, and biochemical control of patients with acromegaly in Italy: A longitudinal retrospective chart review study.


*Authors:* Colao A, Grasso L, Di Cera M, Cheng WY, Thompson-Leduc P, Cheung HC, Duh MS, Neary MP, Pedroncelli AM, Maamari R, Pivonello R.
Patient characteristics of premix insulin users in China: An analysis of electronic medical record data.

Abstract: ISPOR 20th Annual European Congress, Glasgow, UK.

Authors: Han S, Wang K, Hou J, Wang J, Wu EQ.

Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey.


Authors: Perez-Nieves M, Ivanova JI, Hadjiyianni I, Zhao C, Cao D, Schmerold L, Kalirai S, King S, DeLozier AM, Birnbaum HG, Peyrot M.

Correlates of basal insulin persistence among insulin-naive people with type 2 diabetes: results from a multinational survey.


Real-world persistence and HbA1c goal attainment in type 2 diabetes mellitus patients initiated on canagliflozin or a glucagon-like peptide-1.


Treatment Satisfaction with ITCA 650, a Novel Drug-device Delivering Continuous Exenatide versus Twice-Daily Injections of Exenatide in Type 2 Diabetics on Metformin.


Authors: Henry R, Rosenstock J, McCarthy JF, Carls G, Alessi T, Yee J, Baron M.

Apolipoprotein C-III and High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III in Relation to Diabetes Risk.


Authors: Aroner SA, Yang M, Li J, Furtado JD, Sacks FM, Tjonneland A, Overvad K, Cai T, Jensen MK.

Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence.


Authors: Carls GS, Tan R, Zhu JY, Tuttle E, Yee J, Edelman SV, Polonsky WH.


Authors: Carls G, Huynh J, Tuttle E, Yee J, Edelman SV.

Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population.


Authors: DerSarkissian M, Bhak RH, Huang J, Buchs S, Vekeman F, Smolarz BG, Brett J, Ganguly R, Duh MS.

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.


Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study.

*Publication: Diabetic Medicine 2017 03; 34: 189. doi: http://dx.doi.org/10.1111/dme.13302.
*Authors: Hassan SW, Hadjiyianni I, Ivanova J, Cao D, Gulati K, Tahbaz A, Perez-Nieves M.

Insulin initiation experiences in people with Type 2 diabetes: Data from the UK.

*Publication: Diabetes UK Professional Conference, Manchester, UK Mar 3-10, 2018.
*Authors: Hassan SW, Gulati K, Hadjiyianni I, Cao D, Tahbaz A, Ivanova J, Perez-Nieves M.

Reasons for treatment persistence patterns in people with Type 2 diabetes after initiation of basal insulin: Data from UK patients.

*Publication: Diabetes UK Professional Conference, Manchester, UK Mar 3-10, 2018.
*Authors: Hassan SW, Gulati K, Hadjiyianni I, Cao D, Tahbaz A, Ivanova J, Perez-Nieves M.

Basal Insulin Persistence, Associated Factors, and Outcomes after Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan.

*Authors: Hadjiyianni I, Desai U, Suzuki S, Ivanova J, Cao D, Kirson NY, Chida D, Enloe C, Birnbaum HG, Perez-Nieves M.

Clinical and economic burden associated with chronic hypoparathyroidism: A retrospective chart review in the United States, Canada, United Kingdom, France, Germany, Italy, and Spain.

*Authors: Chen K, Krasner A, Li N, Xiang CQ, Souroutzidis A, Xie J.

Glycaemic control, weight loss, and use of other antihyperglycaemics in patients with type 2 diabetes initiated on canagliflozin or sitagliptin: A real-world analysis.


Real-world persistence and HbA1c goal attainment in type 2 diabetes patients initiated on canagliflozin or a glucagon-like peptide-1.


Renal outcomes with DPP-4 inhibitors compared with sulfonylurea as add-on to metformin among patients with type 2 diabetes.

*Authors: Teh HH, Desai U, Kirson NY, Hellstern M, Leigh PS, Mukherjee J, Khunti K.

Systematic literature review of clinical, humanistic, and economic burden in cushing’s disease.

*Authors: Watchko S, Nellesen D, Neary MP.

Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.

*Authors: Carls GS, Tuttle E, Tan R-D, Huynh J, Yee J, Edelman SV, Polonsky WH.
Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes.


*Authors:* Bonora B, Maran A, Ciciliot S, Avogaro A, Fadini GP.

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.


*Authors:* Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH.

A cloud-based electronic health records study of treatment intensification patterns in type 2 diabetes patients uncontrolled on >2 oral anti-diabetes drugs.

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany  Sep 12-16, 2016.


*Authors:* Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS.

Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.

*Publication:* Menopause 2016 06; 23(6): 600-610. doi: http://dx.doi.org/10.1097/GME.0000000000000590.

*Authors:* Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.


*Authors:* Perez-Nieves M, Kabul S, Desai U, Ivanova JI, Kirson NY, Cummings AK, Birnbaum HG, Duan R, Cao D, Hadjiyianni I.

Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder.


*Authors:* Zhang JJ, Nellesen D, Ludlam WH, Neary MP.

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.


Disease progression of diabetic nephropathy in adults with type 2 diabetes in the US.

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany  Sep 12-16, 2016.

The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.

Authors: Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhania A, Wu E.

The healthcare costs and utilisation associated with diabetic nephropathy in adult patients with type 2 diabetes in the US.

Abstract: 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany   Sept 12-16, 2016.

Maintenance of weight loss or stable weight in subjects with obesity: A retrospective longitudinal analysis of electronic medical record data.

Authors: Der Sarkissian M, Bhak R, Huang J, Buchs S, Vekeman F, Ganguly R, Duh MS.

Patterns of Weight Loss, Maintenance, and Gain in Patients with Obesity.

Authors: Huang; J, Buchs; S, DerSarkissian; M, Bhak; R, Vekeman; F, Ganguly; R, Duh; MS.

The Prevalence of Hyperkalemia in the United States.

Authors: Betts K, Woolle JM, Mu F, McDonald E, Tang W, Singhania A, Pham H, Hollenack K, Wu EQ.


Authors: Lefebvre P, Chow W, Pilon D, Emond B, Lafeuille M, Pfeifer M, Rupnow MF, Duh MS.

Real-world weight change among patients treated with GLP-1, SU, or DPP-4 therapy for type 2 diabetes and the influence of medication adherence.

Abstract: 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany  Sep 12-16, 2016.
Authors: Carls GS, Tan RD, Tuttle E, Yee J, Polonsky WH, Edelman SV.

Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.

Abstract: 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany  Sep 12-16, 2016.
Authors: Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

Glycated hemoglobin (Hba1c) control in patients with Type 2 Diabetes Mellitus (T2DM) treated with canagliflozin in a realworld setting.

Authors: Lefebvre P, Pilon D, Robitaille M, Lafeuille M, Chow W, Pfeifer M, Duh MS.

Real-world evaluation of weight loss in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin (CANA) - an electronic health-record (EHR)-based study.

Abstract: Obesity Week, Los Angeles, CA  Nov 2-6, 2015.
Authors: P; L, W; C, D; P, B; E, MH; L, M; P, MFT; R, MS; D.
Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated with Topical Testosterone.
Authors: Muram D, Kaltenboeck A, Boytsov N, Hayes-Larson E, Ivanova J, Birnbaum HG, Swindle R.

Glycemic and Cholesterol Control versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.

For a Step Change to Curb the Obesity Epidemic.
Authors: Frois C, Cremieux PY.

Authors: Chawla AS, Hsiao CW, Romney MC, Cohen R, Rubino F, Schauer P, Cremieux P.

Policy Makers’ Views of Obesity-Related Challenges Around the World: An interview between Pierre Cremieux (of Analysis Group, Inc., and Guest Editor of this Special Issue) and policy makers from Brazil (Patricia Constante Jaime), Canada (Kimberly Elmslie), China (Bin Wang), France (Francois Cremieux), and the USA (Mark McClellan).
Authors: Cremieux P.

Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.
Authors: Rice JB, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Skornicki M, Margolis DJ, Parsons N.

Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.
Authors: Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ.

Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.
Authors: Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Economic outcomes among Medicare patients receiving skin substitutes for treatment of diabetic foot ulcers.
Authors: Rice JB, Desai U, Ristovska L, Cummings AG, Birnbaum HG, Skornicki M, Margolis D, Parsons N.

The burden of "serial non-adherence" in type 2 diabetic patients.
Authors: Frois C, Dea K, Ling D, Dunn J, Baron M.
Daily dose and costs associated with maintenance therapy of topical testosterone agents among hypogonadal
men.
Abstract: ISPOR 17th Annual European Congress, Amsterdam, Netherlands
Nov 8 - 12, 2014.
D, Swindle R.

Units and costs per day per claim of comparable insulins supplied to Medicaid patients.
Authors: Ivanova JI, Foster S, Desai U, Hayes-Larson E, King S, Birnbaum HG, Swindle R.

Which newly-diagnosed diabetics should receive dietary counseling services? Estimating individualized
treatment allocations that optimize cost-effectiveness in real-world data.
Authors: Signorovitch J, Betts KA, Meng X, Zhuo Y, Wu EQ, Shi L.

Burden of diabetic foot ulcers for Medicare and private insurers.
Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB.

Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a
retrospective claims data analysis.

Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s disease.
Publication: European Journal of Endocrinology of the European Federation of Endocrine Societies 2014 07; 171(1):
Authors: Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M,
Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M.

Costs after initiating saxagliptin, sulfonylurea, or sitagliptin in patients with T2DM.
Authors: Kaltenboeck A, Ivanova J, Birnbaum H, Yushkina Y, Schwiep F, Bell K, Thomas N.

Daily dose and costs associated with maintenance therapy of topical testosterone agents among hypogonadal
men.
Abstract: 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America, Miami, FL Nov 20-23,
2014.
Authors: Kaltenboeck A, Boytsov N, Hayes-Larson E, San Roman AM, Ivanova J, Birnbaum HG, Foster SA, Vazquez JA,
Muram D, Swindle RW.

Management of patients using combination therapy with pioglitazone and a dipeptidyl peptidase-4 inhibitor:
an analysis of initial versus sequential combination therapy.
Authors: Bron M, Ayyagari R, Sharma H, Chen K, Bozas A, Wu E.

Budget impact of pasireotide for the treatment of Cushing’s disease, a rare endocrine disorder associated with
considerable comorbidities.
Authors: Truong HL, Nellesen D, Ludlam WH, Neary MP.
Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.

Authors: Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

Opportunities for Improving Attainment of Quality Measures in Patients with Type 2 Diabetes Mellitus.

Publication: American Journal of Managed Care 2014 01; 20(1).
Authors: Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meining R, Rupnow M.

Quality measure attainment in patients with type 2 diabetes mellitus.

Publication: American Journal of Managed Care 2014 01; 20(1 Suppl): s5-15.
Authors: Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Systematic Review of real-world evidence on treatment of Acromegaly.

Authors: Guérin A, Xu Y, Hiscock R, Begelman SM, Mu Y, Agha M, Wu EQ.

Clinical characteristics, quality measure attainment, and diabetes-related health care costs in elderly versus overall people living with type-2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).

Authors: Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Cost predictors in type 2 diabetes mellitus: A retrospective claims database analysis.

Authors: Ionescu-Ittu R, Bron M, Latremouille-Viau D, Guerin A, Samp J, Wu E.

Health care resource use and costs in patients with type 2 diabetes mellitus after treatment initiation with saxagliptin or sitagliptin.

Authors: Kaltenboeck A, Ivanova J, Thomas N, Bell K, Yushkina Y, Schwiep FA, Birnbaum H.

Medical, drug, and work-loss costs of diabetic foot ulcers.

Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skorniick M, Parsons N.

Venous thromboembolism and cardiovascular disease complications in women using transdermal versus oral menopausal estrogen therapy.

Authors: Simon JA, Laliberte F, Duh MS, Pilone D, Kaler KH, Nyirady J, Davis PJ, Lefebvre P.

Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.

Authors: Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA.

Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naive adult patients with type 2 diabetes.

Authors: Virdi NS, Lefebvre P, Parisi H, Duh MS, Pilone D, Laliberte F, Sundaresan D, Garber L, Dirani R.
Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.


**Authors:** Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

Economic Outcomes Associated with Hba1c and Ldl-C Goal Achievement In Patients with Type 2 Diabetes Mellitus.

**Abstract:** International Society for Pharmacoeconomics and Outcomes Research, May 18-22, 2013.

**Authors:** Shi L, Ye X, Lu M, Wu E, Sharma H, Thomason D, Fonseca V.

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs.


**Authors:** Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger JB, Frier BM.

Clinical characteristics, quality measure attainment, and diabetes-related healthcare costs in patients with type 2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).

**Abstract:** 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

**Authors:** Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

Distribution of costs in patients with type 2 diabetes mellitus: A retrospective claims database analysis.

**Abstract:** 49th Annual Meeting of the European Association for the Study of Diabetes, Barcelona, Spain Sep 23-27, 2013.

**Authors:** Bron M, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Lopez C, Viswanathan P, Wu E.

Effects of insulin adherence and delivery device on real world outcomes among patients with Type 2 Diabetes Mellitus (T2DM).

**Abstract:** 73rd Scientific Sessions of the American Diabetes Association, Chicago, IL Jun 21-25, 2013.

**Authors:** Ayyagari R, Wei W, Cheng D, Pan C, Wu EQ.

Improved clinical outcomes associated with dual-goal (HBA1C and LDL-C) achievement in newly diagnosed type 2 diabetes mellitus.

**Abstract:** American Heart Association’s Epidemiology and Prevention/Physical Activity, Nutrition and Metabolism 2013 Scientific Sessions, New Orleans, LA Mar 3-22, 2013.

**Authors:** Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Kang AL, Fonseca VA.

Trend in economic burden of diabetes in urban china from 2009 to 2011.

**Abstract:** International Society for Pharmacoeconomics and Outcomes Research, May 18-22, 2013.

**Authors:** Wu E, Xie J, Du E, Liu M, Liu G.

Clinical and resource utilization outcomes: Elderly type 2 diabetes patients initiating insulin pens versus vials.

**Abstract:** ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

**Authors:** Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.

Comparison of clinical and economic outcomes associated with DPP4i versus SU in combination with MET or PIO for the treatment of type 2 diabetes mellitus.

**Abstract:** 48th Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany Oct 2-5, 2012.

**Authors:** Chen K, Wu E, Cheng D, Bensimon A, Bron M.

Economic burden of type 2 diabetes mellitus in China.

**Abstract:** ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

**Authors:** Zheng Y, Wu EQ, Xie K, Zheng B, Yang HY, Xie J, Wu J.
Glycemic control and quality of life for patients with type 2 diabetes mellitus in China.
Authors: Xie K, Wu J, Xie J, Zheng Y, Yang HY, Wu EQ.

HbA1c reduction associated with initial versus sequential combination therapy with pioglitazone (PIO) and dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with type 2 diabetes mellitus (T2DM).
Authors: Bron M, Chen K, Ayyagari R, Sharma H, Wu EQ.

Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin.
Authors: Signorovitch J, Macaulay D, Diener M, Wu EQ, Gruenberger JB, Frier BM.

The importance of adjustment for placebo-arm effects in indirect comparisons of glycemic control in type 2 diabetes mellitus.
Abstract: 1st American Diabetes Association Middle East Congress., Dubai, UAE Dec 4-6, 2012.
Authors: Ayyagari R, Ong SH, Signorovitch JE, Rikun A, Gruenberger JB.

Physician beliefs about insulin pens versus vials, therapy choice factors, and patient characteristics among elderly type 2 diabetes patients.
Authors: Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.

Predictors of reaching HbA1c goal in T2DM patients using dipeptidyl peptidase-4 inhibitors (DPP-4IS) combination therapy: A subgroup analysis.
Authors: Chen K, Bron M, Cheng D, Sharma H, Wu EQ.

Risk of developing micro- and macrovascular complications in diabetes patients with psoriasis.
Authors: Armstrong AW, Guérin A, Sundaram M, Faust E, Mulani PM.

Effect of diabetes patient characteristics on the willingness-to-pay for a new basal insulin-a discrete choice experiment.
Authors: Yang M, Lin P, Wintfeld N, Frois C.

Health utility for patients with type 2 diabetes mellitus in China.
Authors: Wu J, Xie J, Han R, Wang L, Yang HY, Wu EQ.

Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital.

The direct and indirect costs among U.S. privately insured employees with hypogonadism.
Authors: Kaltenboeck A, Foster S, Ivanova J, Diener M, Bergman R, Birnbaum H, Kinchen K, Swindle R.
Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization.

Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Authors: Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ.

Assessment of Preferences and Willingness-to-Pay for a New Basal Insulin Across Insulin Naïve and Experienced Patients.
Authors: Yang M, Lin P, Wintfeld N, Frois C.

A Discrete Choice Experiment to Evaluate Diabetes Patients Preferences and Willingness-to-Pay for a New Basal Insulin.
Authors: Yang M, Lin P, Wintfeld N, Frois C.

PDB17 Comparison of Clinical and Economic Outcomes Associated with Dpp4 Inhibitors (DPP4I) versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM).
Authors: Bron M, Chen K, Cheng D, Bensimon A, Wu E.

Comparison of hypoglycaemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus in a U.S. population.
Authors: Yang H, Marynchenko M, Bron M, Wu E, Yu AP.

Comparison of hypoglycemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus.
Authors: Yang HY, Marynchenko M, Bron M, Wu EQ, Yu AP.

Cost and frequency of hypoglycemic events in adult and elderly diabetics from an insured managed care population in the U.S.
Abstract: IDF World Diabetes Congress, Dubai, United Arab Emirates Dec 4-8, 2011.
Authors: Bron M, Yang HY, Yu AP, Marynchenko M, Fan L.

The direct and indirect costs associated with hypogonadism among privately-insured employees in the United States.
Authors: Kaltenboeck A, Foster S, Thomas N, Ivanova J, Diener M, Bergman R, Birnbaum H, Swindle R.

Direct healthcare and indirect workloss costs associated with the addition of rosiglitazone (RSG) versus sitagliptin (STG) therapy to metformin (MET).
Authors: Lefebvre P, Sarda SP, Laliberte F, Ramamurthy P, Wei R, Arondekar B, Menditto L, Martin AA, Duh MS.
Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system versus oral estrogen-only hormone therapy.
Authors: Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Abstract: ISPOR 14th Annual European Congress, Madrid, Spain  Nov 5-8, 2011.
Authors: Wu EQ, Guerin A, Latremouille-Viau D, Day R, Khan Z, Zhang F.

Economic burden of psoriatic arthritis and diabetes in patients with psoriatic arthritis in the United States.
Abstract: ACR/ARHP Annual Scientific Meeting, Chicago, IL  Nov 4-9, 2011.
Authors: Guérin A, Gauthier G, Day R, Khan Z, Zhang F.

Factors associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during a hospitalization.
Abstract: 93rd Annual Meeting and Expo of the Endocrine Society, Boston, MA  Jun 4-7, 2011.
Authors: Wu E, Zhou S, AP. Y, Lu M, Graf TR.

Hypoglycaemia in adult vs. elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence in a U.S. population.
Authors: Bron M, Marynchenko M, Yang H, Yang Y, Wu E, Yu AP.

Hypoglycemia in adult versus elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence.
Authors: Bron M, Marynchenko M, Yang HY, Yang Y, Wu EQ, Yu AP.

Hypoglycemia risk factors among veterans with type 2 diabetes treated with oral antidiabetic drugs.
Authors: Shi L, Bron M, Zhao Y, Marynchenko M, Yu AP, Bensimon AG, Wu EQ.

Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes (T2D) initiated on insulin during hospitalization.
Abstract: 93rd Annual Meeting and Expo of the Endocrine Society, Boston, MA  Jun 4-7, 2011.
Authors: Wu E, Zhou S, Yu AP, Lu M, Graf TR.

Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during hospitalisation.

Outcomes associated with insulin therapy disruption after hospital discharge in patients with type 2 diabetes.
Authors: Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

Uncontrolled serum uric acid in veteran gout patients is associated with a higher risk of diabetes.
Abstract: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL  Nov 4-9, 2011.
Use of insulin during and after hospitalization and factors associated with therapy disruption after hospital discharge in type 2 diabetes patients.
*Authors:* Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

Does route of administration for estrogen hormone therapy and estradiol transdermal system dosage strength impact risk of venous thromboembolism.
*Authors:* Kahler KH, Nyirady J, Beresford E, Laliberte F, Dea K, Sheng Duh M, Lefebvre P.

Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.
*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.
*Authors:* Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB.

Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity.

Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.
*Authors:* Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ.

Prevalence rates and costs of metabolic syndrome and associated risk factors using employees’ integrated laboratory data and health care claims.
*Authors:* Birnbaum HG, Mattson ME, Kashima S, Williamson TE.

Association between hypoglycemia and medication possession ratio among veterans with type 2 diabetes mellitus (T2DM).
*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 05-08, 2011.
*Authors:* Zhao Y, Shi L, Fonseca V, Campbell C, Wu EQ.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.
*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

Low lipoprotein cholesterol goal attainment in dyslipidemic patients with existing statin therapy: A chart extraction-based approach.
*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.
*Authors:* Ivanova J, Frois C, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Zhao Z.
Outcomes following insulin therapy disruption after hospital discharge in patients with type 2 diabetes.
Authors: Wu E, Zhou S, Peng Yu A, Lu M, Sharma H, Graf T.

Weighing the clinical benefits and economic impact of bariatric surgery in morbidly obese patients with diabetes.
Authors: Cremieux PY, Eapen S, Trask SW, Ghosh A.

Diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs.
Authors: Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, Wu EQ.

Economic effect of the clinical impact of bariatric surgery on morbidly obese patients with diabetes.
Authors: Ghosh A, Cremieux PY, Klein S, Eapen S, McGavock T.

Relationship of hypoglycemia with medication, discontinuation and costs in type 2 diabetes mellitus patients.
Authors: Bron M, Yu AP, Marynchenko M, Yang H, Sun SX, Dabbous O.

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.
Authors: Laliberte F, Dea K, Dub MS, Kahler KH, Rolli M, Lefebvre P.

The impact of bariatric surgery on comorbidities and medication use among obese patients.
Authors: Cremieux PY, Ledoux S, Clerici C, Cremieux F, Buessing M.

Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
Authors: Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA.

Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes--an application of marginal structural models.
Authors: Yu AP, Yu YF, Nichol MB.

PDB5 Total and diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs from a large US managed care cohort.
Abstract: International Society for Pharmacoeconomics and Outcomes Research, Sep 5-7, 2010.
Authors: Bron M, Yu A, Marynchenko M, Sun S, Yang H, Wu E.

Medical costs in a US managed care cohort with oral antidiabetics maintenance therapy in type 2 diabetes patients who achieved HbAlc<7.0.
Authors: Pandya BJ, Bron M, Yu AP, Chen K, Wu E, Kaltenboeck A, Mattson M, Sun S.
Anti-hypertensive drug use and risk of dementia in patients with diabetes mellitus (DM).
Authors: Johnson ML, Parikh NM, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Morgan R.

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
Publication: Journal of Managed Care Pharmacy 2009 05; 15(4): 312-322.
Authors: Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

Risk factors for dementia in elderly patients with diabetes mellitus.
Authors: Parikh NM, Morgan R, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Johnson M.

Five Minutes with... The Economic Impact of Bariatric Surgery Study Investigators.
Publication: Bariatric Times 2008 11.
Authors: Cremieux P, Buchwald H, Shikora S, Ghosh A, Yang E, Buessing M.

A study on the economic impact of bariatric surgery.
Publication: American Journal of Managed Care 2008 09; 14(9): 589-596.
Authors: Cremieux PY, Buchwald H, Shikora SA, Ghosh A, Yang HE, Buessing M.

Direct and indirect costs among employees with diabetic retinopathy in the United States.
Authors: Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, Birnbaum HG.

Achieving Glycemic Goal with Initial Combination Therapy versus Sequential Augmentation Therapy using Metformin and Pioglitazone.
Abstract: 44th EASD Meeting, Rome, Italy Sep 7-11, 2008.
Authors: Pandya BJ, Yu A, Wu EQ, Chen K, Kaltenboeck A, Seale J, Mattson M, Bron M, Baran RW.

Comparative Glycemic Goal Achievement among Type 2 Diabetes Mellitus Patients Treated with Oral Antidiabetic Monotherapies.
Authors: Wu EQ, Pandya BJ, Yu A, Chen K, Seale J, Kaltenboeck A, Mattson M, Bron M, Baran RW.

Productivity costs associated with cardiometabolic risk factor clusters in the United States.
Authors: Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.
Publication: Current Medical Research and Opinion 2007 09; 23(9): 2035-2042. doi: 10.1185/030079907X210516.
Authors: Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.
Publication: Current Medical Research and Opinion 2007 09; 23(9): 2157-2169. doi: 10.1185/030079907X219544.
Authors: Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.

Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.
Authors: Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.
Authors: Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S.

Authors: Wu E, Xie J, Crémieux P, Sullivan P.

Authors: Wu E, Xie J, Sullivan P.

Glycemic Control, Hypoglycemic Therapy and Subsequent Weight Change among Type 2 Diabetes Patients.

Obesity’s Impact on Diabetes Patients’ Health-Related Quality Of Life In The U.S.
Authors: Crémieux P, Xie J, Greenberg P, Wu EQ, Castor A.

Prevalence of diabetic peripheral neuropathy and associated pain in French adults.
Abstract: Journal of Neurology.

Short Term Economic Impact of Weight Change among Patients with Type 2 Diabetes.

Employment and Income Associated with Obesity and Overweight in the US.
Authors: Wu EQ, Xie J, Sullivan PW.

Employment and Income Associated with Obesity and Overweight in the US.
Abstract: AMCP.

Quality of Life of Obese Adults in the US.
Abstract: International Society for Quality of Life Research.
Authors: Wu EQ, Xie J, Hill JO, Wyatt H, Sullivan PW.

Cost-Effectiveness of Duloxetine versus Routine Treatment for Painful Diabetic Neuropathy in a Randomized Trial from a Societal Prospective.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Birnbaum H, Mareva M, Le TK, Rosen A, Robinson R.

Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.
Authors: Birnbaum H, Leong S, Kabra A.

PDB6: Factors associated with high-risk diabetic patients in the California Medicaid populations (medi-cal).
Authors: Chaikledkaew U, Wu E, Johnson K.
PDB10: A Methodology to identify high-risk patients with diabetes in the California Medicaid population (MEDI-CAL).
Authors: Chaikledkaew U, Wu E, Johnson K.

Productivity and medical costs of diabetes in a large employer population.
Authors: Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P.

Identification of Diabetes Patients Using Claims Data: An Economic Analysis.
Authors: Summers K, Leong S, Birnbaum H, Greenberg P, Kemner J, Ramsey S.

Gastrointestinal

Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome.
Authors: Chen KS, Xie J, Tang W, Zhao J, Jeppesen PB, Signorovitch JE.

Real-world use of faecal calprotectin testing in patients with inflammatory bowel disease.
Authors: Rubin DT, Yang M, Wu EQ, Skup M, Lee WJ.

Public health impact of Rotarix vaccination among commercially insured children in the United States.
Authors: Krishnarajah G, Kageleiry A, Korves C, Lefebvre P, Duh MS.

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.

Publication: Current Medical Research and Opinion 2017 03; 33(3): 529-536. e-pub ahead of print Published online: 12 Jan 2017; doi: 10.1080/03007995.2016.1267616.
Authors: Rubin DT, Patel H, Shi S, Mody R.

Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.

P676 Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
Association of clinical complications and surgery treatment on recurrence of acute diverticulitis.
Authors: Kawatkar AA, Chu L, Nichol MB.

Association of socio-demographics and clinical complications with future medical expenditures in diverticulitis.
Authors: Kawatkar AA, Chu L, Nichol MB.

Evaluation of age, multimorbidity and clinical complications as risk factors for urgent surgical treatment for diverticulitis.
Authors: Kawatkar AA, Chu L, Nichol MB.

Incremental expenditures associated with recurrence of diverticulitis.
Authors: Kawatkar AA, Chu L, Nichol MB.

Realworld adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).
Authors: Patel AK, Duh MS, Barghout VE, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

Trajectories of expenditures associated with acute gastrointestinal diseases.
Authors: Kawatkar AA, Chu L, Nichol MB.

Predictors of response to teduglutide among patients with parenteral nutrition-dependent short bowel syndrome.
Authors: Seidner DL, Joly F, Gabe SM, Mu F, Xie J, Kelkar SS, Chen K, Olivier C.

Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis.
Authors: Guandalini S, Tundia N, Thakkar R, Macaulay D, Essenmacher K, Fuldeore M.

Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn’s disease in Argentina, Brazil, Colombia and Mexico.

Cost-analysis model of colonoscopy preparation using split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).
Authors: Huynh L, Yermakov S, Davis M, Campbell R, Cleveland M, Farraye FA, Yenikomshian M.
Variation in Care for Patients with Irritable Bowel Syndrome in the United States.
Authors:  Lacy BE, Patel H, Guerin A, Dea K, Scopel JL, Alaghband R, Wu EQ, Mody R.

Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.

Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance.
Authors:  Calnan M, Krishnarajah G, Duh MS, Haider BA, Yermakov S, Davis M, Yan S.

Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication.

Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States.
Authors:  Krishnarajah G, Duh MS, Korves C, Demissie K.

Assessment of the real-world safety profile of vedolizumab using the united states food and drug administration adverse event reporting system (FAERS).
Authors:  Cross R, Vekeman F, Xiao Y, Wu EQ, Chao J, Wang A.

Diagnostic testing in IBS patients: Which factors are most strongly associated with more frequent diagnostic tests and procedures?
Authors:  Luo M, Guerin A, Ayyagari R, Shi S, Lopez A, Lacy B.

Identifying higher-value subpopulations for treatment in heterogenous rare diseases: An example study of early responders to teduglutide for short bowel syndrome.
Authors:  Chen K, Xie J, Tang C, Zhao J, Olivier C, Jeppesen PB, Signorovitch J.

Predictors of response to teduglutide among patients with parenteral nutrition-dependent short bowel syndrome.
Authors:  Joly F, Gabe SM, Seidner DL, Mu F, Xie J, Kelkar SS, Chen K, Olivier C.

Comparison of real-world outcomes of adalimumab and infliximab for patients with moderate or severe ulcerative colitis in the United States.
Authors:  Sakuraba A, Sandborn W, Skup M, Macaulay D, Reichmann W, Chao J.
A cost comparison of split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).


Authors: Huynh L, Yermakov S, Davis M, Campbell R, Cleveland M, Farraye FA, Yenikomshian M.

Direct costs in patients with celiac disease—a retrospective claims analysis.


Authors: Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

Direct costs in patients with celiac disease—a retrospective claims analysis.


Authors: Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

Effect of adalimumab dose escalation on hospitalization risk in patients with moderately to severely active ulcerative colitis.


Prevalence of comorbidities in patients with celiac disease.


Authors: Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

Prevalence of comorbidities in patients with celiac disease.


Authors: Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

Cost of hospitalisations among moderate-to-severe Ulcerative Colitis patients treated with adalimumab and conventional non-biologic therapies.


Authors: Wang S, Yang H, Faust E, Bao Y.

Economic Impact of Expanded Use of Biologic Therapy for Crohn's Disease In Latin American Countries.

Abstract: ISPOR 5th Latin America Conference, Santiago, Chile Sept 6-8, 2015.

Authors: Kotze PG, Tundia N, Gumen A, Macaulay D, Chaves L, Bao Y.

Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.


Authors: Cohen R, Skup M, Ozbay AB, Rizzo J, Yang M, Diener M, Chao J.

A cost comparison of split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).


Authors: Cleveland M, Yermakov S, Davis M, Campbell R, Huynh L, Farraye F, Yenikomshian M.

Cost-Utility Analysis of Adalimumab for The Treatment of Moderate-To-Severe Ulcerative Colitis In Patients In Spain.


Authors: Wang S, Yang H, Yang M, Bao Y.
Age-related health care disparities in patients with irritable bowel syndrome: Findings from a sample of commercially insured patients.


Comparison of cost per responder and remitter in patients with inflammatory bowel disease in the united states: An indirect comparison of adalimumab and vedolizumab.

Authors: Liu Y, Ozbay AB, Skup M, Reichmann W, Diener M, Chao J.

Cost-effectiveness of adalimumab for the treatment of moderately to severely active ulcerative colitis in Canada.

Authors: Ghosh S, Desjardins O, Skup M, Wang S, Yang M, Yang H, Qi C, Bao Y, Chao J.

Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis (sub-acute) in the UK.


Indirect comparison of adalimumab and vedolizumab in inflammatory bowel disease in the United Kingdom: cost per responder/remitter analysis.


Regional variation of care for irritable bowel syndrome in the United States.


Prevalence and risk of developing comorbid conditions in patients with chronic constipation.


Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States.

Authors: Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M.

Gastrointestinal comorbidities associated with atrial fibrillation.

Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Schein JR, Lefebvre P.

The impact of moderate-to-severe Crohn’s Disease on employees’ salary growth.

Authors: Loftus EV, Jr., Skup M, Ozbay AB, Wu E, Guerin A, Chao J, Mulani P.

The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.

Authors: Guerin A, Carson RT, Lewis B, Yin D, Kaminsky M, Wu E.
Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation.

Budgetary impact of linaclotide in the treatment of US adult patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC).
Authors: Taylor DCA, Carson RT, Xie J, Dean J, Du EX, Sarocco P, Blum SI.

Impact of the FDA safety communication on prescription trends of clopidogrel in combination with proton pump inhibitors.
Authors: Guerin A, Mody R, Carter V, Wu E.

Medical costs associated with treatment failure with over-the-counter or prescription constipation treatments in patients with IBS-C in a Medicaid population.
Authors: Guérin A, Carson RT, Yin D, Kaminsky MS, Taylor DCA, Sarocco P, Wu EQ.

Quality of life and life enjoyment: An analysis of end colostomy patients.
Authors: Yan S, Yang M, Hoch J, van den Broek N, Xie J, Warusavitarne J.

High risk of leaving the workforce in US employees with ulcerative colitis.
Authors: Cohen R, Rizzo J, Yang M, Skup M, Macaulay D, Behrer C, Fok B, Mulani PM, Chao J.

A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
Publication: Journal of Managed Care Pharmacy 2013 11; 19(9): 755-764.
Authors: Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT.

A health-related quality-of-life study comparing Vitala continence control device versus traditional pouch system only in patients with end colostomy.
Authors: Hoch J, Yang M, Yan S, van den Broek N, Xie J, Warusavitarne J.

Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade.
Authors: Nellesen D, Chawla A, Oh DL, Weissman T, Lavins BJ, Murray CW.

Association between adherence to adalimumab therapy and health care costs for patients with crohn's disease: Claims database analysis.
Authors: Schifrien B, Yen E, Liu Y, Skup M, Tundia N, Ayyagari R, Yang H, Bao Y, Mulani P, Chao J.
Indirect comparison of adalimumab and infliximab in ulcerative colitis: Cost per remitter analysis.
Authors: Liu Y, Reichmann B, Yan S, Macaulay D, Skup M, Mulani P, Chao J.

Su2017 Impact of Chronic Constipation Severity on the Risk of Developing Colorectal Cancer and Benign Neoplasm.
Abstract: Digestive Disease Week, Orlando, FL May 18-21, 2013.
Authors: Guérin A, Mody R, Fok B, Wu EQ, Lasch K, Talley NJ.

Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE.

Assessing preference for deep remission in patients with Crohn’s disease.

Cost-effectiveness model of adalimumab for the treatment of moderate to severe ulcerative colitis in the United Kingdom.
Authors: Ali T, Yang M, Skup M, Yang M, Wu EQ, Chao J, Mulani PM.

Cost-effectiveness of adalimumab for treatment of CROHN’s disease in Germany.
Authors: Yang M, Skup M, Zhou ZY, Hengst N, Wolff M, Mulani PM, Chao J.

Development of three practical indices for mucosal healing among patients with moderate to severe Crohn’s disease.
Authors: Sandborn WJ, Panaccione R, Colombel J-F, Louis E, Yang M, Thakkar R, Chao J, Mulani PM.

Direct and indirect utilization and costs associated with ulcerative colitis.
Authors: Cohen R, Rizzo J, Diener M, Yang M, Skup M, Mulani P, Chao J.

The economic burden of treatment failure in Medicaid patients with irritable bowel syndrome with constipation.
Authors: Guérin A, Carson RT, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ.

The economic burden of unmet treatment needs in Medicaid patients with chronic constipation.
Authors: Carson RT, Guerin A, Lewis B, Yin D, Kaminsky M, Ramakrishnan K, Wu EQ.

Prevalence and risk of developing gastrointestinal conditions in patients with chronic constipation.
Prevalence and risk of developing non-gastrointestinal physical and mental comorbidities in patients with chronic constipation.


Treatment patterns and indicators of unmet needs in Medicaid patients with irritable bowel syndrome with constipation and chronic constipation.

Authors: Carson R, Guérin A, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ.

Comparative colorectal cancer risk in patients with ulcerative colitis treated with adalimumab versus conventional therapy.

Authors: Colombel JF, Thakkar R, Robinson A, Yang M, Skup M, Swallow E, Betts K, Chao J, Mulani P.

Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis in the US.

Authors: Ali T, Skup M, Yang M, Wu E, Mulani P, Chao J.

Risk of developing colorectal cancer and benign neoplasm in patients with chronic constipation.


Risk of gastrointestinal conditions among patients with atrial fibrillation.

Authors: Laliberte F, Dea K, Lamori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

Risk of malignancy, infection, serious infection, and acute health care use in patients with Crohn’s disease treated with adalimumab vs. Immunosuppressants.

Authors: Colombel JF, Thakkar R, Castillo M, Robinson A, Skup M, Yang M, Swallow E, Sorg R, Chao J, Mulani P.

Treatment benefit-risk preferences of patients with early Crohn’s disease.

Authors: Loftus E, Yang M, Skup M, Ivanova J, Sorg R, Chao J, Mulani P.

Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).

Authors: Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, M TA.

Cost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritis.

Authors: Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.
Direct and indirect utilization and costs associated with ulcerative colitis.
Authors: Cohen R, Rizzo J, Diener M, Yang M, Skup M, Mulani P, Chao J.

Gastrointestinal conditions among patients with atrial fibrillation.
Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge M, Damaraju CV, Duh MS, Schein J, Lefebvre P.

Impact of induction dosing on maintenance outcome with adalimumab in Crohn’s disease.

Risk of gastrointestinal conditions among patients with atrial fibrillation.
Authors: Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

The economic and quality of life burden of illness in chronic constipation (CC) and irritable bowel syndrome (IBS): A systematic review.
Authors: Yee K, Nellesen D, Chawla A, Carson R, Lewis B.

A retrospective comparison of health care outcomes in Crohn’s disease patients with and without prolonged steroid monotherapy.
Authors: Siegel CA, Yang HY, Yu AP, Yang M, Mulani PM, Chao J.

Impact of induction dosing on maintenance outcome with adalimumab in Crohn’s disease.

Markov model projection of remission status for early versus delayed step-up adalimumab use in moderate to severe crohn’s disease.
Authors: Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

Markov model projection of remission status for early vs. delayed step-up adalimumab use in moderate to severe Crohn’s disease.
Authors: Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

Increased risks of developing anxiety and depression in young patients with Crohn’s disease.
Authors: Loftus EV, Jr., Guerin A, Yu AP, Wu EQ, Yang M, Chao J, Mulani PM.
Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease.
Publication: Inflammatory Bowel Diseases 2011 01; 17(1): 127-140. doi: 10.1002/ibd.21341.
Authors: Loftus EV, Jr., Johnson SJ, Wang ST, Wu E, Mulani PM, Chao J.

Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (Compairs).
Authors: Sussman DA, Kubiliun N, Chao J, Mulani PM, Gillis CA, Yang M, Lu M, Abreu MT.

C-reactive protein levels in moderate to severe crohn’s disease patients decreased rapidly and significantly during adalimumab therapy.
Authors: Ghosh S, Wu E, Bensimon A, Mulani P, Yang M, Chao J.

Racial differences in use of biologics for crohn’s disease in a Medicaid population.
Authors: Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R.

Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (compairs).
Authors: Sussman D, Kubiliun N, Chao J, Mulani P, Gillis C, Yang M, Lu M, Abreu M.

Racial differences in use of biologics for crohn’s disease in a Medicaid population.
Authors: Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R.

Markov model projection of remission status for early vs. delayed step-Up Adalimumab use in moderate to severe crohn’s disease.
Authors: Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
Authors: Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD.

Systematic review: the costs of ulcerative colitis in Western countries.
Authors: Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J.
M1047 Quality-of-Life Benefits for Adalimumab-Treated Patients with Moderate to Severe Crohn’s Disease are Predicted by Early Mucosal Healing Status.

Authors: Rutgeerts PJ, Thakkar R, Wu EQ, Kaltenboeck A, Yang M, Mulani P, Chao J.

T1065 Impact of Nighttime Symptoms (NTS) on Treatment Patterns and Healthcare Costs Among Gastroesophageal Reflux Disease (GERD) Patients.

Authors: Mody R, Beaulieu N, Wu EQ, Dabbous F, McHale J, Chey WD.

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn’s disease.

Authors: Loftus EV, Jr., Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM.

Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.

Authors: Kothari S, Nelson SP, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

Adalimumab Therapy is Associated with Improvements in Clinical Laboratory Parameters in Patients with Moderately to Severely Active Crohn’s Disease.


Impact of compliance with proton pump inhibitors on NSAID treatment.

Authors: Duh MS, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA.

Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy.

Authors: Nelson SP, Kothari S, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease.


Authors: Chey WD, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, Beaulieu N, Lu M.

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn’s disease: results from the CHARM trial.


S1136 Increased Risk of Clinical Relapse Is Associated with Longer Disease Duration in Crohn’s Disease.

Authors: Rubin DT, Bensimon AG, Yu AP, Wu E, Chao J, Mulani P.
P246-Young patients with Crohn's disease are at increased risk for psychiatric disorders.
Authors: Loftus E, Guérin A, Yu A, Wu E, Chao J, Mulani P.

Corrigendum: Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients with Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial.
Authors: Loftus EV, Feagan BG, Colombel J-F, Rubin DT, Wu EQ, Yu AP, Pollack PF, JINGDONG C, Mulani P.

Cost-effectiveness analysis of adalimumab vs. certolizumab maintenance therapies for moderate to severe Crohn's disease.
Authors: Jonasson S, Kaltenboeck A, Horn C, Mulani P, Majethia S, Chao J.

The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.
Abstract: International Society for Pharmacoeconomics and Outcomes Research 2009.
Authors: Gosselin A, Luo R, Lohoues H, Toy E, Lewis B, Crawley J, Duh MS.

Number-needed-to-treat (NNT) analysis: Remission rates for adalimumab vs. Infliximab in Crohn’s disease.
Authors: Jonasson S, Kaltenboeck A, Horn C, Wu E, Majethia S, Mulani P, Chao J.

Rate of dosage escalation in patients with crohn’s disease treated with infliximab.
Authors: Plevy S, Wu E, Yu A, Chao J, Mulani P.

S1030 Increased Risk of Psychiatric Disorders in Young Patients with Crohn’s Disease.
Authors: Loftus EV, Guérin A, Yu AP, Wu E, Chao J, Mulani P.

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trial.
Authors: Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study.

Loss of treatment response to infliximab maintenance therapy in Crohn’s disease: a payor perspective.
Authors: Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF.

The costs of Crohn’s disease in the United States and other Western countries: a systematic review.
Publication: Current Medical Research and Opinion 2008 02; 24(2): 319-328. doi: 10.1185/030079908X260790.
Authors: Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J.
An evaluation of adalimumab on the risk of hospitalization in patients with Crohn's disease, data from CHARM: O-007.
*Publication*: Inflammatory Bowel Diseases 2008 01; 14: S2-S3.

Adalimumab maintenance therapy for patients with Crohn's Disease is cost effective compared with nonbiologic maintenance therapy: P-0074.

Adalimumab maintenance therapy is cost effective for maintaining remission in patients with Crohn's disease.

Adalimumab Treatment Significantly Reduces Hospitalization Risk for TNF-Antagonist–Naïve Patients with Crohn’s Disease.
*Authors*: Loftus E, Feagan B, Colombel JF, Wu EQ, Yu A, Chao J, Mulani P.

Adherence to Infliximab Maintenance Therapy and Its Impact on Hospitalization of Patients with Crohn's Disease.
*Abstract*: ISPOR 13th Annual International Meeting, Toronto, ON, Canada May 3-7, 2008.
*Authors*: Kane S, Wu EQ, Chen L, Yu A, Tsaneva M, Chao J, Mulani P.

Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn’s disease.
*Authors*: Wu E, Yu A, Tang J, Atanasov P, Chao J, Mulani P.

Health-Related Quality Of Life in TNF-Antagonist–Naïve Patients with Crohn’s Disease during Short- and Long-Term Adalimumab Treatment.
*Authors*: Rubin D, Rutgeerts P, Colombel JF, Wu EQ, Yu A, Chao J, Mulani P.

Infliximab Dosage-Increase Rate in Patients with Crohn's Disease.
*Authors*: Plevy S, Wu EQ, Yu A, Chao J, Mulani P.

M1033 Nighttime Symptoms and Sleep Impairment Among Patients with Gastro-Esophageal Reflux Disease (GERD) Receiving Prescription (Rx) Proton Pump Inhibitors (PPIs).
*Authors*: Chey WD, Mody R, Chen L, Kothari S, Persson B, Wu E, Lu M.

M1041 Are Proton Pump Inhibitors (PPIs) Sufficient in Controlling Symptoms of Gastro-Esophageal Reflux Disease (GERD)?: A Community-Based US Survey Study.
*Authors*: Chey WD, Mody R, Kothari S, Wu E, Chen L, Persson B, Beaulieu N, Lu M.

PGI17 Adherence to infliximab maintenance therapy and its impact on hospitalization of patients with crohn's disease.
*Abstract*: International Society for Pharmacoeconomics and Outcomes Research, 2008.
*Authors*: Kane S, Wu E, Chen L, Yu A, Tsaneva M, Chao J, Mulani P.
T1061 Improvement in short inflammatory bowel disease questionnaire scores in adalimumab-treated Crohn’s disease patients who failed infliximab (CHOICE trial).
Authors: Lichtiger S, Present DH, Wu E, Beaulieu N, Kent JD, Lomax KG, Chao J, Mulani P.

T1062 Improvement in Work Productivity with Adalimumab in Crohn’s Disease Patients Who Failed Prior Infliximab: An Analysis of the CHOICE Trial.
Authors: Lichtiger S, Present DH, Persson B, Wu E, Kent JD, Lomax KG, Chao J, Mulani P.

T1197 A Risk-Benefit Analysis of Adalimumab vs. Standard of Care in Patients with Crohn’s Disease.
Authors: Loftus EV, Colombel J-F, Johnson SJ, Wu E, Chao J, Mulani P.

Differences in Health Care Visits Coded for Potential Proxy Conditions/Symptoms of Gastroesophageal Reflux Disease (GERD) before and after a GERD Diagnosis: A Pediatric Database Study.
Authors: Nelson SP, Kothari S, Wu EQ, Persson B, Beaulieu N, Arana M, Orenstein SR, El-Serag H.

Healthcare Utilization and Cost in Pediatric Gastroesophageal Reflux Disease (GERD) Patients on Continuous vs. Intermittent Proton Pump Inhibitor (PPI) Treatment Regimens.
Authors: Nelson SP, Kothari S, Wu EQ, Persson B, Beaulieu N, Arana M, Lu M.

Impact of adalimumab (HUMIRA (R)) on Patient-Reported Outcomes among Patients with Fistulizing Crohn’s Disease in the CHARM Trial.
Authors: Colombel JF, Wu EQ, Yu AP.

Lower Disease Activity And Clinical Remission Are Associated with Reduced Hospitalization Risk In Crohn’s Disease.
Authors: Wu EQ, Yu AP, Tang J, Atanasov PD, Chao J, Mulani PM.

PGI13 Lower disease activity and clinical remission are associated with reduced hospitalization risk in crohn’s disease.

Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation.
Authors: Sands BE, Duh MS, Cali C, Ajene A, Bohn RL, Miller D, Cole JA, Cook SF, Walker AM.

Loss of Treatment Response among Crohn’s Disease Patients Receiving Infliximab Maintenance Therapy.
Authors: Wu EQ, Yu A, Tang J, Yermakov S, Naeem A, Beaulieu N, Mulani P.

The economic consequences of irritable bowel syndrome: a US employer perspective.
Authors: Leong SA, Barghout V, Birnbaum HG, Thibeault CE, Ben-Hamadi R, Frech F, Ofman JJ.
Alternative Management Strategies for Dyspepsia.
Authors: Wu E, Hay J.

Hematology
Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.
Authors: Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, Duh MS, Nandal S, Blinder M.

Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.

Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis.
Publication: Critical Care Medicine 2018 05; 46(5); 691-698. e-pub ahead of print 2017/12/23; doi: 10.1097/CCM.0000000000002928.

Health resource burden among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: A retrospective chart review study.
Publication: Value in Health 2018 05; 21 (Supplement 1); S259-S260.
Authors: Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin JH, Roy A, Bobbili PJ, Duh MS, Peffault De Latour R.

Value of transfusion independence in severe aplastic anemia from patients’ perspectives – a discrete choice experiment.
Authors: Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Mühlbacher AC, Roy A, Duh MS.

Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
Publication: American Journal of Hematology 2018 93(5); 664-671. doi: http://dx.doi.org/10.1002/ajh.25059.

Health care resource burden among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: A retrospective chart review study.
Authors: Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, Duh MS, De Latour RP.

Health care resource utilization and costs associated with treatment of acute bleeding events among patients with hemophilia A in the United States.
Authors: Song J, Chamberlain C, Rokito A, Cammarota J, Ma E, Xu Y, Betts K.
Matching-adjusted indirect comparisons (MAICs) of efficacy and consumption of bay 94-9027 versus three recombinant factor VIII (RFVIII) for prophylaxis of severe hemophilia A.


*Authors:* Ayyagari R, Deschaseaux C, Vashi PB, Kessabi S, Gao W.

Mediation by patient-reported outcomes of the association between filmcoated or dispersible formulations of deferasirox and serum ferritin reduction: A post hoc analysis of the eclipse trial.


*Authors:* Taher AT, Origa R, Perrotta S, Kouraklis A, Huong V, Han J, Brueederle A, Bobbili PJ, Cheng WY, Duh MS, Porter JB.

Symptoms Following Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy After Achieving an Adequate Response in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).


*Authors:* Ritchie EK, Sadek I, Pivneva I, Guerin A, Latremouille-Viau D, Ndife B, Joseph GJ, Atallah EL.


*Authors:* Carls G, Huynh J, Tuttle E, Yee J, Edelman SV.

Disease-stratified adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.


*Authors:* Cheng WY, Duh MS, Xiao Y, Coe A, Hao Y, Vekeman F, Bobbili PJ, Blinder M.

A Risk Score for Fluconazole Failure among Patients with Candidemia.


Pharmacokinetic parameters, prophylaxis frequency and bleed outcomes of severe hemophilia a patients treated with BAY 81-8973.


Bay 81-8973 prophylaxis frequency and long-term bleed outcomes in the leopold i extension study.


*Authors:* Saxena K, Sajeev G, Ayyagari R, Dua A, Church N, Sanabria M, Afonja OO.

Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.


*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Yermakov S, Karner P.
Impact of U.S. FDA approval of lenalidomide maintenance therapy in the first-line treatment of multiple myeloma after autologous hematopoietic stem cell transplant on total healthcare costs.

**Abstract:** 22th Congress of the European Hematology Association, Madrid, Spain  June 22-25, 2017.

**Authors:** Parikh K, Xie J, Chen C, Yang C, Farrukh A, Cockrum P, Agarwal AB, Abouzaid S.

Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.


**Authors:** Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Yermakov S, Karner P.

Pharmacokinetic parameters, prophylaxis frequency and bleed outcomes of severe hemophilia A patients treated with BAY 81-8973.

**Abstract:** 69th Annual National Hemophilia Foundation meeting Meeting, Chicago, IL  Aug 24-26, 2017.

**Authors:** Sajeev G, Ayyagari R, Shah A, Wang Y, Church n, Guerin A, Afonja O.

Real-world adherence to iron chelation therapy: Comparing a film-coated tablet versus dispersible tablet of deferasirox.

**Abstract:** 22th Congress of the European Hematology Association, Madrid, Spain  June 22-25, 2017.

**Authors:** Cheng W, Xiao Y, Bobbili P, Coe A, Hao Y, Paley C, Said Q, Huang V, Duh MS, Blinder M.

A retrospective chart review to assess burden of illness among patients with severe aplastic anemia with insufficient response to immunosuppressive therapy.

**Abstract:** 59th Annual Meeting of the American Society of Hematology, Washington, DC  Dec 9-12, 2017.

**Authors:** De Latour RP, Huynh L, Ivanova JI, Bilginsoy M, Totev T, Antin JH, Roy A, Duh MS.

Value of transfusion independence in severe aplastic anemia from patients' perspectives-a discrete choice experiment.

**Abstract:** ISPOR 22nd Annual International Meeting, Boston, MA  May 20-24, 2017.

**Authors:** Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Muhlbacher AC, Roy A, Duh MS.

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.

**Abstract:** European Association for the Study of the Liver, 50th International Liver Congress, Vienna, Austria  Apr 22-26, 2015.


Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.


**Authors:** Pocsoki J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J.

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.


**Authors:** Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispencer A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV.
Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.


*Authors:* Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, Duh MS, Paley C, Adams-Graves P.

**Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.**


**Bleed occurrence after bay 81-8973 injection and characteristics of patients who respond to prophylaxis: Analyses from leopold I and II.**

*Abstract:* 9th Annual Congress of the European Association for Haemophilia and Allied Disorders, Malmo, Sweden Feb 3-5, 2016.


**Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.**


**Economic burden of hematologic adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).**


**Epidemiologic and clinical characteristics of thalassemia (THAL) intermedia (TI) in the US.**


**History of sucrose-formulated recombinant factor VIII (rFVIII-FS) Use and reduction in bleeds following bay 81-8973 prophylaxis in leopold I.**


*Authors:* Pocoski J, Ayyagari R, Church N, Sajeev G, Shi S, Mass Enriquez M, Xie J.

**Matching-adjusted indirect comparisons (MAICS) of efficacy of bay 81-8973 vs. 2 Recombinant Factor VIII (rFVIII) for prophylaxis of severe hemophilia A.**

*Abstract:* 9th Annual Congress of the European Association for Haemophilia and Allied Disorders, Malmo, Sweden Feb 3-5, 2016.

*Authors:* Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Xie J.

**A descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV) and/or sofosbuvir (SOF)-based regimens: findings from a U.S. payer database.**


*Authors:* Forlenza J, Fortier J, Laliberté F, Lefebvre P, Tandon N.
Economic consequences of cytomegalovirus disease among stem cell transplant recipients.
Authors: Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snydman DR.

Epidemiologic and clinical characteristics of thalassemia intermedia in the United States.

Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.
Authors: Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

Comparative efficacy and tolerability of combination treatment with daclatasvir and asunaprevir versus peginterferon alpha ribavirin based regimens for patients infected with genotype 1B hepatitis C virus.
Authors: Signorovitch J, Betts K, Song Y, Sorg R, Li J, Behl A, Kalsekar A.

Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor IX FC fusion protein and other recombinant factor IX products.
Authors: Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Karner P.

Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor VIII FC fusion protein and other recombinant factor VIII products.
Authors: Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Karner P.

Factor consumption for prophylaxis and treatment of bleeding: Recombinant factor IX FC fusion protein compared with conventional recombinant factor IX.
Authors: Iorio A, Krishnan S, Myren K, Lethagen S, McCormick N, Karner P.

Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.
Authors: Blinder MA, Duh MS, Sasane M, Trahey A, Paley C, Vekeman F.

Direct and Indirect Cost Burden of Chronic Hepatitis C.

Costs and Resource Utilization Associated with Anemia and Rash in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Agents in the United States.
Publication: Clinical Therapeutics 2015 06. doi: 10.1016/j.clinthera.2015.05.503.
Authors: Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ.
Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.

**Publication:** J Manag Care Spec Pharm 2015 04; 21(4): 308-318.

**Authors:** Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ.

Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.

**Publication:** Leukemia and Lymphoma 2015 03; 56(10): 2803-2811. doi: 10.3109/10428194.2015.1016933.

**Authors:** Vekeman F, Cheng WY, Sasane M, Huynh L, Duh MS, Paley C, Mesa RA.

Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.

**Publication:** Current Medical Research and Opinion 2015 03; 31(3): 513-523. doi: 10.1185/03007995.2014.998815.


Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with thalassemia.

**Abstract:** ISPOR 20th Annual International Meeting, Philadelphia, PA  May 16-20, 2015.

**Authors:** Vekeman F, Sasane M, Cheng WY, Agnihotram RV, Fortier J, Duh MS, Paley C, Adams-Graves P.

Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis c genotype 3: A matching-adjusted indirect comparison.

**Abstract:** 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress, Vienna, Austria  Apr 22-26, 2015.

**Authors:** Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J.

Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in patients with chronic hepatitis C coinfected with HIV: A matching-adjusted indirect comparison.


**Authors:** Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J.

Comparisons of factor consumption for routine prophylaxis and bleeding during episodic therapy with recombinant factor VIII FC fusion protein and conventional recombinant factor VIII.

**Abstract:** ISPOR 18th Annual European Congress, Milan, Italy  Nov 7-11, 2015.

**Authors:** Iorio A, Krishnan S, Myren K, Lethagen S, McCormick N, Karner P.

The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients.

**Abstract:** 57th Annual Meeting of the American Society of Hematology, Orlando, FL  Dec 5-8, 2015.

**Authors:** Guerin A, Ray S, Gauthier G, Hsu L.-I, Zhdanava M, Wu E.

Patterns of prior treatment and bleeds among patients with severe hemophilia a: Impact on frequency of dosing with bay 81-8973 in the leopold I trial.

**Abstract:** 57th Annual Meeting of the American Society of Hematology, San Diego, CA  Dec 3-6, 2016.

**Authors:** Church N, Ayyagari R, Pocsoki J, Sajeev G, Kelkar SS, Du EX, Mass-Enriquez M, Xie J.

Associations between clinical outcomes, health care resources utilization, and quality of life among patients with severe hemophilia A.

**Abstract:** World Federation of Hemophilia, World Congress Melbourne, VIC Australia  May 11-15, 2014.

**Authors:** Lin PL, Pocsoki J, Du EX, Kelkar SS, Silberman C, Xie J.
Demographics, Comorbidities, Clinical Characteristics, and Post-treatment Outcomes for Treated Patients with Chronic Hepatitis C (CHC): A Descriptive Analysis of Real-world U.S. Commercially-insured and Medicare Populations.

Authors: Forlenza JB, Fortier J, Laliberté F, Lefebvre P, Tandon N.

High cost patients and cost patterns from pediatric to adult care in a Medicaid population with sickle cell disease.

Authors: Blinder MA, Sasane M, Fortier J, Paley CS, Duh MS, Vekeman F.

High utilizers of health care resources: Results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy.


Impact of chronic hepatitis C (CHC) treatment on post therapy healthcare cost.

Authors: Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

An indirect comparison of the efficacy of prophylactic use of rF VIII Fc and other rFVIII products and model of the effect of compliance.

Authors: Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

An indirect comparison of the efficacy of prophylactic use of rFIXFc and other rFIX products and simulation of the effect of compliance on effectiveness.

Authors: Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

Indirect comparison of the efficacy of recombinant factor IX Fc fusion protein and other factor IX products for prophylaxis: Simulating the effect of compliance on real-world effectiveness.

Authors: Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

Indirect comparison of the efficacy of recombinant factor VIII Fc fusion protein and other factor VIII products for prophylaxis modeling the effect of compliance.

Authors: Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

Medical complications and resource utilization in blood transfusion-dependent patients with myelofibrosis by iron chelation therapy use.

Authors: Vekeman F, Huynh L, Sasane M, Cheng W, Duh MS, Paley C, Mesa R.

Subcutaneous (SQ) bortezomib (BTZ) in patients (PTS) with relapsed mantle cell lymphoma (MCL): Retrospective, observational study of treatment patterns and outcomes in US community oncology practices.

Authors: Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, Ng Y, Van De Velde H, Dow E, Niculescu L, Bonthapally V, Goy A.
Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
Authors: Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenz RL.

A cost-analysis model for anticoagulant treatment in the hospital setting.
Authors: Mody SH, Huynh L, Zhuo DY, Tran KN, Lefebvre P, Bookhart B.

Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease.
Authors: Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Duh MS, Paley C, Adams-Graves P.

Associations between joint damage and quality of life among patients with severe hemophilia a in the 3-year spinart trial.
Authors: Pocoski J, Lin PL, Hong W, Kelkar SS, Jiao T, Du EX, Humphries TJ, Xie J.

Working title: Contraindications for HCV therapy in United States patients with untreated chronic hepatitis C (CHC).
Authors: Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

Age-related emergency department reliance (EDR) and health care resource utilization in patients with sickle cell disease (SCD).
Authors: Blinder M, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

Direct and indirect cost burden of chronic hepatitis c infection in privately-insured patients, stratified by liver disease severity.

Direct and indirect cost burden of chronic hepatitis C stratified by liver disease severity in privately insured patients.
Abstract: Digestive Disease Week, Orlando, FL May 18-21, 2013.

Impact chronic hepatitis C (CHC) treatment on post therapy healthcare cost.
Authors: Tandon N, Balart L, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

Age-related emergency department reliance (EDR) and healthcare resource utilization in patients with sickle cell disease (SCD).
Authors: Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.
Final results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.

Medical complications in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.
Authors: Vekeman F, Cheng WY, Sasane M, Huynh L, Kaminsky M, Duh MS, Paley C, Mesa RA.

Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Authors: Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS.

Comparable outcomes with bortezomib-cyclophosphamide-dexamethasone (VCD) and bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM).

Final results from the multicenter compact study of complications in patients with sickle cell disease (SCD) and utilization of iron chelation therapy: A retrospective medical records review.

Key cost drivers in the cost of care for sickle cell disease patients: Results of a systematic literature search and a survey of payers and key opinion leaders.
Authors: Jordan L, Duh MS, Vekeman F, Matter S, Bieri C, Sasane M.

Transition from pediatric to adult care of high cost patients in a Medicaid population with sickle cell disease.
Authors: Blinder MA, Sasane M, Fortier J, Paley CS, Duh MS, Vekeman F.

Age-related emergency department reliance and healthcare resource utilization in patients with sickle cell disease.
Authors: Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

Development and validation of a classification algorithm for prophylactic versus on-demand factor VIII therapy in patients with hemophilia A.
Authors: Vekeman F, Pocoski J, Cheng W, Trahey A, Sarda SP, Valluri S, Preblick R, Duh MS.

Improvement in health-related quality of life (HRQoL) with long-term eltrombopag treatment in adults with chronic immune thrombocytopenia (ITP): Results of extend from june 2006 to february 2011.
Authors: Grotzinger K, Bieri C, Olney H, Saleh M, Sheng Duh M, Brainsky A.
Interim results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.

**Abstract:** 17th Congress of the European Hematology Association, Amsterdam, Netherlands Jun 24-17, 2012.


**Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.**


**Authors:** Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

**Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia.**


**Authors:** Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM.

**Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.**


**Authors:** Lafeuille MH, Bailey RA, Vekeman F, Scott McKenzie R, Lefebvre P.

**Development and validation of a classification algorithm for prophylactic versus on-demand factor VIII therapy in patients with hemophilia A.**

**Abstract:** 30th International Congress of the World Federation of Hemophilia, Paris France July 8-12, 2012.

**Authors:** Pocoski J, Vekeman F, Cheng W, Trahey A, Sarda S, Valluri S, Preblick R, Duh M.

**Development and validation of a classification algorithm for prophylactic vs. on-demand factor VIII therapy in patients with hemophilia a.**

**Abstract:** 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

**Authors:** Vekeman F, Pocoski J, Cheng W, Trahey A, Sarda S, Valluri S, Preblick R, Duh M.

**Dynamics of improvement in health-related quality of life (HRQoL) with long-term eltrombopag treatment in adults with chronic immune thrombocytopenia (ITP) in EXTEND.**

**Abstract:** 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

**Authors:** Grotzinger KM, Bussel JB, Saleh MN, Bieri C, Orlova Y, Brainsky A.

**Final results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.**

**Abstract:** 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.


**Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients.**

**Abstract:** ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

**Authors:** Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P.

**Transfusion iron overload (TIO) monitoring and treatment: Findings from an electronic medical records review study at the Moffitt cancer center and research institute.**

**Abstract:** ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

**Authors:** Duh MS, Wetzstein G, Guo A, Sasane M, Sarda SP, Korves C, Wang ST, Wei R, Clinton B, Ray L.
Age-related iron chelation utilization and healthcare costs in patients with Sickle Cell Disease (SCD).


*Authors:* Blinder MA, Vekeman F, Trahey A, Sasane M, Paley CS, Duh MS.

The economics of the hematopoietic growth factors.


*Authors:* Eldar-Lissai A, Lyman GH.

Age-related blood transfusion patterns in patients with Sickle Cell Disease (SCD) and the association with sickle cell complications.


*Authors:* Blinder MA, Vekeman F, Trahey A, Sasane M, Paley CS, Duh MS.

Preoperative hemoglobin levels, characteristics, and resource utilization in total hip replacement patients with an anemia diagnosis versus without an anemia diagnosis: An electronic medical record analysis.


*Authors:* Forlenza JB, Ellis L, Parise H, Lafeuille MH, Lefebvre P.

Risk of venous thromboembolism complications.


*Authors:* Lefebvre P, Laliberte F, Nutescu E, Duh MS, Lamori J, Bookhart BK, Olson W, Dea K, Schein J, Kaatz S.

Monitoring and treatment of transfusional iron overload: Findings from an electronic medical records review study at the Moffitt cancer center and research institute.

*Abstract:* 52nd Annual Meeting of the American Society of Hematology, Orlando, FL  Dec 4-7, 2010.


Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease (SCD).


*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

Persistence and compliance of deferoxamine (DFO) versus deferasirox (DFX) in Medicaid patients with sickle-cell disease (SCD).


*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

Monitoring and treatment among patients with transfusional iron overload: Preliminary findings from an electronic medical records review study at H. Lee moffitt cancer center and research institute.


*Authors:* Ray LA, Wetzstein GA, Korves C, Wang ST, Clinton B, Wei R, Corral M, Duh MS.

Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.


*Authors:* Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbeta M, Piech CT, Lefebvre P.

Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.


*Authors:* Lefebvre P, Vekeman F, Cremieux PY.
Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
*Authors:* Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS.

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
*Authors:* Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.

Association of health-related quality of life (HRQoL), bleeding, and platelet levels in chronic idiopathic thrombocytopenic purpura (itp): Results from RAISE and EXTEND.
*Authors:* Bussel J, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Brainsky A.

Comparison of infection-related hospitalization risk among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
*Authors:* Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

Improvement in fatigue and health-related quality of life (HRQoL) with long-term Eltrombopag therapy in chronic idiopathic thrombocytopenic purpura: results of phase 3, double-blind study(raise).
*Authors:* Provan D, Bussel JB, Cheng G, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Aivado M.

Improvement in fatigue and health-related quality of life with long-term Eltrombopag treatment in adults with chronic idiopathic thrombocytopenic purpura: The EXTEND study.
*Authors:* Bussel J, Saleh M, Salama A, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Aivado M.

Pattern of utilization of pegfilgrastim (PEGFIL) in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.
*Authors:* Skarin AT, Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS.

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
*Authors:* Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Duh MS.

Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.
*Authors:* Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P.

Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
*Authors:* Vekeman F, McKenzie RS, Bookhart BK, Laliberte F, Duh MS, Tak Piech C, Lefebvre P.
An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.

*Authors:* Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.

Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia.

*Authors:* Toy EL, Porter CL, Books P, Vekeman F, Barghout V, Duh M, Skarin AT.

Comparison of infection-related hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

*Authors:* Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML, Esseltine DL, Garrison L.

The cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States.

*Authors:* Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, Van De Velde H, Esseltine DL, Garrison L.

Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.

*Authors:* Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS, Skarin AT.

Persistence and compliance of deferoxamine versus deferasirox in medicaid patients with sickle-cell disease.

*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: Data from multi-center clinical practices.

*Authors:* Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.


*Authors:* Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S.

Anaemia and the risk of injurious falls in a community-dwelling elderly population.

*Authors:* Duh MS, Mody SH, Lefebvre P, Woodman RC, Buteau S, Piech CT.

Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.

*Authors:* Sikand H, Decter A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeeem A.

Management of anemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.

*Publication:* Pharmacoeconomics 2008 01; 26(2): 99-120.
*Authors:* Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE.
Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer’s perspective.
Authors: Moyneur E BB, Mody SH, Founier A, Mallet D, Duh MS.

Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.
Authors: Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS.

Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?
Authors: Wu WK, Duh MS, Lefebvre P.

Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.
Authors: Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF.

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Publication: Drugs and Aging 2006 12; 23(12): 969-976.
Authors: Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.
Authors: Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH.

Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.
Authors: Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS.

Impact and treatment of anemia in the elderly: clinical, epidemiological and economic perspectives.
Authors: Duh MS, Latypova A, Greenberg P.

Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
Authors: Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application.
Authors: Cremieux P, Vekeman F, Lefebvre P.

Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
Authors: Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.
Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.
Publication: Current Medical Research and Opinion 2006 09; 22(9): 1623-1631. doi: 10.1185/030079906X120968.
Authors: Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.

Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
Authors: Chu E, Einhorn LH, Lefebvre P.

Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
Authors: Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.

Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer.
Authors: Gosselin A, McKenzie R, Lifebvre P, Mody S, Piech C, Duh M.

Health-Related Quality Of Life of Anemia Patients in the U.S.
Authors: Cremieux P, Xie J, Wu EQ, Castor A.

Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.
Authors: Campos SM, Duh MS, Lefebvre P, Rosberg J.

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
Authors: Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.

Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia.
Authors: Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA.

Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia.
Authors: Duh MS, L Mark T.

Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve.
Authors: Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman R J.

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia : a meta-analysis.
Authors: Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT.
Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia.
Publication: Journal of Managed Care Pharmacy 2004 11; 10(6): 531-537.
Authors: Cremieux PY, Fastenau JM, Kosicki G, Piech CT, Fendrick AM.

The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.
Authors: Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ.

Red blood cell transfusion and ventilator-associated pneumonia: A potential link?
Authors: Shorr AF, Duh MS, Kelly KM, Kollef MH.

PCN6: Dose conversion of erythropoietic agents in chemotherapy-induced anemia: A meta-analysis.
Authors: Rosberg J, Oster E, Wu E, Fastenau J, Piech C.

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
Authors: Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy.
Authors: Gabrilove JL, Sarokhan B, Cremieux P.

Anemia-related costs for cancer patients.
Authors: Barnett A, Cremieux P, Fendrick A, George M, Slavin M.

Cost Effectiveness of rHuEPO in Oncology.
Authors: Cremieux P, Dial E, Gustafson M, Saroekhan B, Slavin M.

Costs Associated with Anemia and Cancer.
Authors: Cremieux PY GM, Holland M, Slavin MB.

Publication: Pharmacoeconomics 1999 11; 16(5 Pt 1): 459-472.
Authors: Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB.

Infectious Diseases
Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis.
Authors: Yan S, DerSarkissian M, Bhak RH, Lefebvre P, Duh MS, Krishnarajah G.
Adherence to antiretrovirals in medicaid-insured patients living with hiv: Predictors and economic consequences.
Publication: Value in Health 2018 05; 21 (Supplement 1): S150-S151.

Comorbidity and treatment burden among HIV-infected patients in a US medicaid population.
Publication: Value in Health 2018 05; 21 (Supplement 1): S148.
Authors: Der Sarkissian M, Bhak R, Oglesby AK, Priest J, Gao E, Macheca M, Sharperson C, Laliberte F, Duh MS.

Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis.

A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.

Can food help retention in HIV care: A cohort study of adults initiating ART in Haiti.
Publication: Topics in Antiviral Medicine 2018 04; 26 (Supplement 1): 504s-505s.

Early treatment with direct-acting antivirals (DAAs) saves medical costs in non-cirrhotic patients with chronic hepatitis C (CHC) virus infection in the United States (US) Abstract: 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA Nov 9-13, 2018.
Authors: Cacoub P, GonzalezYS, Ionescu-Ittu R, Bondin M, Macaulay D.

Diagnostic yield of active case finding for tuberculosis and HIV at the household level in slums in Haiti.

Retention in Care among Patients with Early HIV Disease in Haiti.
Authors: Hennessey KA, Leger TD, Rivera VR, Marcelin A, McNairy ML, Guiteau C, Devieux JG, Marcelin Y, Charles B, Cremieux PY, Koenig SP, Pape JW.

The Impact of a Community-Based Intervention Including a Monthly Food Ration on Food Insecurity Among HIV-Positive Adults During the First Year of Antiretroviral Therapy.
Publication: AIDS and Behavior 2017 08. e-pub ahead of print 2017/08/30; doi: 10.1007/s10461-017-1897-0.
Authors: Rothman J, Kayigamba F, Hills V, Gupta N, Machera F, Niyigena P, Franke MF.
Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial.

Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy.
Authors: Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS.

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.
Authors: Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J.

Assessing patient preferences for and relative importance of features of new direct acting antiviral (DAA) treatments for chronic hepatitis C virus (HCV) infections.
Abstract: 68th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC.
Authors: Welzel TM, Yang M, Sajeev G, Pinsky B, Mehta D, Bao Y, Wu E, Chen YJ.

A claims-based analysis of hepatitis a, b, and a/b vaccination series completion and compliance among US adults.
Authors: Patterson BJ, Cheng WY, Trofa AF, Duchesneau ED, Macheca M, Masseria C, Duh MS.

The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: Real-world evidence from the United States.
Authors: Reau N, Vekeman F, Wu E, Bao C, Gonzalez YS.

Real-world burden of care for patients with chronic hepatitis C before, during and after treatment with novel direct-acting antiviral agents (DAAs).
Authors: Yang M, Mu F, Macaulay D, Kort JJ, Chen YJ.

Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for the treatment of chronic hepatitis c genotype 1 in Japanese patients: A matching-adjusted indirect comparison.
Abstract: 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Milan, Italy   Nov 7-11, 2015.
Authors: Swallow E, Kelley C, Ristovska L, Signorovitch JE, McPhee F, Wygant G.

Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Abstract: European Association for the Study of the Liver, 50th Internaional Liver Congress, Vienna, Austria   Apr 22-26, 2015.
Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study.

Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients.

Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
*Authors:* Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F.

Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.

Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance.
*Authors:* Calnan M, Krishnarajah G, Duh MS, Haider BA, Yermakov S, Davis M, Yan S.

Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States.
*Authors:* Krishnarajah G, Duh MS, Korves C, Demissie K.

Comparative hepatotoxicity of echinocandins in hospitalized patients (pts): A retrospective cohort study.

Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.

Indirect comparison of daclatasvir-asunaprevir vs sofosbuvir/ledipasvir for HCV in Japanese patients.
*Authors:* Swallow E, Kelley C, Signorovitch J, McPhee F, Wygant G.

Predictors of CD4 count recovery in the CIPRA HT-001 trial of early ART.
*Authors:* Collins SE, Calnan M, Juste MAJ, Severe P, Secours R, Bernard D, Batavia A, Fitzgerald DW, Koenig SP, Pape JW.
Daclatasvir (DCV) combined with sofosbuvir (SOF) or simeprevir (SMV) in liver transplant (LT) recipients with severe recurrent HCV genotype 1 infection.


A descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV)- and/or sofosbuvir (SOF)-based regimens: findings from a U.S. payer database.


Authors: Forlenza J, Fortier J, Laliberté F, Lefebvre P, Tandon N.

Economic consequences of cytomegalovirus disease among stem cell transplant recipients.


Authors: Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snydman DR.

Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.


Authors: Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

Comparative efficacy and tolerability of combination treatment with daclatasvir and asunaprevir versus peginterferon alpha ribavirin based regimens for patients infected with genotype 1B hepatitis C virus.


Authors: Signorovitch J, Betts K, Song Y, Sorg R, Li J, Behl A, Kalsekar A.

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.


Authors: Signorovitch JE, Betts KA, Song Y, Sorg RA, Li J, Behl AS, Kalsekar A.

A second look at the association between gender and mortality on antiretroviral therapy.


Authors: Koenig SP, Bornstein A, Severe K, Fox E, Devieux JG, Severe P, Joseph P, Marcelin A, Bright DA, Pham N, Cremieux P, Pape JW.

Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.


Direct and Indirect Cost Burden of Chronic Hepatitis C.


Simulations Show Diagnostic Testing For Malaria In Young African Children Can Be Cost-Saving Or Cost-Effective.
*Authors:* Phillips V, Njau J, Li S, Kachur P.

Costs and Resource Utilization Associated with Anemia and Rash in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Agents in the United States.
*Publication:* Clinical Therapeutics 2015 06. doi: 10.1016/j.clinthera.2015.05.503.
*Authors:* Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ.

Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.
*Publication:* J Manag Care Spec Pharm 2015 04; 21(4): 308-318.
*Authors:* Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ.

The epidemiology of herpes zoster and its complications in Medicare cancer patients.
*Authors:* Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS.

CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.

Association of Obesity with 30-day readmission rates among patients Hospitalized with Acute Bacterial Skin and Skin-Structure Infections (ABSSI).
*Authors:* Ayyagari R, Revol C, Tang W, Faust E, Tuttle EG.

Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis c genotype 3: A matching-adjusted indirect comparison.

Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in patients with chronic hepatitis C coinfected with HIV: A matching-adjusted indirect comparison.

Contraindications for HCV therapy in U.S. patients with untreated chronic hepatitis C.
*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

Cost burden of cytomegalovirus (CMV) disease among solid organ transplant recipients.

Cost-effectiveness of single versus multiple tablet regimens for treatment of HIV-1 infection.
*Authors:* Sweet DE, Zhuo DY, Macalalad AR, Signorovitch J.
Demographics and clinical characteristics associated with high healthcare resource utilization (hru) and costs among chronic hepatitis C (CHC) patients.
Authors: LaMori J, Tandon N, Laliberte F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

Demographics, Comorbidities, Clinical Characteristics, and Post-treatment Outcomes for Treated Patients with Chronic Hepatitis C (CHC): A Descriptive Analysis of Real-world U.S. Commercially-insured and Medicare Populations.
Authors: Forlenza JB, Fortier J, Laliberté F, Lefebvre P, Tandon N.

Impact of chronic hepatitis C (CHC) treatment on post therapy healthcare cost.
Authors: Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

Real-world persistence with single versus multiple tablet regimens for HIV-1 treatment.
Authors: Sweet DE, Kim Y, Song J, Zhong Y, Signorovitch J.

Treatment patterns, health care resource utilization and costs in united states patients diagnosed with chronic hepatitis C infection.
Authors: Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Arunajadai SG, Wei J, Wu EQ.

Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
Authors: Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States.
Authors: Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M.

Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.
Authors: Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL.

The pharmacoeconomics review of 7-valent pneumococcal conjugate vaccination in Asian-pacific region.
Authors: Zhu L.

Working title: Contraindications for HCV therapy in United States patients with untreated chronic hepatitis C (CHC).
Authors: Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

Budget impact analysis of liposomal amphotericin b and amphotericin b lipid complex for treating invasive fungal infections in hospitalized patients.
Authors: Chaudhari P, Yang H, Zhou ZY, Patel C, Wu EQ.
Direct and indirect cost burden is higher in HCV infection compared with a matched non-HCV infected cohort in a privately-insured population.


Direct and indirect cost burden of chronic hepatitis C infection in privately-insured patients, stratified by liver disease severity.


Direct and indirect cost burden of chronic hepatitis C stratified by liver disease severity in privately insured patients.

*Abstract:* Digestive Disease Week, Orlando, FL  May 18-21, 2013.

*Authors:* Tandon N, Balart L, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

Impact chronic hepatitis C (CHC) treatment on post therapy healthcare cost.


Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naive HIV-1 patients treated with atazanavir/ritonavir versus darunavir/ritonavir.


*Authors:* Xie J, Juday TR, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors.


*Authors:* Rushani D, Kaufman JS, Ionescu-Ittu R, Mackie AS, Pilote L, Therrien J, Marelli AJ.

The epidemiology of herpes zoster (HZ) and its complications in Medicare cancer patients.


*Authors:* Yenikomshian MA, La Casce AS, AT. S, Trahey A, Guignard A, Haguinet FF, Karner PE, Duh MS.

Comparative efficacy at 48 weeks of atazanavir/ritonavir versus darunavir/ritonavir in treatment naive HIV-1 patients: A matching adjusted indirect comparison of randomized trials.


*Authors:* Xie J, Juday T, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

Current trends in utilization and dosage patterns of micafungin and caspofungin in the United States.


*Authors:* Wu EQ, Chaudhari P, Sharma H, Macalalad AR, Horn D.

Prevalence of pseudomonas aeruginosa infection and antibiotic resistance by age group in the CFF patient registry in 2003 and 2008.


*Authors:* Latremouille-Viau D, Zhang J, DeBonnet L, Signorovitch J, Von Wartbu M, Wu EQ, Shi L.
*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.
*Authors:* Shi L, Liu J, Kissinger P, Khan M, Wu EQ.

PIH14 Rates and Predictors of Chlamydia re-Screening among Privately insured Patients with Chlamydia in 2007-2009.
*Abstract:* ISPOR 14th Annual European Congress, Nov 5-8, 2011.
*Authors:* Shi L, Liu J, Kissinger P, Khan M, Wu E.

Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications.
*Authors:* Michna E, Duh MS, Korves C, Dahl JL.

Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?
*Authors:* Wu WK, Duh MS, Lefebvre P.

Lower respiratory tract infections: impact on the workplace.
*Publication:* Pharmacoeconomics 2003 06; 21(10): 749-759.
*Authors:* Birnbaum H, Morley M, Leong S, Greenberg P, Colice G.

Economic burden of respiratory infections in an employed population.
*Publication:* Chest 2002 08; 122(2): 603-611.
*Authors:* Birnbaum HG, Morley M, Greenberg PE, Colice GL.

Neurology

Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer’s Disease.
*Authors:* Kirson NY, Scott Andrews J, Desai U, King SB, Schonfeld S, Birnbaum HG, Ball DE, Kahle-Wrobleski K.

The economic burden of bipolar I disorder in the United States in 2015.
*Authors:* Cloutier M, Greene M, Guerin A, Touya M, Wu E.

Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis.
*Authors:* Pilon D, Amos TB, Kamstra R, Manceur AM, El Khoury AC, Lefebvre P.

Epilepsy treatment patterns among patients with tuberous sclerosis complex.
Health Care Resource Utilization and Costs Associated with Transitioning to 3-Month Paliperidone Palmitate Among US Veterans.

Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States.
Authors: Zhou Z, Betts KA, Bocharova I, Kinrich D, Spalding WM.

Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials.
Authors: Slater J, Chung S, Huynh L, Duh MS, Gorin B, McMicken C, Ziemann A, Isojarvi J.

Treatment patterns among adults with ADHD receiving long-acting therapy.
Publication: American Journal of Managed Care 2018 07; 24(8 Spec No.): Sp329-sp337. e-pub ahead of print 2018/07/19.
Authors: Zhou Z, Zhou ZY, Kellar SS, Sikirica V, Xie J, Grebla R.

Examining a Statewide Educational Consulting Program for Pediatric Brain Injury.
Authors: Myers RK, Eagan-Brown BL, Conway AT, Nagele DA, Vaccaro MJ, Kendi S, Zonfrillo MR.

Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States.
Authors: Zhou Z, Zhou ZY, Kelkar SS, Sikirica V, Xie J, Grebla R.

One-Year Effect of the Medicare Annual Wellness Visit on Detection of Cognitive Impairment: A Cohort Study.
Authors: Fowler NR, Campbell NL, Pohl GM, Munsie LM, Kirson NY, Desai U, Trieschman EJ, Meiselbach MK, Andrews JS, Boustani MA.

Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.
Authors: Kantor D, Johnson K, Vieira MC, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera V.

Authors: Dell’Agnello G, Desai U, Kirson NY, Wen J, Meiselbach MK, Reed CC, Belger M, Lenox-Smith A, Martinez C, Rasmussen J.
Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.

Authors: Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE.

Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics.
Authors: Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K.

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
Authors: Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA.

Development of a prognostic model for 1-year change in timed 4 stair-climb in duchenne patients.
Authors: Goemans N, Vanden Hauwe M, Signorovitch J, Sajeev G, Yao Z, Jenkins M, McDonald E, Dieye I, Ward SJ.

The humanistic burden of postpartum depression: A systematic literature review.
Abstract: ISPOR 23rd Annual International Meeting
Baltimore, MD May 19-23, 2018.
Authors: Reinhart M, Patton C, Chawla A, Clemson C, Huang M.


Outcomes among medicaid recipients with schizophrenia treated with once-every-three month paliperidone palmitate.
Abstract: ISPOR 23rd Annual International Meeting
Baltimore, MD May 19-23, 2018.
Authors: Joshi K, Lafeuille M, Pilon D, Emond B, Romdhani H, Lefebvre P, El Khoury AC.

Treatment patterns and medicaid spending in comorbid schizophrenia populations: Once-monthly paliperidone palmitate vs oral atypical antipsychotics.
Abstract: ISPOR 23rd Annual International Meeting
Baltimore, MD May 19-23, 2018.
Authors: Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K.
Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?
Authors: Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

Authors: Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP.

Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States.

Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.

Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
Authors: Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ.

Authors: Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K.

Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.

Health care resource utilization before and after perampanel initiation for the treatment of epilepsy in the United States.

Health Services Utilization Among Fee-for-Service Medicare and Medicaid Patients Under Age 65 with Behavioral Health Illness at an Urban Safety Net Hospital.
Authors: Cancino RS, Jack BW, Jarvis J, Cummings AK, Cooper E, Cremieux PY, Burgess JF, Jr.
Authors: Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak RH, Duh MS, Shiner B, Young-Xu Y.

Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis.
Authors: Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S.

Is the annual wellness visit adequate to impact cognitive care?
Authors: Fowler NR, Campbell NL, Pohl GM, Munsie LM, Kirson NY, Desai U, Trieschman EJ, Meiselbach MK, Andrews JS, Tanaka Y, Boustan MA.

Trends in health service use and potentially avoidable hospitalizations prior to Alzheimer’s disease diagnosis: A matched, retrospective study of U.S. medicare beneficiaries.

Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome.
Authors: Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Saurer TB, Isojarvi J.

Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.

Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.
Authors: Nelson WW, Laliberte F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P.

Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program.
Authors: Pilon D, Amos TB, Germain G, Lafeuille MH, Lefebvre P, Benson CJ.

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.
Authors: Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V.

Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.
Authors: Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D.
Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.


*Authors:* Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, Lefebvre P.

Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States population-based survey.

*Publication:* Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring 2017 02; 6: 65-74. doi: http://dx.doi.org/10.1016/j.dadm.2016.11.005.

*Authors:* Desai U, Kirson NY, Enloe CJ, Ristovska L, King S, Birnbaum HG.

Real-world costs of ischemic stroke by discharge status.


*Authors:* Mu F, Hurley D, Betts KA, Messali AJ, Paschoalin M, Kelley C, Wu EQ.

Adherence and Persistence on Long-acting Monotherapy and Combination Therapy in Adults with Attention-Deficit Hyperactivity Disorder (ADHD) in the US.


*Authors:* Zhou Z, ZY Zhou, Kelkar SS, Xie J, Grebla R.

Assessing Preferences for Attributes of Disease-Modifying Therapies among Patients with Relapsing-Form of Multiple Sclerosis: A Discrete Choice Study.


The Burden of Tardive Dyskinesia Secondary to Antipsychotic Medication Use among Patient with Mental Disorders.


*Authors:* McEnvoy J, Park T, Schilling T, Terasawa E, Ayyagari R, Carroll B.

Deflazacort or prednisone treatment for duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.


*Authors:* Signorovitch JE, Sajeev G, McDonnell E, Yao Z.

Economic burden of illness for patients with traumatic brain injury resulting in chronic motor impairment.


Healthcare costs among patients with lennox-gastaut syndrome treated with clobazam.


*Authors:* Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Shen Y, Duh MS, Chatamra K, Kymes SM.

Healthcare resource utilization among patients with lennox-gastaut syndrome treated with clobazam.


Healthcare resource utilization and costs among adult schizophrenia patients using once-monthly versus
twice-monthly long-acting antipsychotics.
Authors: Benson C, Alcusky M, Pilon D, Durkin M, Xiao Y, Thompson-Leduc P, Lafeuille M, Lefebvre P.

Impact of ocrelizumab vs. interferon beta-1a in delaying the deterioration of patients' daily functions and
associated costs in relapsing-remitting multiple sclerosis.
Authors: Yang H, Duchesneau ED, Geruin A, Ma E, Thomas NP.

Incremental risk of ischemic stroke over time in newly diagnosed heart failure patients without atrial
fibrillation.
Abstract: 66th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in
Authors: Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

Stroke and myocardial infarction risk among newly diagnosed heart failure patients with reduced, borderline,
and preserved left ventricle ejection fraction.
Abstract: 21st Annual Scientific Meeting of the Heart Failure Society of America, Gravevine, TX Sept 16-19, 2017.
Authors: Fonarow GC, Peterson ED, Greenberg B, Berger JS, Laliberte F, Zhao Q, Germain G, Lejeune D, Lefebvre P.

A systematic literature review and meta-analysis of epidemiologic studies in chronic and episodic migraine.

A systematic literature review and meta-analysis of prevalence estimates in migraine.
Abstract: 11th European Headache Federation Congress Jointly with 31st Congress of the Italian Society for the Study

Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.
Authors: Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pesa J, Clancy Z, Fastenau J, Durkin M.

Impact of Paliperidone Palmitate versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs
in Veterans with Schizophrenia.
Publication: Journal of Clinical Psychiatry 2016 10; 77(10): e1332-e1341. e-pub ahead of print 2016/08/31; doi:
10.4088/JCP.16m10745.
Authors: Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B.

Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular
Dystrophy.
Publication: PloS One 2016 10; 11(10): e0164684. e-pub ahead of print 2016/10/14; doi:
10.1371/journal.pone.0164684.
Authors: Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J, Collaborative Trajectory Analysis P.

Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists.
Authors: Kirson NY, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Ye W, Andrews JS, Ball D, Kahle-Wrobleski K.

Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
Authors: Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ, Group DMDI, Trajectory Analysis P.

Excess Costs Associated with Possible Misdiagnosis of Alzheimer’s Disease Among Patients with Vascular Dementia in a UK CPRD Population.
Authors: Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Reed C, Belger M, Lenox-Smith A, Price D.

Persistent use of dalfampridine extended release on healthcare resource utilization and cost in multiple sclerosis: A claims database analysis.
Authors: Krieger S, Niyazov A, Macaulay D, Terasawa E, Wu E, Aupperle P, Guo A.

Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective.

Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine.
Authors: Joseph A, Cloutier M, Guerin A, Nitulescu R, Sikirica V.

Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
Authors: Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.

Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.
Authors: Vollmer T, Huynh L, Kelley C, Galebach P, Signorovitch J, DiBernardo A, Sasane R.

Adherence to QD vs. BID medications in nvaf patients is associated with reduced risk of ischemic stroke: A modeling study using rct and claims data.

Association of Rescue Medication Use with Clinical Outcomes and Health Care Costs in Patients with Seizure Clusters.
Can indirect comparison methods mitigate evolving trial populations in adjunctive antiepileptic drug trials? A propensity score matched indirect comparison of brivaracetam and levetiracetam.

Authors: Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.
Authors: Quinlan SC, Cheng WY, Ishihara L, Irizarry MC, Holick CN, Duh MS.

Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare resource use and costs in veterans with schizophrenia with limited antipsychotic exposure in the prior 12 months.
Authors: Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak R, Kageleiry A, Duh MS, Shiner B, Young-Xu Y.

Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the first-HD and tetra-HD trials.
Authors: Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D.

A life-course assessment of medication use and medical costs of lennox-gastaut syndrome (LGS).
Authors: Montouris G, Pina-Garza JE, Vekeman F, Cheng WY, Tuttle EG, Giguere-Duval P, Duh MS, Isojarvi J.

Non-motor symptoms in advanced Parkinson’s disease patients treated with levodopa/carbidopa intestinal gel, deep brain stimulation, or continuous subcutaneous apomorphine: A systematic literature review and pooled analysis.

Persistent use of dalfampridine extended release on healthcare resource utilization and cost in multiple sclerosis: A claims database analysis.
Authors: Krieger S, Niyazov A, Macaulay D, Terasawa E, Wu E, Aupperle P, Guo A.

Prognostic model for 1-year change in 6-minute walk distance (6MWD) in patients with duchenne muscular dystrophy (DMD).
Abstract: 14th International Congress on Neuromuscular Diseases, Toronto, CA    July 5-9, 2016.
Authors: Goemans NM, Signorovitch J, Swallow E, Song J, Ward SJ.

Real-world costs of ischemic stroke by discharge status.
Authors: Mu F, Hurley D, Betts K, Messali A, Paschoalin M, Wu EQ.

Authors: Fox E, Johnson K, Lin F, Signorovitch J, Li N, Peeples M, Ristovska L, Souroutzidis A, Hong W, Herrera V.
Risk of ischemic stroke in newly diagnosed heart failure patients.
Authors: Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
Authors: Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.

Development of a classifier to identify Lennox-Gastaut Syndrome.
Authors: Piña-Garza JE, Vekeman F, Cheng WY, Tuttle E, Giguerue-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Isojarvi J, Montouris GD.

Functional limitations and healthcare resource utilization for individuals with cognitive impairment without dementia: Findings from a U.S. population-based survey.

Healthcare resource utilization associated with rescue medication use in adult patients with seizure clusters: A retrospective chart review.
Authors: Vazquez B, Sidovar M, Squillacote D, Wu E, Macaulay D, Sorg R, Guo A.

A life-course assessment of treatment patterns and healthcare costs of Lennox-Gastaut syndrome.
Authors: Montouris GD, Piña-Garza JE, Vekeman F, Cheng WY, Tuttle E, Giguerue-Duval P, Duh MS, Shen V, Isojarvi J.

Predicting factors for reaching stabilized maintenance with once-monthly paliperidone almitate in Medicaid patients with schizophrenia.
Authors: Muser E, Pilon D, Emond B, Xiao Y, Amos T, Lefebvre P, Benson C.

Predictors of receiving at least 5 claims for once monthly paliperidone palmitate among Medicaid patients with schizophrenia.
Authors: Lafeuille MH, Xiao Y, Muser E, Pesa J, Fastenau J, Duh MS, Lefebvre P.

Real-world treatment outcomes in adults with attention deficit/hyperactivity disorder treated with lisdexamfetamine versus atomoxetine following methylphenidate treatment.
Authors: A. Joseph, M. Cloutier, A. Guérin, R. Nitulescu, V. Sikirica.
Treatment patterns in schizophrenia patients reaching stabilized maintenance therapy with once-monthly paliperidone palmitate.

Authors: Amos T, Pilon D, Muser E, Emond B, Xiao Y, Lefebvre P, Benson C.

Development of a risk score to guide individualized treatment selection in attention-deficit/hyperactivity disorder.


Systematic literature review and mixed treatment comparison of guanfacine extended release (GXR) versus other pharmacotherapies in children and adolescents with attention deficit/hyperactivity disorder (ADHD).

Authors: Joseph A, Xie J, Bischof M, Zhanabekova Z, Cai S, Zhuo Y, Huss M, Sikirica V.

The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis.
Authors: Vollmer T, Signorovitch J, Huynh L, Galebach P, Kelley C, DiBernardo A, Sasane R.

Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.
Authors: Kruse G, Wong BJ, Duh MS, Lefebvre P, Lafeuille MH, Fastenau JM.

Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
Abstract: International Society for Pharmacoeconomics and Outcomes Research, Sep 2015.
Authors: Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder MH.

Patient and Caregiver Burden Associated with Fragile X Syndrome in the United States.
Authors: Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P.

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.

Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients.
Authors: Xiao Y, Muser E, Lafeuille MH, Pesa J, Fastenau J, Duh MS, Lefebvre P.

Medical costs of Alzheimer’s disease misdiagnosis among US Medicare beneficiaries.
Authors: Hunter CA, Kirson NY, Desai U, Cummings AK, Faries DE, Birnbaum HG.
Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.
Authors: Zhou ZY, Sun S, Chopra P, Zhong Y, Totev T, Signorovitch J.

Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.
Authors: Yermakov S, Davis M, Calnan M, Fay M, Cox-Buckley B, Sarda S, Duh MS, Iyer R.

Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.
Authors: Lefeuille MH, Grittner AM, Fortier J, Muser E, Fasteneau J, Duh MS, Lefebvre P.

The economic burden of adults with major depressive disorder in the United States (2005 and 2010).
Authors: Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC.

The Growing Economic Burden of Depression in the U.S.
Publication: Scientific American MIND Guest Blog 2015 02.
Authors: Greenberg P.

Bone pain, skeletal related events and opioid use in patients with prostate cancer and bone metastases.
Authors: Valderrama A, Eapen S, Hennessey KA, Jones C, Wen L, Germino J, Duh MS.

The burden of treatment switch in patients with major depression: A US retrospective administrative claims analysis.
Authors: Perez V, Gauthier G, Guerin A, Francois C, Merikle E.

Description of prophylactic drug utilization patterns in migraine patients.
Authors: Shei A, Woolley JM, Desai PR, Enloe CJ, Kirson NY, Birnbaum HG, Corey-Lisle PK, Sapra S.

Healthcare Utilization and costs among Adults with Major depressive Disorder treated with Vilazodone vs. Other selective Serotonin Reuptake Inhibitors.
Authors: Zhou Z, Sun SX, Chopra P, Zhong Y, Totev T, Signorovitch JE.

Relative efficacy and tolerability of vortioxetine versus approved antidepressants for major depressive disorder: A meta-regression of clinical trials.
Authors: Diamand F, Danchenko N, Brignone M, Rive B, Perez V, Ereshefsky L, Francois C, Merikle E.

A systematic review and network meta-analysis of eslicarbazepine acetate and other recently-approved anti-epileptic drugs for adjunctive treatment of partial-onset seizures in adults.
Authors: Betts K, Bolli V, De G, Blum D, Velez F.
Treatment patterns among chronic users of immediate-release oxycodone initiating treatment with extended-release opioids.
Authors: Pergolizzi JV, Kirson NY, Bell J, Jones C, Mantovanelli F, Cummings AG, Birnbaum HG, Ben-Jospeh R.

Assessing the economic burden of Alzheimer’s disease patients treated by specialists within three months of preliminary diagnosis of cognitive decline.
Abstract: Alzheimer’s Association International Conference, Copenhagen, Denmark July 12-17, 2014.

Assessing the impact of time-dependent treatment with once-monthly paliperidone palmitate or oral atypical antipsychotics on healthcare resource utilization and Medicaid spending among patients with schizophrenia using marginal structural models.
Authors: Muser E, Lafeuille M, Xiao Y, Lefebvre P, Pesa J, Fastenau J, Duh MS.

Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.
Abstract: 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting Boston, MA Sept 9-13, 2014.

Comparison of healthcare resource utilization and Medicaid spending among patients with schizophrenia treated with once monthly paliperidone palmitate or oral atypical antipsychotics using the inverse probability of treatment weighting approach.
Authors: Muser E, Lafeuille M, Xiao Y, Lefebvre P, Pesa J, Fastenau J, Duh MS.

Comparison of re-hospitalization and emergency room visit patterns among patients with schizophrenia receiving paliperidone palmitate or oral atypical antipsychotics in an inpatient setting.
Authors: Lafeuille MH, Grittner AM, Fortier J, Muser E, Fastenau J, Duh MS, Lefebvre P.

Comparison of re-hospitalization, emergency room visits, and hospital costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics in an inpatient setting.
Authors: Lafeuille MH, Grittner AM, Fortier J, Muser E, Fastenau J, Duh MS, Lefebvre P.

The economic burden of central nervous system events among patients with partial onset seizures treated with antiepileptic drugs.

Effect of improving adherence to disease-modifying agents on health care resource utilization and medical costs in patients with multiple sclerosis.
Authors: Yermakov S, Davis M, Calnan M, Fay M, Duh M, Iyer R.
Excess costs associated with possible misdiagnosis of Alzheimer’s disease among patients with vascular dementia in a UK CPRD population.

*Abstract:* Alzheimer’s Association International Conference, Copenhagen, Denmark  Jul 12-17, 2014.

*Authors:* Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Price D, Belger M, Hunter CA, Lenox-Smith AJ, Reed CC.

Factors associated with performance on the Medicaid HEDIS measure: Continuity of antipsychotic (AP) medications for treatment of schizophrenia.


*Authors:* Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pesa JA, Clancy Z, Fastenau J, Durkin M.

Healthcare resource utilization prior to first diagnosis in patients with newly diagnosed fragile x syndrome (FXS): A multi-state Medicaid perspective.


*Authors:* Signorovitch J, Wu E, Li N, Chopra P.

Impact of improved adherence to disease-modifying therapies on healthcare resource utilization and medical costs for patients with multiple sclerosis.

*Abstract:* 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA  Sep 10-13, 2014.

*Authors:* Yermakov S, Davis M, Calnan M, Fay M, Buckley B, Sarda S, Duh MS, Iyer R.

Impact of treatment-associated adverse events on healthcare resource utilization and costs among patients with partial onset seizures: A longitudinal analysis.


Medical specialists involved in caring for patients with fragile x syndrome (FXS): a Medicaid perspective.


Medication use, medical services and comorbidities associated with fragile x syndrome (FXS): A multi-state Medicaid perspective.


*Authors:* Signorovitch J, Wu E, Li N, Chopra P.

The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis.

*Abstract:* 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA  Sep 10-13, 2014.


*Abstract:* 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA  Sep 10-13, 2014.

*Authors:* Nazareth T, Marvel J, Sikirica S, Xie J, Reichmann W, Zhao C, Sasane R.
Pulse pressure and stroke risk: development and validation of a new stroke risk model.

Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in Quebec.

Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in Quebec.

Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder.
Authors: Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson TM, Xie J, Erder MH, Dammerman RS, Robertson B, Wu EQ.

Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review.
Authors: Gajria K, Lu M, Sikirica V, Greven P, Zhong Y, Qin P, Xie J.

Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.
Authors: Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.
Authors: Betts KA, Sikirica V, Hodgkins P, Zhou Z, Xie J, DeLeon A, Erder MH, Wu EQ.

Burden of schizophrenia on selected comorbidity costs.
Authors: Lafeuille MH, Dean J, Fastenau J, Panish J, Olson W, Markowitz M, Duh MS, Lefebvre P.

HD-PRO-TRIAD Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease.
Publication: Tremor Other Hyperkinet Mov (N Y) 2014 04; 4: 223. doi: 10.7916/D8PN93NZ.

Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives.
Publication: Tremor Other Hyperkinet Mov (N Y) 2014 04; 4: 224. doi: 10.7916/D8JW88WS.
Implications of early treatment among Medicaid patients with Alzheimer’s disease.
Authors: Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN.

Authors: Mortimer R, Privopoulos M, Kumar S.

Clinical characteristics and treatment pattern in cluster seizures: A preliminary chart review analysis.
Authors: Vazquez B, Wu E, Macaulay D, Sidovar M, Roberts H, Squillacote D, Rabinowicz AL, Guo A.

Healthcare resource utilization preceding first diagnosis for fragile x syndrome (fxs).

Pulse pressure and stroke risk: Development and validation of a new stroke risk model.
Authors: Vekeman F, Ayyagari R, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Systematic literature review and mixed treatment comparison of GXR versus other treatments in children and adolescents with attention deficit hyperactivity disorder (ADHD).
Authors: Joseph A, Ayyagari R, Bischof M, Cai S, Xie M, Zhanabekova Z, Sikirica V.

Systematic review of long-acting injectables (LAI) versus oral atypical antipsychotics (OA) on hospitalization in schizophrenia.
Authors: Lafeuille MH, Cloutier M, Fortier J, Duh MS, Fastenau J, Dirani R, Lefebvre P.

Treatment patterns of patients receiving paliperidone palmitate in an inpatient setting.
Authors: Lafeuille MH, Fortier J, Grittner AM, Muser E, Fastenau J, Duh MS, Lefebvre P.

Assessing the impact of a Medicaid prior authorization (PA) policy for duloxetine on antipsychotic use among patients with depression.
Authors: Birnbaum HG, Ivanova JI, Waldman T, Swallow E, Cummings AK, Clark T, Peng X, Swindle R.

Burden of schizophrenia on selected comorbidities costs.
Authors: Lafeuille MH, Dean J, Fastenau J, Panish JM, Olson WH, Markowitz M, Duh MS, Lefebvre P.

A meta-analysis of efficacy and safety of prescription opioids, including formulations with tamper-resistant technologies, in non-cancer pain management.

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.
Authors: Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS.
Glioblastoma treatment patterns and outcomes and resource use in the United States.

Guanfacine immediate release vs. Guanfacine extended release: Comparative medication adherence, resource utilization, and healthcare costs among children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
Authors: Sikirica V, Xie J, He TL, Erder MH, Hodgkins P, Yang H.

Cost utility of hub-and-spoke telestroke networks from societal perspective.
Publication: American Journal of Managed Care 2013 12; 19(12): 976-985.
Authors: Demaerschalk BM, Switzer JA, Xie J, Fan L, Villa LF, Wu EQ.

Authors: Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ.

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.
Authors: Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS.

Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.
Authors: Setyawan J, Guerin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH.

Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
Authors: Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH.

Costs of Parkinson’s disease in a privately insured population.
Authors: Johnson SJ, Kaltenboeck A, Diener M, Birnbaum HG, Grubb E, Castelli-Haley J, Siderowf AD.

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis.
Authors: Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS.

Pre-diagnosis excess acute care costs in Alzheimer’s patients among a US Medicaid population.
Authors: Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN.
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.


*Authors:* Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu EQ, Erder MH.

Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.


*Authors:* Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B.

Authors’ reply to Alatorre et al.: “cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison”.


*Authors:* Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.


*Authors:* Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ.

An economic model of Parkinson’s disease: implications for slowing progression in the United States.


*Authors:* Johnson SJ, Diener MD, Kaltenboeck A, Birnbaum HG, Siderowf AD.

Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals’ perspectives.


*Authors:* Switzer JA, Demaerschalk BM, Xie J, Fan L, Villa KF, Wu EQ.


*Abstract:* American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL  Mar 1-5, 2013.

*Authors:* Cather JC, Sundaram M, Horn EJ, Yang M, Signorovitch JE.

Development and validation of a claims-based algorithm to identify urinary retention in patients receiving antiepileptic drugs.


*Authors:* Duh MS, Ishihara L, Cheng W, Quinlan SC, Zhao Y, Irizarry M.

An economic model of improved acute stroke care in the management of acute ischemic stroke from a state Medicaid perspective.


*Authors:* Zhou ZY, Fan L, Chen E, Xie J, Wu EQ.

Excess costs associated with misdiagnosis of Alzheimer’s disease among u.s. Medicare beneficiaries with vascular dementia or parkinson’s disease.


*Authors:* Kirson N, Hunter C, Desai U, Cummings A, San Roman A, Faries D, Hardwick C, Birnbaum H.
Health care resource use and direct costs associated with fragile x syndrome (FXS) in the United States.

*Authors:* Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P.

Health care resource utilization and costs associated with atypical antipsychotics use in children and adolescents with attention deficit/hyperactivity disorder in Quebec, Canada.


Incidence of stimulant augmentation among children and adolescents with attention/deficit hyperactivity disorder (ADHD) during 2010.

*Authors:* Betts KA, Sikirica V, Hodgkins P, Du E, Zhou Z, Erder HM, Wu EQ.

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.

*Authors:* Lafeuille MH, Gravel J, Lefebvre P, Fasteneau J, Muser E, Doshi D, Dug MS.

Period prevalence of therapy combination and switching among children and adolescents with attention deficit/hyperactivity disorder (ADHD) treated with stimulants in the Canadian province of Quebec.


Pulse pressure and stroke risk: Development and validation of a stroke risk equation.

*Authors:* Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

Therapy combination: a prevalent pattern among children and adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with stimulants in the Canadian province of Quebec.

*Abstract:* World Congress on ADHD, Milan, Italy June 6-9, 2013.

Associations of hypertension with risk of cardiovascular events among Chinese stroke patients in the US.

*Authors:* Fung G, Kahler K, Xie J, Marynchenko M, Wu E, Kam I, Yang W.

Comparison of discontinuation risk in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of attention deficit/hyperactivity disorder (ADHD): A retrospective claims analysis.

*Abstract:* 20th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, Paris France Jul 21-25, 2012.

A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. nonantipsychotics.

*Authors:* Betts KA, Piszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH.
A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. nonantipsychotics.

Authors: Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH.

Period prevalence of stimulant augmentation among pediatric attention deficit/hyperactivity disorder (ADHD) patients during 2009: A retrospective analysis of a managed care population.

Authors: Sikirica V, DiBello J, Betts KA, Hodgkins PS, Zhou ZY, Xie J, DeLeon A, Erder MH, EQ W.

Risk of cardiovascular events associated with hypertension among chinese and caucasian stroke patients in the US.

Authors: Fung G, Kahler K, Xie J, Liu N, Wu E, Kam I, Yang W.

Treatment patterns, resource utilization and costs associated with guanfacine immediate release versus guanfacine extended release among children and adolescents with attention deficit/hyperactivity disorder (ADHD).

Authors: DiBello J, Sikirica V, Samuelson T, Xie J, He T, Erder MH.

Urgent care utilization for adolescents treated with atypical antipsychotics or nonantipsychotics: A comparison of rates and reasons.

Authors: Pliszka SR, Sikirica V, Betts K, Hodgkins PS, Samuelson TM, Xie J, Dammerman R, Robertson B, Wu EQ, Erder MH.

An application of group-based modeling approach for trajectory recognition: The developmental courses of hyperactivity and inattentive symptoms.

Authors: Cheng W, Goodwin R, Wu P, Vitaro F, Tremblay R.

Economic value of screening for early parkinson’s disease.

Authors: Johnson S, Siderowf A.

Economic value of screening for early parkinson’s disease in a european setting.

Authors: Johnson S, Siderowf AD.

Economic value of slowing parkinson’s disease in germany: Modelling progression through hoehn and yahr stages.

Authors: Johnson SJ, Birnbaum HG, Siderowf AD.

Economic value of slowing parkinson’s disease to payers and patients: Modeling progression through hoehn and Yahr stages.

Authors: Johnson S, Diener M, Kaltenboeck A, Birnbaum H, Grubb E, Siderowf A.
The impact of long-acting injectable versus oral antipsychotics on hospitalization rates in patients with schizophrenia: A systematic review and meta-analysis.

**Abstract:** ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

**Authors:** Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

Impact of long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients.

**Abstract:** ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

**Authors:** Lafeuille MH, Laliberte-Augier F, Lefebvre P, Frois C, Fastenau J, Duh MS.

Incremental clinical and economic burden of uncontrolled partial-onset seizures in a privately-insured population.

**Abstract:** ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

**Authors:** Paradis PE, Parise H, Duh MS, Bowers BW, Faught E.

Model of rasagiline versus standard of care for parkinson’s disease: Comparison of progression effects.

**Abstract:** ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

**Authors:** Johnson S, Wang ST, Birnbaum H, Grubb E.

Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.

**Publication:** Journal of Managed Care Pharmacy 2012 11; 18(9): 676-689.

**Authors:** Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.


**Authors:** Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.

Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.

**Publication:** Neurology 2012 10; 79(18); 1908-1916. doi: 10.1212/WNL.0b013e31827f77e.

**Authors:** Manjunath R, Paradis PE, Parise H, Lafeuille MH, Bowers B, Duh MS, Lefebvre P, Faught E.

Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl.


**Authors:** Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Peterson K, Ben-Joseph RH, Berner T, Summers KH.

Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy.


**Authors:** Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.


**Authors:** Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.


*Authors:* Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.

Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.


*Authors:* Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH.

Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.


*Authors:* Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ.

Direct costs and survival of Medicare beneficiaries with early and advanced Parkinson's disease.


*Authors:* Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrants ML, Siderowf AD.

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.


*Authors:* Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM.

Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.


*Authors:* Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, Kosinski M.

Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a Medicaid population.

*Publication:* Managed Care 2012 01; 21(1): 49-58.

*Authors:* Wu EQ, Ben-Hamadi R, Lu M, Beaulieu N, Yu AP, Erder MH.

Atypical antipsychotics versus non-antipsychotics: Comparative treatment patterns, resource utilization, and costs in stimulant-treated adolescents with ADHD who require subsequent pharmacotherapy.


*Authors:* Sikirica V, Pliszka SR, Betts K, Hodgkins P, Samuelson T, Xie J, Dammerman R.

Characteristics and use patterns of chronic hydrocodone users.

*Abstract:* 31st Annual Scientific Meeting of the American Pain Society, Honolulu, HI May 16-19, 2012.

*Authors:* Rice J, Samuelson T, Birnbaum H, Katz N.

Characteristics, clinical and economic outcomes in Medicaid pediatric vagus nerve stimulation (VNS) therapy patients for the treatment of refractory epilepsy.


*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.


*Authors:* Geldmacher D, Kirson N, Birnbaum H, Eapen S, Cummings K, A, Joish V.
Authors: Switzer J, Demaerschalk B, Xie J, Fan L, Villa K, Wu E.

Cost-utility analysis of hub-and-spoke telestroke networks for the management of acute ischemic stroke from a societal perspective.
Authors: Demaerschalk B, Switzer J, Xie J, Fan L, Villa K, Wu E.

Differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.
Authors: Van Vollenhoven RF, Shaw JW, Cifaldi MA, Signorovitch J, Wu EQ, Samuelson T, Faust E, Emery P.

Economic value of screening for early Parkinson’s disease in a European setting.
Authors: Johnson S, Birnbaum HG, Kaltenboeck A, Diener M, Siderowf A.

Economic value of slowing Parkinson’s disease in Germany: Modeling progression through Hoehn and Yahr stages.
Authors: Johnson S, Birnbaum HG, Kaltenboeck A, Diener M, Siderowf A.

The impact of long-acting injectable vs oral antipsychotics on hospitalization rates in patients with schizophrenia: A systematic review and meta-analysis.
Authors: Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

Impact of long-acting injectable vs. oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients.
Authors: Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS.

Impact of the frequency of multiple sclerosis relapses on the direct and indirect cost burden of family caregivers.
Authors: Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B.

PMH65 Comparison of Deviation Rates from the Labeled Daily Average Consumption in Patients Initiated on Stimulant Medication for the Treatment of Attention-Deficit/Hyperactivity Disorder.
Authors: Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder M.

Prevalence, comorbidity burden and treatment of Alzheimer’s disease among the elderly in the United States.
Assessment of parkinson’s disease progression rates by stage of disease.
Authors: Johnson SJ, Kaltenboeck A, Diener M, Tarrants M, Birnbaum H.

Burden of uncontrolled epilepsy in a privately insured population.
Authors: Manjunath R, Faught E, Paradis PE, Parisé H, Lafeuille MH, Lefebvre P, Duh MS.

Comparative efficacy of guanfacine extended release and atomoxetine for the treatment of oppositional symptoms in children with attention-deficit/ hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD).
Authors: Signorovitch JE, Sikirica V, Lu M, Xie J, Wu EQ, Erder MH.

Comparison of real-world health care costs after the initiation of second-line duloxetine or generic selective serotonin reuptake inhibitors in patients with major depressive disorder.
Authors: Swindle R, Ivanova JI, Birnbaum HG, Cummings AK, Kantor E, Schiller M, Clark T, Reed C.

Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of ADHD: A retrospective study.
Authors: Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH.

Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate vs. other medications for the treatment of attention-deficit/ hyperactivity disorder: A retrospective study.
Authors: Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH.

The cost-effectiveness of guanfacine extended release (GXR) versus atomoxetine (ATX) for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children and adolescents.
Authors: Erder M, Chen K, Wu EQ, Hodgkins P, Sikirica V.

Direct and indirect costs of privately-insured patients treated with oxymorphone extended-release or oxycodone controlled-release tablets.
Authors: Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Ben-Joseph RH, Berner T, KH S.

Impact of vagus nerve stimulation (VNS) therapy on clinical outcomes and costs in Medicaid patients with drug-resistant epilepsy.
Authors: Duh MS, Faught E, Guerin A, Sarda SP, Samuels TM, Bunker MT, Olin BD, Jackson SD, Helmers SL.

Relationship between adherence to disease-modifying drugs and severe relapses, direct and indirect costs among employees with multiple sclerosis.
Authors: Philips AL, Ivanova JI, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM.
Treatment patterns, resource utilization, and costs associated with atypical antipsychotics vs. non-antipsychotics added to or switched from stimulants among children with attention-deficit/ hyperactivity disorder (ADHD).

Authors: Sikirica V, Betts KA, Erder MH, Xie J, Samuelson TM, Hodgkins PS, Wu EQ.

Uncontrolled epilepsy in a Medicaid population.
Authors: Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Mishagina N, Parise H, Rovba L, Lefebvre P, Faught E.

Economic Outcomes of Switching Treatment in Major Depressive Disorder Patients.
Authors: Marynchenko M YA, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder HM, Bose A.

Early retirement and income loss in patients with early and advanced Parkinson’s disease
Authors: Johnson S, Davis M, Kaltenboeck A, Binnbaum H, Grubb E, Tarrants M, Siderowf A.

Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy.
Authors: Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by Medicaid or private insurance.
Publication: American Journal of Managed Care 2011 08; 17(8): e314-323.
Authors: Ivanova Ji, Binnbaum HG, Chen L, Duhig AM, Dayoub EJ, Kantor ES, Schiller MB, Phillips GA.

Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs.
Authors: Yu AP, Ben-Hamadi R, Wu EQ, Kaltenboeck A, Bergman R, Xie J, Blum S, Erder MH.

Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.
Authors: Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder MH.

Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
Authors: Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.

Switch to generic SSRIs may boost costs in MDD.
Authors: Wu E.

Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram.
Authors: Wu EQ, Greenberg PE, Ben-Hamadi R, Yu AP, Yang EH, Erder MH.

Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine.
Authors: Yang M, Rendas-Baum R, Varon SF, Kosinski M.
Physicians' decisions to prescribe antidepressant therapy in older patients with depression in a US managed care plan.
Authors: Ivanova JI, Bienfait-Beuzon C, Birnbaum HG, Connolly C, Emani S, Sheehy M.

Characteristics and clinical and economic outcomes in Medicaid patients receiving vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy.
Authors: Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelsion TM, Faught E.

Characteristics, clinical and economic outcomes in Medicaid patients 17 years and younger receiving vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy.
Authors: Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Economic outcomes of switching to another generic SSRI, escitalopram, or an SNRI among MDD patients treated with generic SSRI therapy.

Effect of treatment timing on risk of institutionalization among patients with Alzheimer's disease.
Abstract: ISPOR 14th Annual European Congress, Madrid, Spain   Nov 5-8, 2011.
Authors: Geldmacher DS, Kirson NY, Birnbaum HG, Kantor E, Eapen S, Joish VN.

Impact of vagus nerve stimulation (VNS) therapy on clinical outcomes and costs in Medicaid patients with drug-resistant epilepsy.
Authors: Duh MS, Faught E, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Helmers SL.

PIH23 Cost-Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Psychostimulant Compared to Psychostimulant Monotherapy for the Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents.
Abstract: 2011 International Society for Pharmacoeconomics and Outcomes Research,   Nov 5-8, 2011.
Authors: Sikirica V, Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu E.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.
Abstract: 30th Annual Scientific Meeting of the American Pain Society, Austin, TX   May 19-21, 2011.
Authors: Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

Cost of illness of post-traumatic stress disorder compared with major depressive disorder.
Authors: Ivanova J, Birnbaum H, Chen L, Dayoub E, Kantor E, Phillips G.

Economic value of lidocaine patch 5% versus gabapentin or pregabalin in Medicaid patients with post-herpetic neuralgia.
Authors: Ivanova J, Puenpatom A, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K.
Economic value of lidocaine patch 5% vs. gabapentin or pregabalin in Medicaid patients with post herpetic neuralgia.

Authors: Ivanova JI, Puenpatom RA, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K.

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis.

Authors: Phillips A, Ivanova J, Bergman R, Birnbaum H, Stewart M, Meletiche D.

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis.

Authors: Ivanova JI, Phillips AL, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM.

Perceptions and prescribing considerations among US psychiatrists regarding drug-drug interactions associated with oral atypical antipsychotics.
Authors: Frois C, Guerin A, Saraogi A, Panish J, Dirani R.

A novel approach to estimate the minimally important difference for the Fatigue Impact Scale in multiple sclerosis patients.
Authors: Rendas-Baum R, Yang M, Cattelin F, Wallenstein GV, Fisk JD.

Authors: Scharre DW, Vekeman F, Lefebvre P, Mody-Patel N, Kahler KH, Duh MS.

Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder.
Authors: Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD.

Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study.
Authors: Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Blum S, Haim Erder M.

Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
Authors: Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, Ben-Joseph RH, Summers KH.

Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%.
Authors: Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Amy Puenpatom R, Ben-Joseph RH, Summers KH.

Economic burden of epilepsy among the privately insured in the US.
Authors: Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Calleo S.
Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.


*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.


*Authors:* Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.

Generic antiepileptic drugs and associated medical resource utilization in the United States.


*Authors:* Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latremouille-Viau D, Lefebvre P, Helmers SL.

Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons.


*Authors:* Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A.

Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative.


Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.


*Authors:* Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States.


*Authors:* Birnbaum HG, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Cremieux PY, Greenberg PE.

The risks and costs of multiple-generic substitution of topiramate (author reply).

*Publication:* Neurology 2010 02; 74(8): 701-702; author reply 701-702. doi: 10.1212/WNL.0b013e3181c7770b.

*Authors:* Sethi NK, Torgovnick J, Sethi PK, Arsura E, Emmanuel Paradis P, Duh MS, Durkin MB, Wan GJ.

Compliance and persistence to single-tablet levodopa/ carbidopa/entacapone compound versus levodopa/carbidopa in idiopathic parkinson’s disease.


*Authors:* Stacy MA, Laliberte F, Kulkarni AS, Somogyi M, Vekeman F, Duh MS, Lefebvre P.

Descriptive profile of Medicaid patients with post herpetic neuralgia treated and untreated with lidocaine patch 5%.

*Abstract:* 29th Annual Scientific Meeting of the American Pain Society, Baltimore, MD May 6-8, 2010.

Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance.  
Authors: Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE.  

Impact of levodopa/carbidopa/entacapone compound versus levodopa/carbidopa on hospitalization rates in patients with idiopathic parkinson’s disease.  
Authors: Stacy MA, Laliberte F, Kulkarni AS, Somogyi M, Vekeman F, Duh MS, Lefebvre P.  

Increased risk of psychiatric disorders in a pediatric population with psoriasis.  
Authors: Kimball A, Yu A, Mulani P, Gupta S.  

Antipsychotic drug use in patients with Alzheimer’s disease treated with rivastigmine versus donepezil: Evidence from health claims data.  
Authors: Lefebvre P, Vekeman F, Kahler K, Mody-Patel N, Duh MS, Scharre DW.  

Assessing the relationship between compliance with antidepressant therapy and costs among employees in the United States.  
Authors: Birnbaum H, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Cremieux P, Greenberg P.  

Economic impact of generic entry of topiramate in Germany.  
Authors: Paradis P, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh MS.  

Evaluation of cardiovascular diseases (CVDs) risk in French patients receiving milnacipran (MLN) relative to patients receiving other antidepressants therapies.  
Authors: Mease PJ, Duh MS, Vekeman F, Guerin A, Boerstoel-Streefland M, Jiang W, Lefebvre P, Zimetbaum PJ.  

Healthcare resource utilization and costs of mild, moderate, and severe depression in the workforce in the united states.  
Authors: Birnbaum H, Kessler R, Joish V, Kelley D, Ben-Hamadi R, M. H, Greenberg P.  

Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version.  
Authors: Cole JC, Lin P, Rupnow MF.  

The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.  
Authors: Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.  

The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.  
Authors: Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D.
Determinants of direct cost differences among US employees with major depressive disorders using antidepressants.


*Authors:* Birnbaum HG, Ben-Hamadi R, Greenberg PE, Hsieh M, Tang J, Reygrobellet C.

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.


*Authors:* Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

The risks and costs of multiple-generic substitution of topiramate.


*Authors:* Duh MS, Paradis PE, Latremouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J.

Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs.


*Authors:* Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH.

Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.


*Authors:* Birnbaum HG, Ivanova JI, Samuels S, Davis M, Cremieux PY, Phillips AL, Meletiche D.

Antidepressant treatment patterns and costs among US employees.


*Authors:* Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R.

Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population.


*Authors:* Yu AP, Ben-Hamadi R, Birnbaum HG, Atanasov P, Stensland MD, Philips G.

Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.


*Authors:* Faught RE, Weiner JR, Guerin A, Cunningham MC, Duh MS.

Clinical consequences of generic substitution of topiramate.


*Authors:* Paradis P, Dominick L, Patrick L, Marie-Helene L, Natalia M, Moore Y, Gaudig M, Duh M.

Comparison of hospitalizations and health care costs of elderly major depressive disorder (MDD) patients treated with escitalopram, generic SSRIs, or SNRIs.


*Authors:* Wu EQ, Cahill KE, Bieri C, Ben-Hamadi R, Yu AP, Erder MH.

Compliance and persistence of oral cholinesterase inhibitors in patients with Alzheimer’s disease.


*Authors:* Vekeman F, Laliberte F, Kahler K, Mody-Patel N, Lefebvre P, Duh MS.
Compliance, persistence, and outcomes in patients with Alzheimer’s disease treated with oral cholinesterase inhibitors.
Authors: Mody-Patel N, Vekeman F, Laliberte F, Kahler KH, Duh MS, Lefebvre P.

Direct costs in older patients with depression treated and untreated with antidepressant therapy.
Authors: Ivanova J, Birnbaum HG, Samuels S, Emani S, Sheehy M, Cattelin F.

Direct costs of patients with treatment resistant and non-treatment resistant major depressive disorder.
Authors: Ivanova J, Birnbaum HG, Kidolezi Y, Subramanian G, Stensland MD, Khan SA.

Economic assessment of second-line treatment: Switching from a generic SSRI to escitalopram, an SNRI, or another generic SSRI by patients with major depressive disorder (MDD).

Economic consequence of switching to citalopram after its generic entry among major depressive disorder patients treated with escitalopram.
Authors: Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Erder H.

Economic impact of generic entry of topiramate in Germany: Conversion of the canadian experience into the settings of Germany.
Authors: Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

Economic impact of generic entry of topiramate in the G4 European countries.
Authors: Paradis PE, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh M.

The economic impact of generic switching for patients with major depressive disorder (MDD) treated with escitalopram or a patented SSRI.

Economic implication of dose escalation in depressed patients treated with escitalopram or venlafaxine XR.
Authors: Yu AP, Bensimon AG, Wu EQ, Ben-Hamadi R, Bourezak A, Erder MH.

The Economic Outcomes of Early Education with Second Generation Antidepressants among Adolescents with Depression.
Authors: Yu AP, Kaltenboeck A, Bergman R, Xie J, Ben-Hamadi R, Wu EQ, Erder H.

Impact of generic substitution of topiramate for patients with epilepsy.
Authors: Paradis PE, Latremouille-Viau D, Lefebvre P, Lafaille MH, Mishagina N, Moore Y, Gaudig M, Duh MS.

Impact of generic substitution of topiramate for patients with epilepsy.
Abstract: 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy.
Authors: Paradis P, Latremouille-Viau D, Lefebvre P, Lafaille M, Mishagina N, Moore Y, Gaudig M, Duh MS.
The impact of generic substitution of topiramate on health care costs: Conversion of the Canadian experience into the settings of G4 European countries.

Authors: Paradis PE, Latremouille-Viau D, Lafeuille MH, Lefebvre P, Gaudig M, Duh M.

The impact of generic substitution of topiramate on healthcare costs: Conversion of the Canadian experience into the settings of Germany.

Authors: Paradis P, Latremouille-Viau D, Lafeuille M, Lefebvre P, Gaudig M, Duh MS.

Physicians’ attitude to prescribing antidepressant therapy in older patients with depression.

Authors: Ivanova JI, Birnbaum HG, Connolly C, Emani S, Sheehy M, Bienfait-Beuzon C.

The potential economic impact of generic substitution of topiramate on health care costs in the G4 European countries.

Authors: Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.

Authors: Yu AP, Atanasov P, Ben-Hamadi R, Birnbaum H, Stensland MD, Philips G.

The risk of coronary heart disease and stroke among psoriasis patients.

Authors: Kimball A, Guerin A, Mulani P, Gupta S.

Health care utilization and costs of depressed patients treated with escitalopram versus SNRIs.

Authors: Erder MH, Wu E, Ben-Hamadi R, Beaulieu N, Lu M.

Treatment compliance and health care costs of Medicaid depressed adult patients treated with escitalopram versus citalopram.

Authors: Erder MH, Wu E, Lu M, Ben-Hamadi R, Beaulieu N.

Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study.
Authors: Faught E, Duh MS, Weiner JR, Guerin A, Cunningham MC.

Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.
Authors: Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH.

**Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population.**

*Publication:* Current Medical Research and Opinion 2008 09; 24(9): 2587-2595. doi: 10.1185/03007990802303525.
*Authors:* Wu E, Greenberg PE, Yang E, Yu A, Erder MH.

**Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.**

*Authors:* LeLorier J, Duh MS, Paradis PE, Latremouille-Viau D, Lefebvre P, Manjunath R, Sheehy O.

**Health Care Resource Utilization and Costs Comparison For MDD Patients on 10mg Escitalopram Who Increased to 20mg Dose vs. Those Who Were Switched to SNRI.**

*Authors:* Wu EQ, Yu A, Buessing M, Ben-Hamadi R, Tang J, Seale J, Erder M, Bose A.

**Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.**

*Publication:* Current Medical Research and Opinion 2007 09; 23(9): 2035-2042. doi: 10.1185/030079907X210516.
*Authors:* Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.

**Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.**

*Publication:* Journal of Managed Care Pharmacy 2007 09; 13(7): 561-569.
*Authors:* Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

**The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.**

*Authors:* Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY.

**Factors related to antipsychotic oversupply among Central Texas Veterans.**

*Authors:* Yang M, Barner JC, Worchel J.

**Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.**

*Publication:* Archives of General Psychiatry 2007 05; 64(5): 543-552. doi: 10.1001/archpsyc.64.5.543.
*Authors:* Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC.

**MH2 Comparison of health care costs and hospitalization days of elderly major depressive disorder patients treated with escitalopram and other antidepressants.**

*Authors:* Wu E, Yang E, Greenberg P, Erder M, Yu A, Buesing M.

**Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.**

*Authors:* Andermann F, Duh MS, Gosselin A, Paradis PE.

**Considering the costs of bipolar depression.**

*Publication:* Behav Healthc 2007 01; 27(1): 45-47.
*Authors:* Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg PE, Hirschfeld RM, Wang PS.
Antidepressant Treatment Patterns and Related Costs among U.S. Employees.  
*Authors:* Birnbaum H, Greenberg P, Tang J, Hsieh M, Wu EQ, Reygrobellet C, Ben-Hamadi R.

Comparing Treatment Compliance and Hospitalization of Elderly MDD Patients on Escitalopram and Other SSRI/SNRIs.  
*Authors:* Wu EQ, Elaine Y, Greenberg P, Erder M.H., Yu A.

Comparing Treatment Compliance, Hospitalization, and Costs of Elderly MDD Patients on Escitalopram and Citalopram.  
*Abstract:* International Health Economics Association, Copenhagen, Denmark  Jul 8-11, 2007.  
*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

Comparing Treatment Compliance, Hospitalizations, and Costs of Elderly MDD Patients on Escitalopram and Citalopram.  
*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

Health care costs and resource use in patients with major depressive disorder: a comparison between escitalopram and other antidepressants (SSRI/SNRI).  
*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Yu A, Buessing M.

Health Economics Impact in the Treatment of Depression.  
*Authors:* Navarro R, Wu EQ.

Treatment Compliance of Adult Depressed Patients on Escitalopram and Citalopram.  
*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach.  
*Authors:* Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R.

Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States.  
*Authors:* Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR.

Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers.  

MH4 Medical costs and hospitalization of adults diagnosed with attention-deficit/hyperactivity disorder who received alternative therapies.  
*Authors:* Wu E, Birnbaum H, Zhang H, Radeva J, Yang E, Castor A.
Employer Burden for Adults Diagnosed with Attention-Deficit/Hyperactivity Disorder who Received Alternative Therapies.
Authors: Wu EQ, Birnbaum H, Zhang HF, Radeva J, Yang E, Castor A.

Health-Related Quality Of Life of Stroke Survivors in the U.S.
Authors: Xie J, Wu EQ, Zheng ZJ, Croft JB, Mensah GA, Labarthe D.

Patterns of Antidepressant Treatment Response in an Employed Population.
Authors: Wu EQ, Birnbaum H, Ben-Hamadi R, Tang J, Greenberg P, Gilloteau I, Smadja E.

PMH7 Annual costs associated with patterns of antidepressant treatment response among employees.

Unemployment drives high cost of schizophrenia in the US.
Authors: Wu E.

PMH37 The economic burden of schizophrenia in the united states in 2002.
Authors: Wu E, Birnbaum H, Shi L, Ball D, Kessler R, Moulis M, Aggarwal J.

The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R).

Economic burden of illness for employees with painful conditions.
Authors: White AG, Birnbaum HG, Mareva MN, Henckler AE, Grossman P, Mallett DA.

The economic burden of schizophrenia in the United States in 2002.
Authors: Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J.

Costs of schizophrenia have shifted.
Authors: Wu E.

The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers.
Authors: Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, Johnston JA, Spencer T, Ustun TB.

Authors: Wu E, Birnbaum H, Aggarwal J, Moulis M.
The economic burden of depression in the US: societal and patient perspectives.
Authors: Greenberg PE, Birnbaum HG.

Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.
Authors: Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR.

Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Birnbaum H, Kessler R, Beaulieu N, Daher M, Aggarwal J, Svanum H, Shi L.

Authors: Wu EQ, Birnbaum H, Kessler R, Shi L, Ball D.

Authors: Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J.

Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients.
Authors: Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux PY, Secnik K.

Economic implications of treatment-resistant depression among employees.
Authors: Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A.

Comorbidities and Cost Associated with Bipolar Disorder.
Authors: Parece A, Wu EQ, Birnbaum H, Greenberg P, Huang Z, Victor T, Kessler RC.

Cost and Comorbidities Associated with Bipolar Disorder.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Parece A, Wu EQ, Birnbaum HG, Greenberg P, Huang Z, Victor T, Kessler RC.

Drug Treatment Patterns of Bipolar Disorder and Associated Costs.

What's so different about anxiety disorders (such as phobias).
Publication: WPA series evidence and experience in psychiatry 2004 7.
Authors: Greenberg P, Birnbaum H, Sisitsky T.

Attention-deficit/hyperactivity disorder: increased costs for patients and their families.
Authors: Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A.

The economic burden of depression in the United States: how did it change between 1990 and 2000?
Publication: Journal of Clinical Psychiatry 2003 12; 64(12): 1465-1475.
Authors: Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK.
Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis.
*Authors:* Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA.

*Authors:* Corey-Lisle PK, Birnbaum H, Greenberg P, Marynchenko M, Dube S.

PNP16: The comparison of different methods for determining the impact of migraine prophylaxis on costs.
*Authors:* Barlev A, Globe D, Wu E, Yu W, Johnson K.

The economic burden of depression with painful symptoms.
*Publication:* Journal of Clinical Psychiatry 2003 05; 64 Suppl 7: 17-23.
*Authors:* Greenberg PE, Leong SA, Birnbaum HG, Robinson RL.

The economics of women and depression: an employer’s perspective.
*Authors:* Birnbaum HG, Leong SA, Greenberg PE.

Identification of a claims data “signature” and economic consequences for treatment-resistant depression.
*Authors:* Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ.

An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.
*Authors:* Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T.

The economic burden of anxiety and stress disorders.
*Authors:* Kessler RC, Greenberg PE.

*Authors:* Greenberg PE, Birnbaum SA.

Measuring Alzheimer’s disease progression with transition probabilities: estimates from CERAD.

Assessing the economic impact of psychiatric disorders: where to begin?
*Authors:* Greenberg PE, Leong SA, Birnbaum HG.

Depression and work productivity: the comparative costs of treatment versus nontreatment.
*Authors:* Simon GE, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Wang PS, Kessler RC.

Survival and Nursing Home Free Survival (NHFS) of Alzheimer’s Disease (AD) Patients.
*Abstract:* 2001 International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
*Authors:* Wu EQ, Hay J.
The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
Authors: Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, Williamson T.

The Economics of Anxiety Disorders.
Authors: Greenberg P, Sisitsky T.

The Impact of an Over-the-Counter Migraine Medication on Quality of Life.
Abstract: International Society for Pharmacoeconomics & Outcomes Research.
Authors: Burk C, Nichol MB, Wu EQ, Gilderman A, Salas J.

Management of major depression in the workplace.
Authors: Birnbaum HG, Cremieux PY, Greenberg PE, Kessler RC.

The workplace burden of depression: underlying causes, recent empirical findings, and future directions.
Authors: Greenberg P, Birnbaum H.

Depression in the workplace: effects on short-term disability.
Authors: Kessler RC, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Simon GE, Wang P.

The economic burden of anxiety disorders in the 1990s.
Authors: Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ.

Workplace burden of depression: a case study in social functioning using employer claims data.
Publication: Drug Benefits Trends 1999 11: 6BH-12BH.
Authors: Birnbaum H, Greenberg P, Barton M, Kessler R, Rowland C, Williamson T.

Workplace performance effects from chronic depression and its treatment.

Improvement in subjective work performance after treatment of chronic depression: some preliminary results.
Chronic Depression Study Group.
Authors: Finkelstein SN, Berndt ER, Greenberg PE, Parsley RA, Russell JM, Keller MB.

Depression in the workplace: an economic perspective.
Authors: Greenberg PE, Kessler RC, Nells TL, Finkelstein SN, Berndt ER.

Authors: Duh MS, Shepard MJ, Wilberger JE, Bracken MB.
The Economics of Clinical Depression.
Authors: Greenberg P.

Depression: a neglected major illness.
Authors: Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER.

The economic burden of depression in 1990.
Authors: Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER.

Oncology
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.
Authors: Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study.

Antiepileptic drug titration and related health care resource use and costs.
Publication: Journal of Managed Care and Specialty Pharmacy 2018 09; 24(9): 929-938a. doi: http://dx.doi.org/10.18553/jmcp.2018.17337.
Authors: Fishman J, Kalilani L, Song Y, Swallow E, Wild I.

Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.
Authors: Stein EM, Yang M, Guerin A, Gao W, Galebach P, Xiang CQ, Bhattacharyya S, Bonifacio G, Joseph GJ.

Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Authors: Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL.

Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial.
Authors: Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG.

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.
Authors: Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.
Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
Authors: Ghate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberte F, Nakasato A, Duh MS.

Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.

Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.

Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.
Authors: Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP.

Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.
Authors: Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Kassabian V.

Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.
Authors: Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Hubucky K, Tang DH, Pivneva I, Gagnon-Sanschagrin P, Joseph GJ.

Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.

Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.
Authors: Li J, Sasane M, Zhang J, Zhao J, Ricculli ML, Yao Z, Redhu S, Signorovitch J.

Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer.
Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis.
Authors: Li J, Sasane M, Zhao J, Horton VG, Zhang P, Ricculli ML, Zhou ZY, Signorovitch J.

Authors: Zhou ZY, Mutebi A, Han S, Bensimon AG, Louise Ricculli M, Xie J, Dalal A, Culver K.

Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.
Publication: Advances in Therapy 2018 06. e-pub ahead of print 2018/06/06; doi: 10.1007/s12325-018-0701-5.
Authors: Dalal AA, Gagnon-Sanschagrin P, Burne R, Guerin A, Gauthier G, Small T, Niravath P.

Economic burden of treatment failure in chronic lymphocytic leukemia patients.
Authors: Wang S, Lafeuille MH, Lefebvre P, Romdhani H, Emond B, Senbetta M.

Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2-Metastatic Breast Cancer.

Assessment of change in quality of life (QoL), carcinoid syndrome (CS) symptoms, and health care resource utilization (HRU) in CS patients treated with somatostatin analogs (SSA)-results from longitudinal patient surveys.
Publication: Value in Health 2018 05; 21 (Supplement 1); S38-S39.

Cost-effectiveness of ceritinib in previously untreated ALK-positive non-small cell lung cancer in the United Kingdom.
Publication: Value in Health 2018 05; 21 (Supplement 1); S29.

Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy
Publication: Current Medical Research and Opinion. 2018 05. doi: http://dx.doi.org/10.1080/03007995.2018.1501351.
Authors: Ghate SR, Ionescu-Ituu R, Burne R, Ndife B, Laliberte F, Nakasato A, Duh MS.

Overall survival in patients with glioblastoma before and after bevacizumab approval.
Authors: Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ituu R, Shi S, Macalalad A, Uhm JH.

Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Authors: Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.
Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers.


*Authors:* Chawla A, Peeples M, Li N, Anhorn R, Ryan J, Signorovitch J.

Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.


*Authors:* Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M, Ionescu-Ittu R.

Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis.


*Authors:* Dalal AA, Guerin A, Mutebi A, Culver KW.

Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.


The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.


*Authors:* Swallow E, Messali A, Ghate S, McDonald E, Duchesneau E, Perez JR.

Assessment of costs associated with adverse events in patients with cancer.


Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States.


Healthcare Resource Utilization (HRU) and Cost Comparison of Infection-Related Complications During Therapy With Dasatinib or Nilotinib in Patients (pts) With Chronic Myeloid Leukemia.


Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer: A Network Meta-analysis.
*Authors:* Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA.

*Authors:* Yang H, Levy BP, Signorovitch JE, Patterson-Lomba O, Xiang CQ, Parisi M.

Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib.
*Authors:* Patel AK, Duh MS, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.


Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.
*Authors:* Mato AR, Samp JC, Gauthier G, Terasawa E, Brander DM.

Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
*Authors:* Dalal AA, Guerin A, Mutebi A, Culver KW.

*Publication:* Advances in Therapy 2018 03. e-pub ahead of print 2018/03/21; doi: 10.1007/s12325-018-0689-x.

Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center.

Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.
Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis.

Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer.
Publication: American Journal of Managed Care 2018 02.
Authors: Nellesen D, Dea K, Guerin A, Culver K, Mutebi A, Dalal A.

Assessing the Value of Nivolumab (NIVO) versus Placebo (PBO) and Ipilimumab (IPI) as Adjuvant Therapy for Resected Melanoma.
Abstract: American Society of Clinical Oncology, Chicago, IL  June 1-5, 2018.
Authors: Freeman M, Shoushtari A, Betts KA, Gupte-Singh K, Du EX, Ritchings C, Rao S.

Characteristics of patients diagnosed de novo with AJCC7 stage III or regionally advanced cutaneous melanoma and trends in adjuvant therapy: An analysis of the SEER cancer registry in the United States.

Authors: Bobbili PJ, Ryan K, Duh MS, Fernandez A, DerSarkissian M, Dua A, Pavilack M, Gomez JE.

Comparative effectiveness of non-cisplatin (cis)-based first-line (1L) regimens in patients with metastatic urothelial carcinoma (mUC): Veterans Affairs control cohorts vs. IMvigor210.

Comparison of Adverse Event Costs of Nivolumab combined with Ipilimumab versus Sunitinib for Previously Untreated Metastatic Renal Cell Carcinoma.
Abstract: American Society of Clinical Oncology, Chicago, IL(abstract accepted as online presentation)  June 1-5, 2018.
Authors: Betts KA, Yang S, Du EX, Johansen J, Rao S.

Comparison of healthcare resource utilization (HRU) and costs related to pleural effusion (PE) between patients newly diagnosed with chronic myeloid leukemia (CML) treated with dasatinib or nilotinib as first-line therapy in the United States.
Abstract: ISPOR 23rd Annual International Meeting . United States, Baltimore, MD.

Deep molecular response in chronic phase-Chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: A multi-country retrospective chart review study.
Authors: Cortes J, Huynh L, Mendelson E, Brandt P, Dalal D, Der Sarkissian M, Cortina D, Narkhede S, Duh MS.
Dosing patterns and economic burden of drug wastage among postmenopausal women with HR+/HER2-metastatic breast cancer receiving palbociclib.


Hematologic, cardiac, and hepatic function monitoring among post-menopausal women with HR+/HER2-metastatic breast cancer.


*Authors:* Dalal AA, Goldschmidt D, Romdhani H, Kelkar S, Guerin A, Gauthier G, Small T, Niravath P.

Incidence of AJCC7 stage III or regionally advanced cutaneous melanoma in the United States.


*Authors:* Tarhini AM, Ghate SR, Nakasato A, Ionescu-Ittu R, Shi S, Ndife B, Burne R, Laliberte F, Duh MS.

Indirect Treatment Comparison of Nivolumab versus Placebo as Adjuvant Therapy for Resected Melanoma.

*Abstract:* American Society of Clinical Oncology, Chicago, IL  June 1-5, 2018.

*Authors:* Shoushtari A, Freeman M, Betts KA, Gupte-Singh K, Du EX, Ritchings C, Rao S.

A model estimating work productivity loss due to premature death associated with hepatic veno-occlusive disease/sinusoidal obstruction syndrome among hematopoietic stem cell transplant patients in the united states.


*Authors:* Zhou ZY, Tang W, Villa K.

Patterns of BRAF testing and treatment in patients with metastatic melanoma presumed BRAF positive.

*Abstract:* Annual Meeting of the American Association for Cancer Research Chicago, IL  April 14-18, 2018.

*Authors:* Ghate S, Nakasato A, Ionescu-Ittu R, Shi S, Ndife B, Burne R, Laliberte F, Duh MS.

Patterns of treatment and recurrence in patients with non-metastatic melanoma who underwent lymph node dissection surgery.

*Abstract:* ISPOR 23rd Annual International Meeting
Baltimore, MD  May 19-23, 2018.

*Authors:* Ndife B, Tarhini A, Ionescu-Ittu R, Maneur AM, Jacques P, Laliberte F, Duh MS, Nakasato A, Ghate SR.

 Patterns of treatment with immune check point inhibitors and targeted therapy in patients with metastatic melanoma presumed BRAF V600 positive.

*Abstract:* Using Smart Source Parsing

*Date of Publication:* July 2018, Chicago, IL  April 14-18, 2018.

*Authors:* Ghate S, Nakasato A, Ionescu-Ittu R, Shi S, Ndife B, Burne R, Laliberte F, Duh MS.


*Abstract:* ISPOR 23rd Annual International Meeting
Baltimore, MD  May 19-23, 2018.

*Authors:* Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Kulke MH.
Authors: Huynh L, Totev T, Dasari A, Bergsland EK, Benson AB, Cai B, Shea J, Duh MS, Neary MP, Kulke MH.

Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC) in the United States.
Authors: Nellesen D, Patton C, Mutebi A, Culver KW.

Surrogate Outcomes in Oncology: How can they be used to predict overall survival in clinical practice and payer decision making?
Authors: Ayyagari R, Xie J, Wu E, Song J.

Symptoms Following Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy After Achieving an Adequate Response in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
Authors: Ritchie E, Sadek I, Pivneva I, Guerin A, Latremouille-Viau D, Ndife B, Joseph G, Atallah E.

Symptoms Following Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy After Achieving an Adequate Response in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
Authors: Ritchie EK, Sadek I, Pivneva I, Guerin A, Latremouille-Viau D, Ndife B, Joseph GJ, Atallah EL.

Systematic literature review of treatments for patients with untreated advanced or metastatic non-small cell lung cancer (NSCLC).
Authors: Song J, Huang M, Kelkar SS, Zhou Z, Zhang Y.

A time and motion study of patients treated with Pembrolizumab and Nivolumab in Australia.
Authors: Pivneva I, Kothari S, Van Koeverden P, Pelissier J, Stone S, Herawati L, Guerin A.

Treatment and monitoring patterns among premenopausal women with HR+/HER2- metastatic breast cancer.
Authors: Guerin A, Dalal AA, Gagnon-Sanschagrin P, Burne R, Gauthier G, Small T, Niravath P.

Treatment patterns among post-menopausal women with HR+/HER2- metastatic breast cancer: a chart review study.
Authors: Dalal AA, Goldschmidt D, Romdhani H, Kelkar S, Guerin A, Gauthier G, Small T, Niravath P.

Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib as First-line and Second-line Therapy in the United States.
First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.

Authors: Tang DH, Li N, Du EX, Peeples M, Chu L, Xie J, Barghout V.

Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.

Authors: Zhou Z, Tang DH, Xie J, Ayyagari R, Wu E, Niravath PA.

Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer.

Authors: Ganti AK, Hirsch FR, Wynes MW, Ravelo A, Ramalingam SS, Ionescu-Ittu R, Ivor Pivniva I, Borghaie H.

Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.

Authors: Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.

Comparing the cost of treatment with octreotide long-acting release versus lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors.

Authors: Ayyagari R, Neary M, Li S, Rokito A, Yang H, Xie J, Benson AB.

Dabrafenib and trametinib combination therapy versus docetaxel in previously treated metastatic NSCLC: An adjusted indirect comparison.

Authors: Sasane M, Li J, Zhang P, Zhao J, Ricculli ML, Signorovitch J.

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.

Authors: Ivanova JI, Saverno KR, Sung J, Duh MS, Zhao C, Cai S, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS.

Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea.


Using FACT-G and PROMIS-29 to evaluate the association between duration of somatostatin analog use and quality of life in patients with carcinoid syndrome in the United States.

Publication: Quality of Life Research 2017 10; 26 (1 Supplement 1): 131-132. doi: http://dx.doi.org/10.1007/s11136-017-1658-6.
Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.  
**Authors:** Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB.

Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases.  
**Authors:** McKay R, Haider B, Duh MS, Valderrama A, Nakabayashi M, Fiorillo M, Ristovska L, Wen L, Kantoff P.

Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.  
**Authors:** Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S.

Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.  
**Authors:** Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L.

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.  

Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.  
**Publication:** Medical Oncology 2017 08; 34(9): 160. e-pub ahead of print 2017/08/11; doi: 10.1007/s12032-017-1014-2.  
**Authors:** Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.

Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer.  
**Authors:** Li N, Du EX, Chu L, Peeples M, Xie J, Barghout V, Tang DH.

**Authors:** Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ.

Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014.  
**Authors:** Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB.

Authors: Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guerin A.

Real-world Characteristics and Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy versus Androgen Receptor-targeted Therapy after Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting.

Authors: Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.

Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.


Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy.

Publication: American Health and Drug Benefits 2017 05; 10(3): 143-152.
Authors: Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA.

Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.

Publication: Medical Oncology 2017 05; 34(5): 88. e-pub ahead of print 2017/04/11; doi: 10.1007/s12032-017-0927-0.
Authors: Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Berge Sland E.

Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries with Chronic Myeloid Leukemia.

Authors: Ritchie EK, Guerin A, Wolff J, Joseph G.

Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice.

Authors: Pilon D, Ellis LA, Behl AS, Gozalo L, Emond B, Lefebvre P, Calabrese R, Prime H, Gaylis F.

Association between time to progression and subsequent survival in previously treated BRAF V600E-mutant metastatic non-small cell lung cancer.

Authors: Sasane M, Li J, Zhang J, Zhao J, Ricculli ML, Redhu S, Signorovitch J.

Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.

Authors: Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G.
Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.


Authors: Pal SK, Signorovitch JE, Li N, Zichlin ML, Liu Z, Ghate SR, Perez JR, Vogelzang NJ.

Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.


Authors: Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guerin A.

Assessment of the association between the burden of carcinoid syndrome symptoms and the quality of life among patients with carcinoid syndrome in the united states based on the FACT-G instrument.


Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling.


Authors: Brown J, Cook K, Adamski K, Lau J, Bargo D, Breen S, Chawla A.

Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide.


Authors: Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA.

Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency.


Authors: Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.

Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.


Authors: Rose DB, Nellesen D, Neary MP, Cai B.

The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.


Authors: Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A.

Anticoagulant treatment patterns for cancer-associated thrombosis in a commercial insurance population.


Authors: Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.


Authors: Stein EM, Yang M, Gao W, Galebach P, Xiang CQ, Bhattacharyya S, Bonifacio G, Joseph GJ.

Assessment of costs associated with adverse events in patients with cancer.


Assessment of the association between the burden of carcinoid syndrome symptoms and the quality of life among patients with carcinoid syndrome in the United States based on the FACT-G instrument.


Association between Duration of Somatostatin Analogs (SSAs) Use and Quality of Life in Patients with Carcinoid Syndrome in the United States Based on the FACT-G Instrument.


Association between duration of somatostatin analogs (SSAS) use and quality of life in patients with carcinoid syndrome in the United States based on the FACT-G instrument.


Authors: Zhou Z, Bensimon A, Cheng J, Dalal A.


Authors: Mutebi A, Zhou Z, Ricculli ML, Han S, Xie J, Dalal A, Culver K.

Burden of illness in patients with acute myeloid leukemia aged 65 years ineligible for intensive chemotherapy.


Authors: Lafeuille MH, Sundaram M, Lefebvre P, Emond B, Romdhani H, Senbeta M.
Clinical benefits of achieving deep remission to second-line therapy in patients with relapse/refractory (R/R) chronic lymphocytic leukemia (CLL) - A real-world study.

Authors: Wierda WG, Gauthier G, Meissner B, Guerin A, Samp JC.

Comparative efficacy with endocrine-based combination versus monotherapy among postmenopausal women with HR+/ HER2- metastatic breast cancer: A network metaanalysis.


Comparison of healthcare resource utilization and costs related to infections between patients newly diagnosed with chronic myeloid leukemia treated with dasatinib and nilotinib as first-line therapy in the United States.


Comprehensive genomic profiling (CGP) versus conventional molecular diagnostic testing of patients with advanced non-small cell lung cancer (NSCLC): Overall survival (OS) and cost in a U.S. Health plan population.

Authors: Signorovitch J, Zhou Z, Ryan J, Chawla A.

Cost burden of first-line antineoplastic treatment failure in patients with chronic lymphocytic leukemia.


Cost consequence analysis of different gene mutation testing modalities for BRAFV600E mutation in advanced non-small cell lung cancer using a decision analytic model.


Cost offsets in the treatment journeys of patients with relapsed/refractory multiple myeloma (RRMM).

Authors: Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin RM.

Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory b-cell acute lymphoblastic leukemia in the united states.

Authors: Hao Y, Eldjerou LK, Yang H, Qi C, Globe D.

Cost-effectiveness of ceritinib in previously untreated alk-positive non-small cell lung cancer in the united states
Authors: Zhou ZY, Mutebi A, Han S, Bensimon A, Ricculli ML, Xie J, Dalal AA, Culver KW.


Authors: Stein EM, Xie J, Duchesneau E, Bhattacharyya S, Ndife B, Bonifacio G, Joseph GJ.
Costs associated with disease progression in advanced melanoma-a claims analysis using a novel staging algorithm.
*Authors*: Song J, Goldschmidt D, Driver M, Buchanan J, Murugappan S.

Drivers of treatment patterns in patients with chronic lymphocytic leukemia (CLL) treated with B cell receptor inhibitors (BCRIs) - A medical chart review study.
*Authors*: Mato AR, Samp JC, Gauthier G, Terasawa E, Brander DM.

Economic analysis of molecular mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.
*Authors*: Dalal A, Dea K, Guerin A, Culver K.

Estimated cost of anticancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study.
*Abstract*: ASCO Annual Meeting, Chicago, IL  Jun 2-6, 2017.
*Authors*: Signorovitch J, Janku F, Wheler JJ, Miller VA, Ryan J, Zhou Z, Chawla A.

Evaluation of the impact of the burden of carcinoid syndrome symptoms on quality of life among treated patients with carcinoid syndrome in the United States based on the PROMIS-29 instrument.

Healthcare cost of Medicare patients with previously treated chronic lymphocytic leukemia.
*Authors*: Reyes C, Gauthier G, Schmerold L, Guerin A.

Healthcare resource utilization associated with venous thromboembolism in cancer patients treated with anticoagulants in a commercial insurance population.
*Authors*: Khorana AA, McClare K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

Impact of FDA approval of lenalidomide maintenance therapy in the first-line treatment of multiple myeloma after autologous stem cell transplant on total healthcare costs.
*Abstract*: ASCO Annual Meeting, Chicago, IL  Jun 2-6, 2017.
*Authors*: Xie J, Parikh K, Chen C, Yang C, Farrukh A, Cockrum P, Agarwal AB, Abouzaid S.

*Authors*: Lafeuille MH, Sundaram M, Hoehn D, Emond B, Romdhani H, Lefebvre P.

A meta-analysis and meta-regression of the efficacy of front-line treatment combinations with ponatinib versus 1st- and 2nd-generation tyrosine kinase inhibitors for ph+ acute lymphoblastic leukemia.
Multi-country retrospective chart audit study to examine deep molecular response (MR4.5) associated with second-line tyrosine kinase inhibitors in chronic phase - Chronic myelogenous leukemia (CML-CP).

Authors: Cortes J, Huynh L, Brandt P, DerSarkissian M, Zaccardelli G, Dalal D, Hussein J, Duh MS.

Oncologist preferences in advanced soft tissue sarcoma: A discrete choice experiment.

Abstract: ASCO Quality Care Symposium, Orlando, FL Mar 3-4, 2017.

Overall Survival In Patients with Glioblastoma Before and After Bevacizumab Approval.

Authors: Johnson DR, Omuro AM, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Uhm JH.

Overall survival in patients with metastatic urothelial cancer by first-line therapy.

Abstract: ISPOR 20th Annual European Congress, Glasgow, UK.

Potential drug-drug interaction events in patients treated with abiraterone acetate plus prednisone or enzalutamide.

Abstract: ASCO Quality Care Symposium, Orlando, FL Mar 3-4, 2017.
Authors: Pilon D, Behl AS, Emond B, Xiao Y, Lefebvre P, Kane CJ.

Predictors of clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or placebo: An exploratory posthoc analysis of COU-AA-302 trial data.

Authors: Pilon D, Behl AS, Kamstra R, Xiao Y, Lefebvre P, Freedland SJ.

Progression-free survival and overall survival in patients with chronic lymphocytic leukemia - Clinical benefits of achieving a deep response to first-line therapy.

Authors: Samp J, Guerin A, Foster R, Meissner B, Meissner R, Enschede SH, Gauthier G.

Progression-free survival with endocrine-based therapies following progression on an non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A network meta-analysis.

Authors: Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Niravath PA.

Prostate-specific antigen (PSA) trajectories correlate with overall survival (OS) in men treated with abiraterone acetate plus prednisone (AA+P) or placebo plus prednisone: A post-hoc analysis of COU-AA-301 trial data

Dominic Pilon.

Authors: Behl AS, Kamstra R, Xiao Y, Lefebvre MH, Lefebvre P, Freedland SJ.

Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: A seer-medicare analysis.

Real world treatment patterns in metastatic and/or unresectable gastric cancer patients in Russia.
Authors: Tjulandin SA, Sholokhova E, Ivanova JI, Cheng WY, Schmerold LM, Thompson-Leduc P, Novick D.

Realworld adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).
Authors: Patel AK, Duh MS, Barghout VE, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

Real-world economic outcomes among patients (pts) who initiated pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.

Real-world outcomes among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.
Authors: Nicholas J. Vogelzang, Sameer R. Ghate, Nanxin Li, Elyse Swallow, Miranda Peeples, Miriam Zichlin, Mark Meiselbach, Jose Ricardo Perez, Neeraj Agarwal.

Real-world outcomes among patients who initiated pazopanib as first targeted therapy for advanced renal cell carcinoma (ARCC): A retrospective analysis of Medicare data.
Authors: Li N, Du EX, Peeples M, Chu L, Xie J, Barghout V, Tang DH.

Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.
Authors: Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP.

Real-world palbociclib dosing patterns and potential wastage associated with dose modifications among post-menopausal women with HR-positive/HER2-negative metastatic breast cancer (mBC).
Authors: Li N, Du EX, Chu L, Peeples M, Xie J, Barghout VE, Tang DH.

Real-world treatment patterns and costs in Medicare beneficiaries newly diagnosed with acute myeloid leukemia.

Real-world treatment patterns and costs in patients with newly diagnosed acute myeloid leukemia.
Reduced healthcare resource utilization in patients with chronic lymphocytic leukemia achieving complete remission to first-line therapy.
*Authors:* Heitner Enschede S, Samp J, Guerin A, Foster R, Meisnner B, Rokito A, Gauthier G.

Refill gaps and dose reductions in patients treated with abiraterone acetate plus prednisone (AA+P) or enzalutamide (ENZ).
*Abstract:* 2017 Genitourinary Cancers Symposium, Orlando, FL.
*Authors:* Pilon D, Behl AS, Emond B, Xiao Y, Lefebvre P, Kane CJ.

Relative progression-free survival over time of novel triplet regimens for the treatment of relapsed/refractory multiple myeloma.
*Authors:* Betts K, Chen C, Zichlin M, Brun A, Signorovitch J, Makenbaeva D.

Severe Adverse Events Impact Overall Survival and Costs In Elderly Patients with Advanced NSCLC On Second-Line Therapy.
*Authors:* Borghaei H, YimYM, Guerin A, Gandhi M, Pivneva I, S S, Ionescu-Ittu R.

Systematic literature review for treatment outcomes (including immuno-oncology treatment) among patients with stage 3 unresectable non-small cell lung cancer (NSCLC).
*Abstract:* ISPOR 20th Annual European Congress Glasgow, UK.
*Authors:* Zhou Z, Song J, Ouwens MJ, Huhn M, Jiang H, Zhang Y, Dalevi D.

Treatment characteristics and deep molecular response in chronic phase-chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: A multi-country retrospective chart review study.
*Authors:* Cortes JE, Huynh L, Mendelson E, Brandt P, Dalal D, Dersarkissian M, Cortina D, Narkhede S, Duh MS.

Treatment Disruption of First-line Endocrine and Chemotherapy among Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer (mBC).
*Authors:* Li N, Du EX, Peeples M, Chu L, Xie J, Barghout V, Tang DH.

*Authors:* Griffin JD, Yang H, Song Y, Kinrich D, Bui CN.

Treatment patterns in patients with advanced gastric cancer in Taiwan.

Treatment patterns in patients with chronic myeloid leukemia in chronic phase in US clinical practice, with a focus on tyrosine kinase inhibitor therapy discontinuation.
Treatment patterns of hypomethylating agents in older (≥65 Years) acute myeloid leukemia patients who did not receive intensive chemotherapy: A retrospective claims database analysis.

Authors: Sundaram M, Lafeuille MH, Hoehn D, Emond B, Romdhani H, Lefebvre P.

Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: A US clinical practice perspective.

Authors: Ritchie EK, Wolff JE, Latremouille-Viau D, Guerin A, Pivneva I, Briggs O, Joseph GJ, Atallah EL.

VTE recurrence and safety of anticoagulants among patients with cancer treated for venous thromboembolism.

Authors: Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB.

What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice?

Authors: Bajaj P, Latremouille-Viau D, Guerin A, Reyes C, Kurian A, Stein A, Cortazar P.

Who is receiving novel therapies for relapsed/refractory follicular lymphoma? A retrospective chart review of recent real-world practice.

Authors: Signorovitch J, Garcia-Horton V, Ricculli ML, McGuire M.

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.


PS01.70: Ceritinib Dosing Patterns and Outcomes of Patients with ALK+ NSCLC in a Real-World Practice in the United States: Topic: Medical Oncology.
Authors: Bendaly E, Dalal A, Culver K, Galebach PJ, Bocharova I, Foster R, Struebbe G, Guerin A.

Association between time to progression and subsequent survival inceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer.
Authors: Liu G, Zhang J, Zhou ZY, Li J, Cai X, Signorovitch J.

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed with Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records from US Community Oncology Practices.
**Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.**


**Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.**


*Authors:* Pilon D, Queener M, Lefebvre P, Ellis LA.

**Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.**


*Authors:* Maziarz RT, Guérin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L.

**Reduction in hospital visits in patients with chronic myeloid leukemia (CML) with better adherence to tyrosine kinase inhibitors (TKI) and increased molecular monitoring frequency.**


*Authors:* Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.

**Temporal trends in overall survival and disease-specific survival among patients with advanced renal cell carcinoma during the targeted therapy era: A SEER-Medicare analysis.**


*Authors:* Vogelzang NJ, Signorovitch JE, Swallow E, Peeples M, Koo V, Perez JR, Ghate S, Pal SK.

**Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.**


**Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.**


**The economic burden of brain metastasis among lung cancer patients in the United States.**


**Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2-Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.**


*Authors:* Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guerin A.

**Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.**


*Authors:* Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.
Real-world treatment patterns of everolimus + exemestane in patients with hormone-receptor-positive, human epidermal growth factor receptor-negative advanced breast cancer by line of therapy: A global chart review.


Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
Authors: Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L.

142PD: The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer.
Publication: Journal of Thoracic Oncology 2016 04; 11(4): S119-S120. doi: http://dx.doi.org/10.1016/S1556-0864%2816%2930252-0.
Authors: Zhang J, Song Y, Zhou ZY, Zhang C, Signorovitch J.

178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC.
Publication: Journal of Thoracic Oncology 2016 04; 11(4): S134-S135. doi: http://dx.doi.org/10.1016/S1556-0864%2816%2930288-X.

Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.
Authors: Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guerin A.

Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Authors: Pal SK, Signorovitch JE, Reichmann WM, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.
Authors: Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispensieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV.

Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
Economic burden of common adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).

Effectiveness of Everolimus versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients with Multiple Metastatic Sites.
*Authors:* Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice.

*Authors:* Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ.

Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: A retrospective claims study in the US.
*Publication:* Current Medical Research and Opinion 2016 02; 32(2): 385-394.
*Authors:* Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Wu EQ, Guerin A.

Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.

Access to biomarker testing in patients with advanced nonsmall cell lung cancer.

Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer.
*Abstract:* 17th World Conference on Lung Cancer, Vienna, Austria Dec 4-7, 2016.
*Authors:* Ganti AK, Hirsch F, Wynes MW, Ravelo A, Ramalingam S, Ionescu-Ittu R, Pivneva I, Borghaei H.

*Authors:* Ganti AK, Borghaei H, Hirsch FR, Wynes M, Ravelo A, Ionescu-Ittu R, Pivneva I, Ramalingam SS.

Ceritinib Dosing Patterns and Outcomes of Patients with ALK+ NSCLC in a Real-World Practice in the United States.
Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.
Abstract: 41st European Society for Medical Oncology Congress
Copenhagen, Denmark Oct 7-11, 2016.
Authors: Heng D, Park J, Signorovitch JE, Yang H, Song J, Weiss J, Dezzani L, Powles TB.

Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy: A US claims study.
Authors: Li N, Hao Y, Tang D, Koo V, Fang A, Peeples M, Kageleiry A.

Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC.
Authors: Daniel Shao-Weng Tan, Geoffrey Liu, Dong-Wan Kim, Michael Thomas, Enriqueta Felip, James Signorovitch, Jie Zhang, Tomek Szczudlo, Alice Shaw, et al.

Cost per month of overall survival and progression-free survival: Everolimus compared with cabozantinib, nivolumab, and axitinib for metastatic renal cell carcinoma.
Authors: Swallow E, Ghate S, Messali A, McDonald E, Duchesneau E, Perez JR.

Disparities in treatment patterns and outcomes between caucasian and African American patients with multiple myeloma (MM).

Economic Benefits Associated with Resolution or Improvement of Carcinoid Syndrome Symptoms Following Treatment with Above-Standard Dose of Octreotide LAR in Patients with Neuroendocrine Tumors: Data From a Multicenter Chart Review Study.
Authors: Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke M, Benson A.

Economic burden of hematologic adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).

Economic burden of relapsed/refractory chronic lymphocytic leukemia.
Abstract: 16th International Workshop on Chronic Lymphocytic Leukaemia, Sydney, NSW Australia Sep 6-9, 2015.
Authors: Guerin A, Ray S, Gauthier G, Hsu Li, Zhdanava M, Heroux J, Wu E.

Economic evaluation of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors.
Authors: Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson AB.
Economic model to examine the cost benefit associated with resolution or improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide in patients with neuroendocrine tumors based on data from a retrospective chart review study at three large tertiary oncology centers in the United States.

Authors: Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke M, Benson A.

Efficacy of front-line treatment combinations with ponatinib versus 1st-and 2nd-generation tyrosine kinase inhibitors for Ph+ acute lymphoblastic leukemia: A meta-analysis and meta-regression.
Authors: Jabbour E, DerSarkissian M, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, Duh MS.

Epidemiological assessment of real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.
Authors: Huynh L, Herring M, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.

Factors and treatment patterns associated with everolimus use among post-menopausal women with HR+/HER2- metastatic breast cancer.

Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC).
Abstract: 41st European Society for Medical Oncology Congress, Copenhagen, Denmark Oct 7-11, 2016.

Impact of symptomatic skeletal events on healthcare resource utilization, health-related quality of life and pain among patients with castration-resistant prostate cancer and bone metastases.
Authors: McKay RR, Haider B, Duh MS, Valdarrama A, Nakabayashi M, Fiorillo M, Ristovska L, Wen LK, Kantoff PW.

The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer.
Authors: Jie Zhang, Yan Song, Zheng-Yi Zhou, Chenxue Zhang, James Signorovitch.

Authors: Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.

Number needed to treat and associated incremental costs to achieve one additional patient free of event: indirect comparison of enzalutamide and abiraterone + prednisone in chemotherapy-naïve metastatic castration-resistant prostate cancer.

Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.
Authors: Heng DYC, Park J, Signorovitch JE, Yang H, Song J, Patel D, Lin C, Powles T.
Overall Survival in Patients with Glioblastoma Before and After Bevacizumab Approval.
Authors: Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Macalalad AR, Shi S, Uhm JH.

Patient characteristics and Overall Survival (OS) in the post-docetaxel Metastatic Castration-Resistant Prostate Cancer (mCRPC) community setting.
Authors: Cheng WY, Miao R, Duh MS, Vekeman F, Sung J, Gauthier-Loisel M, Fortier J, Dhawan R, Oh WK.

Authors: Ghate S, Li N, Swallow E, Zichlin M, Duchesneau E, Kang B, Perez JR.

Quality of life by smoking status in patients with metastatic or advanced NSCLC from Phase 2 clinical trial of veliparib with carboplatin and paclitaxel.
Authors: Bonnet P, Cloutier M, McKee MD, Loisel MG, Qian J, Mu F, Qin QQ, Guerin A, Wu EQ, Giranda VL.

Real-world analysis of medical costs and healthcare resource utilization in elderly women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy.
Authors: Hao Y, Li N, Fang A, Koo V, Peeples M, Kageleiry A.

Authors: Nicholas J. Vogelzang, Sumanta K. Pal, Sameer Ghate, Nanxin Li, Elyse Swallow, Miranda Peeples, Miriam Zichlin, Jose Ricardo Perez, Neeraj Agarwal.


Real-World Treatment Patterns and Brain Metastases Development in ALK-Positive Non-Small Cell Lung Cancer.
Authors: Betts K, Song J, Guo J, Wong W, Ravelo A, M. S.

Real-world treatment patterns in advanced Pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.
Authors: Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.

Severe adverse events impact overall survival (OS) and costs in elderly patients with advanced NSCLC on second-line therapy.
Authors: Borghaei H, Yim YM, Guerin A, Gandhi M, Pivneva I, Shi S, Ionescu-Ittu R.
Survival and Tumor Response Outcomes in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Systematic Literature Review.
Authors: Signorovitch J, Li N, Zhang C, Shaw J, Dastani H, Orsini L.

Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2- metastatic breast cancer: A retrospective chart review study in the US.
Authors: Li N, Ohashi E, Koo V, Xie J, Hao Y, Tang DH.

Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.
Authors: Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.

Treatment patterns and healthcare costs in newly diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States: A retrospective claims database analysis.
Authors: Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon-Sanschagrin P, Chen L.

Treatment patterns and key factors associated with high treatment costs among commercially insured patients with advanced basal cell carcinoma.
Authors: Migden M, Wei J, Tang W, Herrera V, Xie J, Palmer J.

Access to cancer directed therapies and cancer specialists in patients with metastatic lung cancer.

Budgetary impact analysis of abiraterone acetate plus prednisone (AA+P) versus enzalutamide (ENZ) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors: Ellis L, Pilon D, Lefebvre P.

Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naive anaplastic lymphoma kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison.

Current treatment characteristics in postmenopausal women with HR+/HER2- metastatic breast cancer.
Authors: Vekeman F, Hao Y, Cheng WY, Fortier J, Robitaille MN, Duh MS.

Diverse characteristics of ALK+ NSCLC patients in the United States.

Overall survival with first line endocrine therapy or chemotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review study in the US.
Authors: Xie J, Hao Y, Li N, Lin PL, Koo V, Ohashi E, Wu EQ.
Patient relevant outcomes in recurrent glioblastoma: a systematic literature review.
Authors: Signorovitch J, Li N, Kim S, Dastani H, Shaw J, Orsini L.

Physician decision-making on modifying or discontinuing crizotinib in ALK+ NSCLC: A survey of U.S. physicians.

Real-world characteristics and outcomes for ALK+ NSCLC in Korea.

Real-world outcomes of patients with relapsed or refractory chronic lymphocytic leukemia with 17p deletion.
Authors: Lamanna N, Hurst D, Latremouille-Viau D, Ionescu-Ittu R, Guerin A, Yim YM, Reyes C.


Symptoms of bone and liver metastases in patients with ALK+ Non-Small Cell Lung Cancer (NSCLC).
Authors: Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ, Macalalad A.

Treatment patterns of recently approved therapies for metastatic castration resistant prostate cancer (mCRPC): Real world evidence from three datasets.
Authors: Ellis L, Lafeuille MH, Gozalo L, P L, Malangone-Monaco E, Wilson K, McKenzie S.

Treatment sequences and pharmacy costs observed for abiraterone and enzalutamide: considerations for U.S. payors.
Authors: Ellis L, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.

Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites.
Authors: Xie J, Hao Y, Li N, Lin P, Ohashi E, Koo V, Wu E.

Real-world effectiveness of Everolimus versus endocrine monotherapy or chemotherapy in HR+/HER2-metastatic breast cancer patients with liver metastasis or multiple metastatic sites.
Authors: Li N, Hao Y, Lin P, Koo V, Ohashi E, Wu E, Xie J.

Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2- metastatic breast cancer: A retrospective claims study in the US.
Authors: Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Guerin A.
Median overall survival meta-analysis comparing brentuximab vedotin with other therapies in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant.


Treatment patterns of endocrine therapy and chemotherapy among post-menopausal women with HR+/HER2-Metastatic Breast Cancer.

Authors: Lin PL, Hao Y, Signorovitch JE, Kelley C, Macalalad AR, Ohashi E, Zhou Z, Wu EQ.

Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.
Authors: Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Wu EQ.

Nilotinib vs Dasatinib as Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) based on Real-World Data.

Abstract: 57th Annual Meeting of the American Society of Hematology, Orlando, FL  December 5-8, 2015.
Authors: Li N, Yang C, Fan L, Totev T, Guerin A, Chen L.

Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment.

Authors: Chen L, Wu EQ.


Authors: Xie J, Hao Y, Zhou ZY, Qi CZ, De G, Gluck S.

Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.

Authors: Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ.


Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer.

Authors: Song Y, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, Wu EQ.

Patient outcomes following curative-intent lung resection among non-small cell lung cancer (NSCLC) patients in China.
Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence after Resection.
Authors: Guerin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP.

Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.
Authors: Toy EL, Vekeman F, Lewis MC, Oglesby AK, Duh MS.

Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.

ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.

Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Authors: Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA.

Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.
Authors: Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ.

Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.
Authors: Ellis LA, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.

Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.

Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.
Authors: Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.
Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.

Authors: Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J.

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.

Authors: Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guerin A, Yim YM.


Authors: Guerin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ.


The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.

Authors: Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V.

Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.

Publication: Drugs Context 2015 03; 4. doi: 10.7573/dic.212274.
Authors: Girvan AC, Carter GC, Li L, Kaltenboeck A, Ivanova J, Koh M, Stevens J, Hayes-Larson E, Lahn MM.

A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments.

Authors: Wagner MJ, Ammodi LI, Duh MS, Korves C, Solleza F, Manson SC, Diaz J, Neary MP, Demetri GD.

The epidemiology of herpes zoster and its complications in Medicare cancer patients.

Authors: Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS.

Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).

Authors: Macalalad AR, Hao Y, Lin PL, Signorovitch JE, Wu EQ, Ohashi E, Zhou Z, Kelley C.

Comparative effectiveness of everolimus and axitinib as second targeted therapy of metastatic renal cell carcinoma in the United States: a retrospective chart review.

Authors: Signorovitch JE, Pal SK, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ, Jonasch E.
**Assessing the prognostic impact of intermediate outcomes on survival time in relapsed/refractory multiple myeloma (RRMM) patients (pts) via a robust and clinically interpretable quantitative procedure.**


*Authors:* Ayyagari R, Cheng WY, Cai X, Jones C, Ma E, Bonthapally V, Zhu Y, Lefebvre P, Wei LJ, Duh MS.

**Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study.**

*Abstract:* 57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL Dec 5-8, 2015.

*Authors:* Leleu X, Mateos M-V, Delforge M, Lewis P, Schindler T, Gibson CJ, Yang M, Weisel K.

**Association between duration of treatment (DOT) and healthcare costs in multiple myeloma (MM) patients receiving initial therapy with bortezomib.**


*Authors:* Xiao Y, Wong BJ, Lefebvre P, Fortier J, Ma E, Bonthapally V, Duh MS.

**Changes in treatment patterns among patients receiving at least two targeted therapies for metastatic renal cell carcinoma (mRCC) in the US: A comparison of retrospective chart reviews conducted in 2012 and 2014.**


*Authors:* Perez JR, Pal SK, Signorovitch JE, Reichmann WM, Li N, Liu Z, Jonasch E, Vogelzang NJ.

**Characteristics and treatment patterns of ALK+ NSCLC patients who receive second-generation ALK inhibitors: A chart review study.**


*Authors:* Cadranel J, Park K, Pless M, Bendaly E, Patel D, Sasane M, Swallow E, Galebach P, Stein K, Marinsek N, Zhang J.

**A chart review of patient characteristics, treatment patterns and response in metastatic breast cancer patients treated with ado-trastuzumab emtansine in first-line therapy and beyond.**


*Authors:* Gauthier G, Guerin A, Zhdanava M, Wu E.

**Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.**


*Authors:* Oh WK, Miao R, Duh MS, Vekeman F, Sung J, Cheng WY, Hennessy D, Gauthier-Loiselle M, Fortier J, Dhawan R.

**Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review.**


**Comparative effectiveness of everolimus versus chemotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US.**


*Authors:* Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

**Comparative effectiveness of everolimus versus endocrine monotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US.**


*Authors:* Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ.
Comparative effectiveness of everolimus vs. fulvestrant monotherapy among postmenopausal women with HR+/HER2-metastatic breast cancer.
*Authors*: Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ.

Comparative efficacy of treatments for previously treated advanced or metastatic non-small cell lung cancer (NSCLC): a network meta-analysis.
*Abstract*: ISPOR 18th Annual European Congress, Milan, Italy  Nov 7-11, 2015.
*Authors*: Zhang J, Zhou Z, Cai X, J. S.

Cost-effectiveness of ceritinib in previously treated patients with crizotinib in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer in Canada.
*Abstract*: ISPOR 18th Annual European Congress, Milan, Italy  Nov 7-11, 2015.

*Abstract*: ISPOR 18th Annual European Congress, Milan, Italy  Nov 7-11, 2015.

Cost-effectiveness of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors (GI-NETs).
*Abstract*: Association of Value-Based Cancer Care, Fifth Annual Conference, Washington, DC  May 3–6, 2015.
*Authors*: Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson AB.

Economic Benefits Associated with Resolution or Improvement of Carcinoid Syndrome Symptoms Following Treatment with Above-Standard Dose of Octreotide LAR in Patients with Neuroendocrine Tumors: Assessment Based on Data from a Multicenter Retrospective Chart Review Study.
*Authors*: Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke MH, Benson AB.

Economic burden of relapsed/refractory chronic lymphocytic leukemia.
*Authors*: Guerin A, Ray S, Gauthier G, Hsu L, Zhdanava M, Heroux J, Wu EQ.

Economic evaluation of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors (GI-NETs).
*Authors*: Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson A B.

The evolving treatment patterns in multiple myeloma (MM): Retrospective database analyses of U.S. community oncology electronic medical records and administrative claims.
*Authors*: MS D, Lefebvre P, Fortier J, Ma E, Bonthapally V, Wong BJ.

Five-year direct cost of pediatric patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (HSCT): An analysis from US payers’ perspective.
*Authors*: Mazariz RT, Guerin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L.
The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients.  
*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL  Dec 5-8, 2015.  
*Authors:* Guerin A, Ray S, Gauthier G, Hsu L.-I, Zhdanava M, Wu E.

The impact of ponatinib versus allogeneic stem cell transplant (SCT) on outcomes in patients with chronic myeloid leukemia (CML) or philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL) with the T315i mutation.  
*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL  Dec 3-6, 2015.  

Is there a difference in outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) who receive chemotherapy (CT) vs androgen receptor-targeted therapy (ART) after 1st-line ART in the community setting?  

Overall Survival (Os) and Quality-of-Life (Qol) Outcomes in Recurrent Or Metastatic Squamous Cell Carcinoma of the Head And Neck (Scchn): A Systematic Literature Review.  
*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy  Nov 7-11, 2015.  
*Authors:* Signorovitch J, Li N, Zhong Y, Shaw J, Dastani H, L, O.

Overall Survival (Os), Quality of Life (Qol), and Neurocognitive Function (Nf) in Recurrent Glioblastoma Multiforme (GbM): A Systematic Literature Review.  
*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy  Nov 7-11, 2015.  
*Authors:* Signorovitch J, Li N, Ohashi E, Dastani H, Shaw J, L, O.

Overall survival in post-menopausal women with HR+/HER2-metastatic breast cancer treated with 1st-line endocrine therapy vs. Chemotherapy.  
*Authors:* Vekeman F, Hao Y, Cheng WY, Fortier J, Robitaille M, Duh MS.

Real-World Dosing and Drug Costs with Everolimus (EVE) and Axitinib (AXI) as 2nd Targeted Therapies (TTs) for Metastatic Renal Cell Carcinoma (mRCC): A Retrospective Chart Review.  
*Authors:* Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.

Real-world effectiveness of everolimus subsequent to different first targeted therapies (TTs) for the treatment of advanced renal cell carcinoma (aRCC): Synthesis of three retrospective chart reviews.  
*Abstract:* 14th International Kidney Cancer Symposium Miami, FL  Nov 6-7, 2015.  
*Authors:* Pal SK, Signorovitch JE, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.

Real-world effectiveness, dosing, and drug costs of everolimus (EVE) and axitinib (AXI) as second targeted therapies (TTs) for advanced renal cell carcinoma (aRCC) in the US: A retrospective chart review.  
*Abstract:* 14th International Kidney Cancer Symposium, Miami, FL  Nov 6-7, 2015.  
*Authors:* Jonasch E, Pal SK, Signorovitch JE, Li N, Liu Z, Perez JR, Vogelzang NJ.
Realworld treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) treated with zivafiblercept (Z) in community oncology practices in the United States (US).

Authors: Ivanova JI, Saverno K, Sung J, Sheng Duh M, Zhao C, Cai X, Vekeman F, Peavyhouse A, Dhawan R, Fuchs CS.

Real-world treatment patterns in advanced Pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.


Authors: Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.


Systematic literature review (SLR) of clinical and realworld observational studies of octreotide LAR for treatment of neuroendocrine tumors (NETs).


Authors: Sorg R, Neary M, Tang C, Song C, Xie J.

Testing and treatment practice of oncologists managing ALK+ NSCLC: International physician survey across four regions.


Time to Progression and Post-Progression Survival in ALK+ Ceritinib-Treated NSCLC.


Authors: Geoffrey Liu, J Zhang, Zheng-Yi Zhou, Junlong Li, Xiaopeng Cai, James Signorovitch.

Treatment patterns and best response in a contemporary cohort of patients with relapsed / refractory chronic lymphocytic leukemia with 17p deletion.

Abstract: Leukemia and Lymphoma Conference, Sydney, NSW Australia Sep 6-9, 2015.

Authors: Lamanna N, Hurst D, Latremouille-Viau D, Ionescu-Ittu, Guerin A, Yim YM, Reyes C.

Treatment patterns and characteristics of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus.


Authors: Vekeman F, Hao Y, Cheng W, Fortier J, Robitaille MN, Duh MS.

Treatment patterns and survival among ALK+ non-small cell lung cancer (NSCLC) patients: A chart review study.


Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients.


Authors: Guerin A, Ray S, Gauthier G, Hsu Ling-I, Zhdanava M, Wu EQ.
What are the real-world treatment patterns and medical costs in patients with metastatic breast cancer treated with ado-trastuzumab emtansine?

*Authors:* Cloutier M, Guerin A, Heroux J, Emond B, Wu E.

What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses.


Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamide-dexamethasone (VCd) compared to bortezomiblenalidomide-dexamethasone (VRd) for initial treatment of newly diagnosed multiple myeloma (MM).

*Authors:* Kumar SK, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille M, Lefebvre P, Cheng W, Dea K, Yap M, Saravanan S, Rembert D, Patt D, Niculescu L, Ma E, Quick M, Rajkumar SV.

Comparative overall survival with treatment sequences for metastatic renal cell carcinoma: A systematic review and meta-analysis of real-world observational studies.


*Authors:* Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.


*Abstract:* SOHO Annual Meeting, Houston, TX  Sep 17-20, 2014.
*Authors:* Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

Description of ALK+ NSCLC patient characteristics and ALK testing patterns.


Description of ALK+ NSCLC patient characteristics and ALK testing patterns.


Duration of treatment by line of therapy among post-menopausal women with HR+/HER2- metastatic breast cancer.

*Authors:* Macalalad AR, Hao Y, Signorovitch JE, Kelley C, Lin PL, Ohashi E, Zhou Z, Wu EQ.

Economic burden and treatments of progression to metastatic disease in ALK+ NSCLC patients.

Economic burden of bone and liver metastases in patients with ALK+ non-small cell lung cancer.
Authors: Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ.

Economic burden of brain metastases among lung cancer patients.
Authors: Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Guérin A.

Impact of underestimation of risk on treatment duration and recurrence in GIST patients.
Authors: Guerin A, Conley AP, Sasane M, Macalalad AR, Huang Q, Schwiep FA, Keir CH, Wu EQ.

Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC).
Authors: Signorovitch J, Wang J, Tan R, Thomason D, Kageleiry A, Swallow E.

Overall survival following initiation of first-line treatment with a non-steroidal aromatase inhibitor or fulvestrant among post-menopausal women with recurrent HR+/HER2- metastatic breast cancer.
Authors: Song Y, Hao Y, Macalalad A, Lin PL, Signorovitch JE, Wu EQ.

Overall survival in patients with HER2+ early stage breast cancer patients treated with trastuzumab in the US department of defense practice setting.

Predictors of treatment (tx) response and progression in BRAF V600E metastatic melanoma (mM) patients (pts) with brain metastases (BM) receiving vemurafenib (vem) in a real-world setting.
Authors: Gibney GT, Gauthier G, Aysa C, Galebach P, Wu EQ, Yeun MY, Sarang A, Reyes C, Guerin A.

Prostate cancer patients demonstrate adherence to medication use while on abiraterone acetate (AA) therapy.
Authors: Kozma C, Slaton TS, Ellis LA, McKenzie RS, Lafueille M, Grittner AM, Lefebvre P.

Real-world corticosteroid utilization in prostate cancer patients treated with two new oral agents.
Authors: Lafueille M, Ellis LA, McKenzie RS, Grittner AM, Lefebvre P.

Real-world treatment durations without chemotherapy (CT) for hormone-receptorpositive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC).

Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL).
Authors: Bonthapally V, Lafueille MH, Fortier J, Duh MS, Ng Y, Van De Velde H, Niculescu L, Ma E, Goy A.
A retrospective analysis of treatment patterns in elderly patients with chronic myeloid leukemia receiving dasatinib or nilotinib as second-line therapy after imatinib.


Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC.


Symptoms of bone and liver metastases in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).

Authors: Guerin A, Sasane M, Nitulescu R, Zhang J, Culver KW, Macalalad AR, Wu EQ.

Treatment failure patterns in patients with mantle cell lymphoma: results of a large U.S. observational study.

Authors: Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.

Authors: Gibney GT, Marynchenko M, Galebach PJ, Ayas C, Liu NS, Wu EQ, Yim YM, Abhyankar SS, Reyes CM, Guerin A.

Treatment patterns and predictors of everolimus use among post-menopausal women with HR+/HER2-metastatic breast cancer in the US.

Authors: Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ.

Twelve-month cost per responder (CPR) analysis of nilotinib and dasatinib as front-line therapy in patients with philadelphia chromosome-positive (PH+) chronic myeloid leukemia in chronic phase (CML-CP).

Authors: Guerin A, Revol C, Ramanakumar AV, Foster R, Wu EQ, Mhatre SK, Chen L.

Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC.


Treatment patterns in metastatic renal cell carcinoma in the US: A retrospective chart review.

Authors: Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Liu Z, Perez JR, Vogelzang NJ.

Treatments and clinical burden among Hodgkin lymphoma patients at high risk of relapse after autologous stem cell transplant: A literature review.

Authors: Bonthapally V, Ayyagari R, Yang H, Wu EQ, Shonukan O.
Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies.

Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.

Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Authors: Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H.

Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population.
Authors: Vekeman F, Cloutier M, Yermakov S, Amonkar MM, Arondekar B, Duh MS.

The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.
Authors: Guerin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ.

Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.

Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients—a chart extract-based approach.
Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.

Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
Authors: Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, Keir C, Wu EQ.
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.
Authors: Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chen L, DeAngelo DJ.

Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Authors: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL.

Authors: Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Vogelzang NJ.

Authors: Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.
Authors: Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D.

Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Authors: Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J.

Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Authors: Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.

Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation.

Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
Authors: DeAngelo DJ, Chen L, Guerin A, Styles A, Giguere-Duval P, Wu EQ.

Real-world treatment patterns among patients with advanced gastric cancer in Taiwan.
Authors: Gebra CC, Anna K, Jasmina I, Astra L, Alexandra SR, Maria K, Helen LHJ, Howard B, Narayan R, Shaila B, Rebecca C, Jen-Shi C.

Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer.
Authors: Lafeuille MH, Grittner AM, Lefebvre P, Ellis L, McKenzie RS, Slaton T, Kozma C.
Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis.
*Authors:* Guerin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG.

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.

Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
*Authors:* Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L.

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.
*Authors:* Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.

Above standard dose of octreotide-lar in patients with neuroendocrine tumors (NET) for control of carcinoid syndrome symptoms: A multi-center retrospective chart review study.
*Authors:* Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

Assessment and management of the risk of recurrence of resected gastrointestinal stromal tumors.
*Authors:* Conley AP, Sasane M, Pelletier CL, Guerin A, Macalalad AR, Huang Q, Wu EQ.

Association between Risk of Recurrence Assessment and Adjuvant Treatment (Tx) Duration in Patients (Pts) with Resected Gastrointestinal Stromal Tumors.
*Authors:* Guérin A, Sasane M, Keir C, Gauthier G, Macalalad A, Wu EQ, Conley AP.

Brain Metastases in Patients with ALK+ Non-Small Cell Lung Cancer: Treatment Patterns and Economic Burden.
*Abstract:* AMCP’s 26th Annual Meeting & Expo, Tampa, FL Apr 1-4, 2014.
*Authors:* Macalalad AR, Sasane M, Zhang J, Culver K, Dea K, Nitulesscu R, Guérin A.

Characteristics, treatment, and outcomes of patients with de novo HR+/HER2- advanced breast cancer: A retrospective chart review of community-based oncology practices.

Comparison of Survival, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy.
Comparison of Treatment Patterns of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy.


Cost Effectiveness of Everolimus plus Exemestane for the Treatment of Advanced HR+, HER2- Breast Cancer in the United States.

Authors: Xie J, Hao Y, Zhou J, Qi C, De G, S G.

Cost of treatment failure in patients with chronic lymphocytic leukemia: Results of a large U.S. observational study.

Authors: Senbetta M, Robitaille M-N, McKenzie RS, Lefebvre P.

Delay in Trastuzumab Initiation Leads to Decreased Overall Survival in Patients with HER2+ Early Stage Breast Cancer.


Incidence of hepatic resection among colorectal cancer patients with liver metastases.

Authors: Betts K, Lu M, Zhuo D, Sharma H, Morlock R, Sommer N, Ogale S.

Monitoring of multifunctional nanocomplex containing gold coated iron oxide particles in human prostate tumoral cells through MRI.

Authors: Oghabian MA, Montazerabadi A, Delavari HH, Irajirad R, Muhamadnejad S.

One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.

Authors: Chen L, Signorovitch JE, Wu EQ, Betts KA, Reichmann WM, Thomason D, Galebach PJ.

Patient characteristics, treatment, and outcomes in recurrent HR+/HER2- advanced breast cancer after adjuvant therapy: A retrospective chart review of community-based practice.


Physician treatment preferences for HR+/HER2- advanced breast cancer patients: A survey of community oncology practices in the United States.


Real-world treatment patterns among patients with advanced gastric cancer in South Korea.

Authors: Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, Roman AS, Koh M, Lee HJ, Rajan N, Ballal S, Birnbaum H, Bang YJ.

Relapse impact on overall survival in trastuzumab-treated women with HER2+ early-stage breast cancer.


Robust feature selection and gene committee predictor for breast cancer patient survival prediction.

Authors: Yang HH, Lee MP.

Treatment and Costs Post Crizotinib Monotherapy in Patients with ALK+ Non-Small Cell Lung Cancer: A Retrospective Claims Database Analysis.

Authors: Guérin A, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Macalalad AR.

Treatment sequencing and duration among HR+/HER2- advanced breast cancer patients in community-based oncology practices.


Underestimation of the Risk of Recurrence in Patients with Primary Resected Gastrointestinal Stromal Tumors.

Authors: Conley AP, Sasane M, Guérin A, Macalalad AR, Huang Q, Schwiep F, Wu E.


Comparison of healthcare resource utilization and costs between patients who received trastuzumab in an outpatient hospital vs. office clinic setting for the treatment of breast cancer.

Authors: Brammer M, Lalla D, Gauthier G, Guérin A, Giguere-Duval P, Wu EQ, Santos E.

Impact of low-grade adverse events (AES) on health-related quality of life (HRQOL) in adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase (PH+CML-CP) from the enestnd trial: 48-month follow-up.


Impact of regular molecular monitoring on tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.

Authors: Guerin A, Chen L, Wu EQ, Dea K, Goldberg SL.

Incremental cost of brain metastases among patients with metastatic melanoma.

Authors: Vekeman F, Cloutier M, Yermakov S, Amonkar M, Arondekar B, Duh MS.
Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).

**Abstract:** ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

**Authors:** Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Multi-center experience with CELLSEARCH circulating tumor cell kit on patients with metastatic breast cancer.

**Abstract:** 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX Dec 10-14, 2013.

**Authors:** Montero AJ, Eapen S, Tran KN, Gorin B, Adler P.

Overall survival and hospitalization rates in Medicare patients diagnosed with advanced NSCLC treated with bevacizumab-paclitaxel-carboplatin vs paclitaxel-carboplatin: A retrospective cohort study.


**Authors:** Langer CJ, Ravelo A, Hazard S, Guerin A L-VD, Ionescu-itlu R, Wu EQ, Ramalingam SS.

Survival advancements in advanced non-small cell lung cancer in the past 20 years: A story of hope.


**Authors:** Ravelo A, Guerin A, Latremouille-Viau D, Ionescu-itlu R, Wu EQ.

Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).

**Abstract:** 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28 2013.

**Authors:** Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).

**Abstract:** 14th International Myeloma Workshop Conference, Kyoto, Japan Apr 3-7, 2013.

**Authors:** Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Association between guideline-adherent imaging and overall survival following 2nd-line targeted therapy for metastatic renal cell carcinoma.

**Abstract:** 12th International Kidney Cancer Symposium, Chicago, IL Oct 25-26, 2013.

**Authors:** Lin PL, Pal SK, Jonasch E, Signorovitch JE, Liu Z, Culver K, Scott JA, Vogelzang NJ.

Comparative effectiveness of 2nd-line targeted therapies for metastatic renal cell Carcinoma: Analysis of two practice-based chart reviews.

**Abstract:** 12th International Kidney Cancer Symposium Chicago, IL Oct 25-26, 2013.


Glioblastoma treatment patterns and outcomes and resource use in the united states.

**Abstract:** 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in Conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology, San Francisco, CA Nov 21-24, 2013.

**Authors:** Girvan A, Carter G, Li L, Kaltenboeck A, Chawla A, Ivanova J, Koh M, Stevens J, Lahn M.


**Abstract:** 12th International Kidney Cancer Symposium, Chicago, IL Oct 25-26, 2013.

**Authors:** Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Liu Z, Wang X, Culver K, Scott JA, George DJ, Vogelzang NJ.
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States (Re:).
Authors: Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population.
Authors: Duh MS, Hackshaw MD, Ivanova JI, Kruse G, Miller LA, Lefebvre P, Karner P, Wong B.

Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison.
Authors: Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P.

Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Authors: Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors.
Authors: Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, Guerin A.

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.
Authors: Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ.


Evaluating the utility of existing patient-reported outcome scales in novel patient populations with pancreatic cancer, lung cancer, and myeloproliferative neoplasms using Medicare current beneficiary survey data.
Authors: Ivanova JI, Mytelka DS, Duh MS, Birnbaum HG, Cummings AK, San Roman AM, Price GL, Swindle RW.

Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases.
Authors: Lefeuille MH, Gravel J, Grittner A, Lefebvre P, Ellis L, McKenzie RS.

Authors: Castellano D, Duh MS, Korves C, Suthoff ED, Neary M, Hernandez Pastor LJ, Bellmunt J.
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.


Authors: Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ.

Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.


Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.


Authors: Guerin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A.

Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.


Authors: Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lefevre MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.

The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.


Authors: Garrison LP, Jr., Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de Velde H, Corzo D, Duh MS.

Above Standard Dose of Octreotide-LAR in Patients wth Neuroendocrine Tumors (NET).


Authors: Goldman J, Hulke MH, Strosberg JR, Huynh L, Duh MS, Sahai V, Rademaker A, Benso AB.

Análisis Costo-Efectividad De Everolimus Más Exemestano Para Pacientes Con Cáncer De Mama Avanzado Con Receptores Hormonales Positivos (RE+) y HER2–, Que Fallaron a Los Inhibidores De Aromatasa No Esteroideos (IANES) En México.


Association between guideline-adherent imaging and overall survival following second-line targeted therapy for metastatic renal cell carcinoma.


Authors: Lin PL, Pal SK, Jonasch E, Signorovitch JE, Liu Z, Culver KW, Scott JA, Vogelzang NJ.

Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews.


Comparison of discontinuation, health care resource utilization (HRU), and costs between metastatic breast cancer (mBC) patients (pts) who received trastuzumab (T) in an office clinic versus outpatient hospital setting.


Authors: Brammer M, Lalla D, Gauthier G, Guerin A, Giguere-Duval P, Wu EQ, Santos E.
Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer.
Authors: Campone M, Yang H, Faust E, Kageleiry A, Signorovitch J, Zhang J, Gao H.

Do oncology patients in an outpatient hospital receive the same care as patients in an office/clinic setting? A case study evaluating patients with non-metastatic HER2+ breast cancer (BC) receiving adjuvant trastuzumab.
Authors: Lalla D, Bramer M, Guerin A, Gauthier G, Giguere-Duval P, Wu EQ, Santos E.

Dose-Escalation of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET).
Authors: Kulke MH, Strosberg JR, Huynh L, Duh MS, Sahai V, Rademaker AW, Benson AB.

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML).
Authors: Chen L, Guerin A, Wu EQ, Dea K, Goldberg SL.

The economic burden of metastatic castration-resistant prostate cancer: U.S. Medicare perspective.
Authors: Eapen S, Andrews R, Gorin B, Higano CS.

Efficacy of brentuximab vedotin and other treatments in patients with relapsed or refractory (RR) systemic anaplastic large-cell lymphoma (SALCL): A systematic review.
Authors: Bonthapally V, Yang H, Macalalad AR, Wu EQ, Lutes R, Shonukan O, Chi A, Huebner D.

Health care resource utilization and cost of Medicare patients with non-small cell lung cancer (NSCLC).
Authors: Yenikomshian M, Hackshaw M, Cai X, Trahey A, Arondekar B, Knoll S, Duh MS.

Observed abiraterone acetate utilization by prostate cancer (PC) patients in a large administrative claims database in the United States.
Authors: Lafeuille MH, Dean J, Lefebvre P, Ellis L, Senbetta M.

Outcomes of second-targeted therapy for mRCC: A retrospective chart review of community practices in the United States.
Authors: Jonasch E, Signorovitch JE, Lin P, Liu Z, Culver KW, Pal SK, Scott JA, Vogelzang NJ.

Predictors of complete response following disease recurrence in gastrointestinal stromal tumor (GIST) patient: A retrospective patient chart review analysis.
Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schweig FA, Keir CH, Magestro M, Wu EQ.

Prescribing decision drivers in patients with recurrent gastrointestinal stromal tumor (GIST) previously treated with adjuvant imatinib: A retrospective chart extract-based approach.
Authors: Guerin A, Sasane M, Gauthier G, Schweig FA, Keir CH, Magestro M, Wu EQ, Conley AP.
Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Authors: Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

Authors: Vogelzang NJ, Signorovitch JE, Lin PL, Liu Z, Culver KW, Scott JA, Pal SK, Jonasch E.

A single-center experience with CELLSEARCH system circulating tumor cell test on patients with metastatic breast cancer.
Authors: Montero AJ, Eapen S, Andrews RM, Gorin B.

Su2017 Impact of Chronic Constipation Severity on the Risk of Developing Colorectal Cancer and Benign Neoplasm.
Abstract: Digestive Disease Week, Orlando, FL May 18-21, 2013.
Authors: Guérin A, Mody R, Fok B, Wu EQ, Lasch K, Talley NJ.


Tumor characteristics and treatment (trt) patterns following disease recurrence in gastrointestinal stromal tumor (GIST) patients (pts) who received adjuvant imatinib (IM) as primary trt: A retrospective chart extract-based approach.
Authors: Gauthier G, Sasane M, Guerin A, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP.

Benefits of early switching from imatinib to a second-generation tyrosine kinase inhibitor following 12 month complete cytogenetic response failure: A chart review analysis.
Authors: DeAngelo DJ, Chen L, Guerin A, Styles A, Aberki C, Giguere-Duval P, Wu EQ.

Budget impact analysis of everolimus for ER+, HER2-metastatic breast cancer patients in the united states.
Authors: Xie J, Diener M, De G, Wu EQ, Namjoshi M.

Characteristics of gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis.
Authors: Guerin A, Conley AP, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

Characteristics of patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy.
Authors: Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD.
Comparison of disease outcomes for patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy.


Authors: Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Wu EQ.

Comparison of treatment changes for patients with chronic myelogenous leukemia in chronic phase switched from imatinib to nilotinib or dasatinib as second-line therapy.


Authors: Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD.

Comparison of treatment patterns and outcomes in metastatic breast cancer (MBC) patients initiated on trastuzumab versus lapatinib: A retrospective analysis.


Authors: Gauthier G, Guerin A, Styles A, Wu EQ, Brammer MG, Lalla D.

Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies.


Authors: Hurvitz SA, Guerin A, Brammer MG, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D.

Economic burden of hepatocellular carcinoma in China.


Frequency of molecular monitoring correlates with long term outcomes in chronic phase chronic myelogenous leukemia treated with first-line imatinib: Results of a community survey.


Authors: Goldberg SL, Chen L, Ericson SG, Macalalad AR, Guerin A, Liu N, Kaminsky M, Wu EQ.

Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with NSCLC treated with an epidermal growth factor receptor inhibitor (EGFRI).


Authors: Bonthapally V, Guerin A, Wu EQ, Gauthier G, Cloutier M, Holen KD, Ray S.

Investigation of gastrointestinal stromal tumor (GIST) care management in GIST patients (pts) receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis.

Abstract: ASCO’s Quality Care Symposium, San Diego, CA Nov 30-Dec 1, 212.

Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

Monitoring and switching patterns in chronic myelogenous leukemia (CML) pts treated with imatinib (IM): A chart review analysis.


Authors: Chen L, Guerin A, Aberki C, Wu EQ, Ericson S, Jabbour E.
Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases.

Authors: Xie J, Diener M, Wu EQ, Sorg R, Yu AP, Namjoshi M.

Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review.


Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase.

Authors: Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L.

Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase (CML-CP).

Authors: Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L.

Risk of disease recurrence and mortality in gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib adjuvant therapy: A chart review analysis.

Authors: Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

Comparison of adherence patterns with second-line nilotinib and dasatinib in patients with Chronic Myeloid Leukemia (CML).

Authors: Chen L, Guerin A, Guo A, Stepner M, Griffin JD, Wu EQ.

Risk of developing colorectal cancer and benign neoplasm in patients with chronic constipation.


Treatment patterns in metastatic renal cell carcinoma in the US: A retrospective chart review in community oncology practices.

Authors: Vogelzang NJ, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Jonasch E.

Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed with Advanced Ovarian Cancer.

Publication: Clinical Ovarian and Other Gynecologic Cancer 2012 12; 5(2); 67-77. e61.
Authors: Johnson SJ, Sorg RA, Borker RD, Duh MS.


Publication: Journal of Medical Economics 2012 12.
Authors: Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.

Authors: Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK.
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis.
Authors: Chen L, Guerin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E.

Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Authors: Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

Beyond the Abstract - Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Authors: Xie J.

The economic burden of metastatic breast cancer: a U.S. managed care perspective.
Authors: Montero AJ, Eapen S, Gorin B, Adler P.

Authors: Wu E, Chen L.

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Authors: Guerin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD.

Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia.
Authors: Lafeuille MH, Vekeman F, Wang ST, Kerrigan M, Menditto L, Duh MS.


Bioevaluation study of 32P-CP-PLLA particle brachytherapy in a rabbit VX2 lung tumor model

Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer.
Authors: Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB.

Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.
Authors: Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.
Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.


*Authors:* Yood MU, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C.

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.


*Authors:* Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antras L, Neary MP, McCann L, Hodge R, Sternberg CN.

Budget impact analysis of everolimus for estrogen receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients in the United States.


*Authors:* Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

Comparison of treatment patterns and outcomes in metastatic breast cancer patients initiated on trastuzumab vs. lapatinib; A retrospective analysis.


*Authors:* Gauthier G, Guerin A, Styles AL, Wu EQ, Masaquel A, Brammer MG, Lalla D.

Drug treatment (tx) patterns and survival among patients (pts) with metastatic or recurrent soft tissue sarcoma (m/rSTS) refractory to at least one prior therapy.


*Authors:* Wagner M, Amodu L, Duh MS, Korves C, Solleza F, Mykletun A, Manson S, Diaz J, Neery MP, Demetri GD.

Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with colorectal cancer treated with an epidermal growth factor receptor inhibitor (EGFRI).


*Authors:* Bonthapally V, Guerin A, Wu EQ, Gauthier G, Holen KD, Ray S.

Meta-analysis of the efficacy and safety of bortezomib retreatment in patients with multiple myeloma (MM).

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Knopf KB, Duh MS, Lafaille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials.


*Authors:* Signorovitch JE, Swallow E, Kantor E, Wang X, Hass T, Klimovsky J, Metrakos P.

PCN42 Health Care Utilization and Costs Among Lung Cancer Patients in China.

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research, Jun 2-6, 2012.


Re: Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases.


*Authors:* XIE J, NAMJOSHI M, WU E.

Review of national institute for health and clinical excellence (NICE) recommendations for anti-cancer agents across multiple drug-indication combinations.


A systematic review of the heterogeneity of treatment effect in ovarian cancer (OC)—Are there implications for outcomes research?


*Authors:* Chawla A, Nellesen D, Yee K, Brown J, Boye ME.

Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma (MRCC) in the United Kingdom: Preliminary results of an ongoing chart review study.


Comparing early intervention with zoledronic acid to no bisphosphonate (BP) therapy in patients with metastatic prostate cancer to bone: A study of the US Veterans Affairs (VA) population.

*Abstract:* 10th International Conference on Cancer-Induced Bone Disease Conference, Sheffield, UK  Sept 22-25, 2010.

*Authors:* Wu EQ, Guo A, Shi L, Lu M, Yu AP, Sharma H, Fan CPS, Vander Velde N.

The cost-effectiveness of bortezomib plus melphalan and prednisone versus lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment for the initial treatment of multiple myeloma in the United States.

*Abstract:* ISPOR 16th Annual International Meeting Baltimore, MD  May 21-25, 2011.

*Authors:* Wang ST, Huang H, Ba-mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, Van De Velde H, Duh MS.

Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia in inpatients.


*Authors:* Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P.

Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.


*Authors:* Yu AP, Namjoshi M, Xie J, Parikh K, Wu EQ, Guo A, Culver KW.

Health care resource utilization and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.


*Authors:* Le TK, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.

New methods to adjust for selective crossover in survival analysis: In assessments of cost-effectiveness of cancer therapies.


*Authors:* Delea TE, Duh MS, Weij J, Robins J.

Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.


*Authors:* Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M.

Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.


*Authors:* Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M.
Patterns of angiogenesis inhibitor treatment in patients with metastatic renal cell carcinoma (MRCC) in Ireland.

Patterns of treatment (trx) and safety of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC) in France.

Real world clinical resource utilization of metastatic prostate cancer patients in the United States: Results from two large claims databases.
Authors: Senbetta M LM, Dean J, McKenzie RS, Lefebvre P.

Treatment patterns and healthcare resource utilization of metastatic prostate cancer patients by physician specialty.
Authors: Senbetta M, Lafeuille MH, Dean J, McKenzie RS, Lefebvre P.

Health care resource utilization and costs associated with bevacizumab versus cetuximab in second-line treatment of metastatic colorectal cancer patients.
Abstract: 23rd Annual Meeting and Showcase of the AMCP, Minneapolis, MN Apr 27-29, 2011.
Authors: Yang H, Yu A, Yim Y, Yu E, Wu E.

Treatment (trx) patterns and toxicity of angiogenesis inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) in United Kingdom (UK).

The economics of the hematopoietic growth factors.
Authors: Eldar-Lissai A, Lyman GH.

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Authors: Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antras L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Publication: Journal of Managed Care Pharmacy 2011 10; 17(8): 621-643.
Authors: Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

5002 ORAL Complications Associated with Chemotherapy in Patients with Metastatic Breast Cancer.
Authors: Brammer M, Lalla D, Guerin A, Latremouille-Viau D, Yu A, Wu E, Hurvitz S.
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
*Authors:* Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N.

Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
*Authors:* Yang H, Yu AP, Wu EQ, Yim YM, Yu E.

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.
*Authors:* Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bolliu VK, Williams D, Wei J, DeAngelo DJ.

The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.
*Publication:* Prostate Cancer and Prostatic Diseases 2011 03; 14(1): 79-84. doi: 10.1038/pcan.2010.49.

Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
*Authors:* Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary M, Duh MS.

Adherence patterns and dose adjustments with second-line nilotinib and dasatinib in patients with chronic myeloid leukemia: Evaluation in a real-world setting.
*Authors:* Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu E.

The association between treatment (TX) modifications due to adverse events (AES) and overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with sunitinib and sorafenib: Results from a multi-country study in europe.
*Authors:* Oudard S, Porta C, Castellano D, McDermott R, Nathan P, McCaffrey J, Neary MP, Korves C, Dial Suthoff E, Duh M.

Chemotherapy-related complication burden in patients with metastatic breast cancer in a real-world setting.
*Authors:* Hurvitz SA, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Brummer M.

Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia.
*Authors:* Guerin A, Bollu VK, Guo A, Stepner M, Griffin JD, Wu EQ.

Complications associated with chemotherapy in patients with metastatic breast cancer.
*Authors:* Brummer M, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Hurvitz S.
Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting.
Authors: Guerin A, Lalla D, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M, Hurvitz SA.

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial.

Impact of pleural effusion (PE) on treatment adherence, discontinuation, switching, and dose modification in patients with chronic myelogenous leukemia (CML).
Authors: Wu EQ, Guerin A, Bollu VK, Guo A, Cloutier M, Ponce de Leon Barido D, Ericson S, Quintas-Cardama A.

Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases.
Authors: Yu AP, Diener M, Wu EQ, Namjoshi M.

A pan-european study of treatment (TRX) patterns and toxicity of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC).

Sunitinib (SU) treatment (trx) patterns and toxicity in patients (pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).

Sunitinib (SU) treatment (Trx) patterns and toxicity in patients (Pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).

Treatment (trx) of metastatic renal cell carcinoma (mRCC) with angiogenesis inhibitors (AIs): Safety and treatment patterns observed in Taiwanese patients.

Treatment (trx) patterns of angiogenesis inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) in Ireland.
Authors: McDermott RS, Donnellan PP, McCaffery J, Sarda SP, Korves C, Luka A, Wei R, Neary M, Hanley R, Duh MS.
Treatment (TX) patterns and toxicity of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC) in Spain.


*Authors:* Castellano D, Duh MS, Dial Suthoff E, Korves C, Vekeman F, Ramamurthy P, Mykletun A, Lyon-Caen S, Neary MP, Bellmunt J.

Treatment patterns and health care resource utilization of metastatic colorectal cancer (mCRC) patients who received bevacizumab or cetuximab in second-line regimen.


*Authors:* Yang H, Yu AP, Yim Y, Yu E, Wu E.

Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia.

*Abstract:* 52nd Annual Meeting of the American Society of Hematology, Orlando, FL Dec 4-7, 2010.

*Authors:* Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu EQ.

Costs of treatment with angiogenesis inhibitors (AIS) in patients with metastatic renal cell carcinoma (MRCC): Results from a medical chart review study.


*Authors:* Oh WK, McDermott DF, Duh MS, Antras L, Chen K, Sarda SP, Luka A, Whittemore S, Ramamurthy P, Neary MP, Choueiri TK.

Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab.


*Authors:* Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh MS.

The economic burden of pleural effusions (PE) in patients with chronic myeloid leukemia (CML).

*Abstract:* 52nd Annual Meeting of the American Society of Hematology, Orlando, FL Dec 4-7, 2010.

*Authors:* Wu EQ, Guerin A, Bollu V, Williams D, Guo A, De Leon Barido DP, Yu AP, Quintas-Cardama A.

Health care costs associated with angiogenesis inhibitors (AIS) and mtor inhibitors (MTORS) in patients with metastatic renal cell carcinoma (MRCC) treated at US community oncology clinics.


*Authors:* Chen K, SP S, Antras L, Whittemore S, Luka A, Ramamurthy P, Scott J, Fortner B, Neary MP, Duh MS, Jolly P.

Health care costs associated with multikinase inhibitors (MKIS) for treatment of metastatic renal cell carcinoma (MRCC) in a clinical practice setting in Italy.


Healthcare costs of second-line (2L) metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BV) versus cetuximab (CX).


*Authors:* Yim Y, Wu EQ, Yu AP, Yang HY, Yu E.

Incidence and cost of adverse events (AEs) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIs).


*Authors:* Dial E, Duh MS, Antràs L, Rodermund D, Neary MP, Choueiri TK, Oh WK.
Active dose re-escalation of nilotinib following dose reduction is associated with improved efficacy in patients with chronic phase chronic myeloid Leukemia (CML-CP) who fail imatinib. 


Puk1 incidence and cost of adverse events (AES) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIS).

Authors: Dial E, Duh MS, Antras L, Rodermund D, Neary MP, Choueiri TK, Oh WK.

Modeling the cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States.

Authors: Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, Van De Velde H, Esseltine DL, Garrison L.

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. 

Authors: Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD.

Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.

Authors: Holloway RW, Grendys EC, Lefebvre P, Vekeman F, McMeekin S.


Lower health care resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients: Evidence from a clinical practice setting study.

Authors: Guerin A, Bollu V, Williams D.

PCN47 Comparison of health care resource utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia (CML).

Authors: Wu E, Bollu V, Guo A, Guerin A, Tsaneva M, Williams D, Griffin J.

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.

Authors: Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J.

Comparison of skeletal complications and treatment patterns associated with early versus delayed zoledronic acid therapy in multiple myeloma.

Abstract: 52nd Annual Meeting of the American Society of Hematology, Orlando, FL Dec 4-7, 2010. 
Authors: Yu AP, Bensimon AG, Marynchenko M, Wu EQ, Namjoshi M, Guo A, Ericson SG, Raje N.
Non-adherence to imatinib in chronic myeloid leukemia (cml) patients is associated with short-and long-term negative impacts on health care resource utilization and costs.

Authors: Guerin A, Bollu V, Guo A, Wu E, Yu A, Sirulnik L, Griffin J.

Adverse events associated with imatinib dose escalation versus switching to dasatinib in patients with chronic myelogenous leukemia.


Health care resource utilization associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.

Authors: Yu AP, Guo A, Guerin A, Latremouille-Viau D, Tsaneva M, Xie J, Signorovitch J, Williams D, Wu E.

Real world treatment patterns of gastrointestinal stromal tumor patients.

Authors: Wu EQ.

Treatment patterns of chronic myelogenous leukemia patients who initiated their treatment on imatinib.

Authors: Guérin A, Guo A, Williams D, Yu AP, Wu EQ, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin JD.

Comparison of infection-related hospitalization risk among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

Authors: Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

Patients (Pts) with metastatic Renal Cell Carcinoma (mRCC) receiving Angiogenesis Inhibitor (AI) therapies:
Treatment efficacy and safety in clinical practice.


Pattern of utilization of pegfilgrastim (PEGFIL) in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.

Authors: Skarin AT, Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS.

Treatment (Tx) and dosing patterns for Angiogenesis Inhibitor (AI) therapies in patients (Pts) with metastatic Renal Cell Carcinoma (mRCC).

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

Authors: Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Duh MS.

Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.

Authors: Duh MS, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK.

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.

Authors: Diel IJ, Weide R, Koppler H, Antras L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.

Adverse events associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.

Publication: J Clin Oncol (Meeting Abstracts) 2009 05; 27(15S): 7092.
Authors: Wu E, Guo A, Williams D, Guérin A, Yu A, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin J, Bollu V.

Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.

Authors: Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P.

Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.

Authors: Vekeman F, McKenzie RS, Bookhart BK, Laliberte F, Duh MS, Tak Piech C, Lefebvre P.

An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.

Authors: Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.

Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia.

Authors: Toy EL, Porter CL, Books P, Vekeman F, Barghout V, Duh M, Skarin AT.

Comparison of healthcare utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia.

Authors: Wu EQ, Bollu VK, Guo A, Guerin A, Tsaneva M, Williams D, Griffin JD.

Comparison of infection-related hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.

Authors: Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab.

Authors: Lefeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh M.
Direct health care and workloss burden of chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and non-small cell lung cancer.

Authors: Pike C, Birnbaum HG, Kaufman R, Muehlenbein CE, Pohl G, Natale R.

Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): A sub-analysis of the ENACT (expanding nilotinib access in clinical trials) study.


Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): Sub-analyses of the ENACT (expanding nilotinib access in clinical trials) study.


Lower healthcare resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients - Evidence from a clinical practice setting study.

Authors: Guerin A, Bollu VK, Williams D.

Molecular response, efficacy and safety analysis of 168 adult french patients with chronic myeloid leukemia (CML) in chronic phase (CP) from the ENACT (expanding nilotinib access in clinical trials) study.


Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs.

Authors: Wu EQ, Bollu VK, Guo A, Guerin A, Yu AP, Sirulnik A, Griffin JD.

Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.

Authors: Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS, Skarin AT.

Patterns and management of selected adverse events of adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) from the enact (expanding nilotinib access in clinical trials) study.


Authors: Pike C, Birnbaum H, Kaufman R, Muehlenbein C, Pohl G, Natale R.
Safety and treatment (trx) patterns of angiogenesis inhibitors (AIs) in patients (pts) with metastatic renal cell carcinoma (mRCC): Evidence from US community oncology clinics.


Safety and treatment (trx) patterns of multikinase inhibitors (MKI) in patients (pts) with metastatic renal cell carcinoma (mRCC) in Italy.


Authors: Di Cesare P, Porta C, Lasagna A, Ferraris E, Imanisio I, Paglino C, Antras L, Chen K, Neary MP, Duh MS.


Authors: Chen L, Antras L, Duh MS, Neary M, O’Brien ME.

Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.


Authors: Duh MS, Reynolds Weiner J, Lefebvre P, Neary M, Skarin AT.

Patients (PTS) with metastatic renal cell carcinoma (MRCC) receiving angiogenesis inhibitor (AIS) therapies: Treatment efficacy and safety in clinical practice.


Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC).


Authors: Choueiri TK, Brick AJ, McDermott D, Clement J, Kwabi C, Shah K, Choueiri TK, Duh MS, Neary MP, Oh WK.

Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer.


Authors: Chen L, Antras L, Duh MS, Levy N, Neary M, O’Brien ME, von Pawel J.

Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.


Authors: Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS.

Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.


Authors: Wu EQ, Mulani P, Farrell MH, Sleep D.

Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?


Authors: Wu WK, Duh MS, Lefebvre P.
The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
Authors: Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antras L, Smith M, Neary MP, Duh MS.

Medical Costs Associated with Imatinib Non-compliance in Chronic Myeloid Leukemia Patients.
Authors: Wu EQ, Feng W, Johnson S, Beaulieu N, Cremieux P, Cortes J.

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Publication: Drugs and Aging 2006 12; 23(12): 969-976.
Authors: Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.
Authors: Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS.

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application.
Authors: Cremieux P, Vekeman F, Lefebvre P.

Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
Authors: Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.

Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.
Publication: Current Medical Research and Opinion 2006 09; 22(9): 1623-1631. doi: 10.1185/030079906X120968.
Authors: Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.

Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Authors: Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, Mallett D, Perez EA.

Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors.
Authors: Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH.

Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
Authors: Chu E, Einhorn LH, Lefebvre P.

Assessing the risk of clinical fracture in men with non-metastatic prostate cancer receiving gonadotropin-releasing hormone agonist therapy.
Publication: Journal of Urology 2006 01; 175(1): 136-139.
Authors: Smith M, Boyce S, Moyneur E, Duh MS, Raut M, Brandman J.
Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.
Authors: Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J.

Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer.
Authors: Gosselin A, McKenzie R, Lifebvre P, Mody S, Piech C, Duh M.

PCN33 Mapping FACT-P and EORTC QLQ-C30 to the EQ-5D health utility in metastatic hormone-refractory prostate cancer patients.
Authors: Wu E, Mulani P, Farrell M, Sleep D.

Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.
Authors: Campos SM, Duh MS, Lefebvre P, Rosberg J.

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
Authors: Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.

Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia.
Authors: Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA.

Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia.
Authors: Duh MS, L Mark T.

Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve.
Authors: Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ.

Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.
Authors: Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia: a meta-analysis.
Authors: Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT.

Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia.
Publication: Journal of Managed Care Pharmacy 2004 11; 10(6): 531-537.
Authors: Cremieux PY, Fastenau JM, Kosicki G, Piech CT, Fendrick AM.
Dose conversion of erythropoietic agents in chemotherapy-induced anemia: A meta-analysis.


Authors: Rosberg J, Oster E, Wu E, Fastenau J, Piech C.

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.


Authors: Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy.


Authors: Gabrilove JL, Sarokhan B, Cremieux P.

Anemia-related costs for cancer patients.


Authors: Barnett A, Cremieux P, Fendrick A, George M, Slavin M.

Cost Effectiveness of rHuEPO in Oncology.


Authors: Cremieux P, Dial E, Gustafson M, Saraokhan B, Slavin M.

The costs of cancer: cancer-related conditions can add dramatically to overall costs of care.


Authors: Cremieux P, Slavin M, Fendrick A, Hiriak T, Kosicki G.

The costs of cancer to a major employer in the United States: a case-control analysis.


Authors: Barnett A, Birnbaum H, Cremieux PY, Fendrick AM, Slavin M.

Cost of outpatient blood transfusion in cancer patients.


Authors: Cremieux PY, Barrett B, Anderson K, Slavin MB.

Costs Associated with Anemia and Cancer.


Authors: Cremieux PY GM, Holland M, Slavin MB.

Understanding the Pharmacoeconomic profile of cancer.


Authors: Cremieux PY BH, Greenberg PE.


Publication: Pharmacoeconomics 1999 11; 16(5 Pt 1): 459-472.

Authors: Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB.

Overall survival and health care costs of Medicare patients with previously treated chronic lymphocytic leukemia.

Publication: Journal of Cancer Therapy 07.

Authors: Reyes C, Gauthier G, Shi S, Guerin A.
Renal

Economic and humanistic burden of dialysis-dependent patients with chronic kidney disease-related anemia: A systematic review.

*Abstract:* 55th Annual Congress of the European Renal Association-European Dialysis and Transplant Association, Copenhagen, Denmark.


Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.


The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States.


Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.


*Authors:* DerSarkissian M, Xiao Y, Duh MS, Lefebvre P, Swensen AR, Bell CF.

Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.


*Authors:* Thomas MC, Paldaniu P, Ayyagari R, Ong SH, Groop PH.

Natural history for adult patients with sporadic angiomyolipoma in the Netherlands.


*Authors:* Vekeman F, Magestro M, Karner P, Fortier J, Duh MS, Zonnenberg BA.

Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.


*Authors:* Quinlan SC, Cheng WY, Ishihara L, Irizarry MC, Holick CN, Duh MS.

The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.

*Abstract:* AMCP Nexus 2016, Baltimore, MD October 3-6, 2016.

*Authors:* Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhania A, Wu E.

Resource utilization of adult patients with sporadic angiomyolipoma in the Netherlands.


*Authors:* Vekeman F, Magestro M, Karner P, Fortier J, Duh MS, Zonnenberg BA.

Kidney involvement in tuberous sclerosis complex: The impact on health care resource use and costs in The Netherlands.


*Authors:* Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Zonnenberg BA.
Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs.


*Authors:* Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

Health care costs among patients who continue therapy or switch antimuscarinic agents for overactive bladder.


*Authors:* Ivanova J, Hayes-Larson E, Sorg RA, Birnbaum HG, Fitzmartin J, Berner T.

The healthcare cost impacts of switching antimuscarinic agents among patients with overactive bladder in a privately insured population.


*Authors:* Ivanova J, Hayes-Larson E, Sorg R, Birnbaum H.

Healthcare costs among patients who continue therapy or switch antimuscarinic agents for overactive bladder.


*Authors:* Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner G.

Kidney dysfunction and healthcare resource utilization in tuberous sclerosis complex patients in the Netherlands.


*Authors:* Magestro M, Vekeman F, Nichols T, Karner P, Duh MS, Srivastava B, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.


*Authors:* Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner T.

Serum urate and incidence of kidney disease among veterans with gout.


*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu E, Tawk RH, Liu J, Shi L.

Development and validation of a claims-based algorithm to identify urinary retention in patients receiving antiepileptic drugs.


*Authors:* Duh MS, Ishihara L, Cheng W, Quinlan SC, Zhao Y, Irizarry M.

Development and validation of a new chronic kidney disease risk equation: The role of pulse pressure.

*Abstract:* European Society of Cardiology, Amsterdam, Netherlands Aug 31 - Sep 4, 2013.

*Authors:* Ayyagari R, Vekeman F, Faust E, Ong S, Trahey A, Lefebvre P, Machnicki G, Duh M.

Impact of mirabegron treatment and symptom severity on work productivity and activity impairment in patients with overactive bladder.


*Authors:* Yan S, Warusavitarne J, Yang M, van den Broek N, Wu EQ, Thomason D, Hoch J.

Cost-effectiveness analysis of mirabegron versus tolterodine extended release in the treatment of patients with overactive bladder in the United States.


*Authors:* Xie J, Zhou ZY, Bui CN, Yan Y, De G, Runken MC, Wu EQ.

Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients.


*Authors:* Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P.

Uncontrolled serum uric acid is associated with an increased risk of developing renal disease in veterans with gout.

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL  Nov 4-9, 2011.


Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy.


*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

Assessment of recent erythropoiesis-stimulating agent guidelines changes on dosing patterns in chronic kidney disease patients not on dialysis.


*Authors:* Lafeuille MH, Bailey RA, Laliberte F, Senbetta M, Vekeman F, McKenzie RS, Blacksmith A, Lefebvre P.

Erythropoiesis-stimulating agent dosing and hemoglobin trends over time in chronic kidney disease patients not on dialysis.


*Authors:* Lafeuille MH, Bailey RA, Laliberte F, Senbetta M, Vekeman F, McKenzie RS, Dea K, Lefebvre P.

Seven year trends of pharmacy benefit erythropoiesis stimulating agent utilization and cost considerations of chronic kidney disease patients not on dialysis.


*Authors:* Vekeman F, Bailey RA, Laliberte F, Senbetta M, McKenzie RS, Lefebvre P.

Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients.


*Authors:* Vekeman F, Yameogo ND, Lefebvre P, Bailey RA, McKenzie RS, Piech CT.

Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.


*Authors:* Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P.

Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.


*Authors:* Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS.
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Authors: Diel IJ, Weide R, Koppler H, Antras L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
Publication: Journal of Managed Care Pharmacy 2009 05; 15(4): 312-322.
Authors: Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis.
Authors: Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P.

The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective.
Authors: Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS.

Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer’s perspective.
Publication: Journal of Health & Productivity 2007 10; 309.
Authors: Moyneur E BB, Mody SH, Fournier A, Mallet D, Duh MS.

Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
Publication: Current Medical Research and Opinion 2007 07; 23(7): 1571-1573; author reply 1573-1574. doi: 10.1185/030079907X199655.
Authors: Einarson T, Machado M, Walker J, Iskedjian M.

The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.
Authors: Lefebvre P, Duh MS, Mody SH, Bookhart B, Piech CT.

Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
Publication: Drugs and Aging 2006 12; 23(12): 969-976.
Authors: Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.
Authors: Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH.

The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.
Authors: Cremieux PY, Van Audenrode M, Lefebvre P.

Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.
Authors: Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.
**Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.**


*Authors:* Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.

**A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis.**


*Authors:* Wu EQ, Birnbaum H, Kang YJ, Parece A, Mallett D, Taitel H, Evans RJ.

**Comorbidity contributes to high treatment cost of interstitial cystitis.**


*Authors:* Wu E.

**Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population.**


*Authors:* Wu EQ, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H.

**Employees with overactive bladder: work loss burden.**


*Authors:* Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D.

**PUK9 Interstitial Cystitis Costs, Treatment and Comorbidities in an Employed Population.**


*Authors:* Wu EQ, Birnbaum H, Parece A, Kang YJ, Mareva MN, Taitel H.

**Cost of stress urinary incontinence: a claims data analysis.**


*Authors:* Birnbaum HG, Leong SA, Oster EF, Kinchen K, Sun P.

**Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.**


*Authors:* Birnbaum H, Leong S, Kabra A.

**Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis.**

*Publication:* Pharmacotherapy 2003 05; 23(5): 690-693; discussion 693-694.

*Authors:* Barnett AL, Cremieux PY.

**Respiratory**

**Health characteristics of patients with asthma, COPD and asthma-COPD overlap in the NHANES database.**


*Authors:* Llanos JP, Ortega H, Germain G, Duh MS, Lafeuille MH, Tiggelaar S, Bell CF, Hahn B.

**Burden of disease associated with a COPD eosinophilic phenotype.**


*Authors:* Ortega H, Llanos JP, Lafeuille MH, Germain G, Duh MS, Bell CF, Sama SR, Hahn B.
Effects of Systemic Corticosteroids on Blood Eosinophil Counts in Asthma: Real-World Data.
Authors: Ortega H, Llanos JP, Lafeuille MH, Duh MS, Germain G, Lejeune D, Sama S, Bell C, Hahn B.

Do blood eosinophils play a role in burden of illness in patients with COPD?
Authors: Hahn B, Ortega H, Bell C, Lafeuille M, Duh M, Germain G, Llanos J.

Characterizing real-world use of lamas in asthma in the US.
Authors: Averell CM, Laliberte F, Duh M, Wu JW, Germain G, Katial R, Faison S.

Healthcare resource utilization of conjunctivitis in the general population and in patients with prior antibiotic-resistant infection: A retrospective US claims-based analysis.
Publication: Value in Health 2018 05; 21 (Supplement 1): S243.
Authors: Cheng WY, McCormick N, Duh MS, Cheung HC, Bobbili PJ, Joseph C, Sarda SP.

Medication adherence and persistence in chronic obstructive pulmonary disease (COPD) patients on triple therapy in a US commercially-insured population.
Authors: Bogart M, Laliberte F, Duh MS, Wu JW, Germain G, Stanford RH.

Procalcitonin guidance in patients with lower respiratory tract infections: A systematic review and meta-analysis.

Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab.

Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.

Claims-Based Risk Model for First Severe COPD Exacerbation.
Publication: American Journal of Managed Care 2018 02; 24(2): e45-e53.

Health care resource utilization of conjunctivitis in the general population and in patients with prior antibiotic-resistant infection: A retrospective US claims-based analysis.
Authors: Cheng W, McCormick N, Duh MS, Cheung HC, Bobbili P, Joseph C, Sarda S.
A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.


Authors: Mapel D, Laliberte F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.

Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized beta2-Agonists.


Authors: Bollu V, Guerin A, Gauthier G, Hiscock R, Wu EQ.

Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.


Authors: Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE.


Authors: Llop CJ, Tuttle E, Tillotson GS, LaPlante K, File TM, Jr.

Burden of systemic glucocorticoid-related complications in severe asthma.


Authors: Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.

Patient Characteristics, Clinical Outcomes and Healthcare Resource Utilization Among IPF Patients Stratified by Lung Function at Diagnosis.


Authors: Nathan S, Macaulay D, Garcia Horton V, Terasawa E, Yu Y.

A prospective assessment of healthcare utilization and costs associated with symptom burden measured by mmrc and cat.


Authors: Stanford RH, Mapel D, Roberts M, Pilon D, Laliberte F, Lefebvre P, Sama S, Emond B, Duh M.

Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma.


Authors: Dalal AA, Duh MS, Gozalo L, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Lefebvre P.

Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.


Authors: Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Vekeman F, Gauthier-Loiselle M, Duh MS, Merrigan JF, Schatz M.
Characteristics and outcomes of patients with hospital-acquired pneumonia (HAP).

Authors: Han S, Xie J, Song H, Zhang C, Wu EQ.

Feasibility of matching-adjusted indirect comparison (MAIC) of omalizumab (OMA) vs. mepolizumab (MEPO) in moderate-to-severe asthma.

Authors: Ayyagari R, Alvares L, Mu F, Hacking V, Martinez R, Signorovitch JE.

Spectrum of idiopathic pulmonary fibrosis severity in clinical practice: implications for clinical trial feasibility and design.

Authors: Macaulay D, Nathan SD, Terasawa E, Yu Y.

Economic and clinical burden of acute and chronic systemic corticosteroid-related complications in asthma patients Respiratory Disease.


Impact of suspected idiopathic pulmonary fibrosis acute exacerbations on clinical and healthcare resource utilization outcomes.

Authors: Nathan SD, Reichmann WM, Macaulay D, Yu YF.

Time to treatment augmentation among patients with chronic obstructive pulmonary disease (COPD) newly initiated on long acting muscarinic agents (LAMA) or inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA) combination therapy.

Authors: Patel J, Mapel DW, Roberts MH, Sama S, Gilmore J, Sundaresan D, Laliberte F, Pilon D, Lefebvre P, Duh M.

Acute and chronic systemic corticosteroid-related complications in patients with severe asthma.

Authors: Lefebvre P, Duham MS, Lafauille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.

Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.

Authors: Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD.

Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.

Authors: Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD.

Clinical and Economic Burden of Pulmonary Exacerbations In Patients with Cystic Fibrosis Who are Homozygous for the F508del Mutation.

Authors: O’Sullivan AK, Signorovitch JE, Fang A, Wagener J, Hodgkins P.
Impact of a telehealth and care management program for patients with chronic obstructive pulmonary disease.


*Authors:* Au DH, Macaulay DS, Jarvis JS, Desai US, Birnbaum HG.

Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.


*Authors:* Lodise TP, Anzueto AR, Weber DJ, Shorr AF, Yang M, Smith A, Zhao Q, Huang X, File TM.

Association of change in forced vital capacity with healthcare resource utilization in patients with newly diagnosed idiopathic pulmonary fibrosis.


*Authors:* Reichmann WM, Yu Y, Macaulay D, Nathan SD.

Change in forced vital capacity and clinical outcomes in newly diagnosed idiopathic pulmonary fibrosis patients.


*Authors:* Nathan SD, Reichmann WM, Macaulay D, Yu YF.

Cost and resource utilization in hospital-treated cap patients.


*Authors:* Tuttle EG, Llop CJ.

Inpatient Burden Among Patients with Cystic Fibrosis Who Are Homozygous for the F508del Mutation.


*Authors:* Hodgkins P, Ayyagari R, Guo J, Wagener J, O'Sullivan AK.

Budget impact model of ORALAIR® for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis in adults and children.


Pulmonary medication adherence and health-care use in cystic fibrosis.


*Authors:* Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, Riekert KA.

Assessment of COPD exacerbation risk: Utilizing health claims data to develop and validate a risk equation.


*Authors:* Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan J, Duh M.

Risk assessment of first severe COPD exacerbation using predictive models based on health claims data.


Burden of illness of patients with allergic asthma versus non-allergic asthma.


*Authors:* Lafeuille MH, Gravel J, Figliomeni M, Zhang J, Lefebvre P.
Development and validation of a claims-based prediction model for COPD severity.
Authors: Macaulay D, Sun SX, Sorg RA, Yan SY, De G, Wu EQ, Simonelli PF.

A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.

Association between consistent omalizumab treatment and asthma control.
Authors: Lafeuille M-H, Gravel J, Zhang J, Gorsl B, Figliomeni M, Lefebvre P.

Impact of integrated telehealth and care management program on resource utilization in Medicare beneficiaries with chronic obstructive pulmonary disease.
Authors: Au DH, Jarvis J, Macaulay D, Birnbaum HG.

Re-hospitalization risk in patients with chronic obstructive pulmonary disease (COPD) initiating nebulized long-acting vs. Short-acting beta2-agonists.

Risk of Hospital Readmissions in Patients with Chronic Obstructive Pulmonary Disease Receiving Arformoterol Tartrate versus Nebulized Short-Acting Beta2-Agonists Following Hospital Discharge.
Authors: Bollu VK, Guérin A, Gauthier G, Hiscock R, Wu EQ.

Assessment of a pulmonary exacerbation risk score among cystic fibrosis patients free of recent exacerbations and not receiving recommended therapies for pulmonary care.

Economic burden associated with acute exacerbations of chronic obstructive pulmonary disease in China.

Development of a pulmonary exacerbation risk score among cf patients not receiving recommended therapies for pulmonary care.

Impact of omalizumab on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids Respiratory Disease.
Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsl B, Lefebvre P.

Annual healthcare costs for patients with cystic fibrosis from a Medicaid perspective.
Authors: Zhang J, Marynchenko M, Chopra P, Ohashi E, Signorovitch J, Wu E.
Association of allergic rhinitis with asthma exacerbations and health care costs in asthma patients Respiratory Disease.

Comparisons of patient characteristics and health care costs by quartile among patients with allergic rhinitis.

Lower adherence to chronic pulmonary medications is associated with increased health service utilization in patients with cystic fibrosis.

Pulmonary medication adherence among individuals with cystic fibrosis.

Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.

Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.

Impact of omalizumab initiation on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids and long-acting beta2-agonists Respiratory Disease.
Abstract: 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012. Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

Impact of omalizumab on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids Respiratory Disease.
Abstract: 2012 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, Orlando, FL Mar 2-6, 2012. Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

A validated claims-based prediction model for COPD severity.
Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.

*Authors*: Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.

Development of a pulmonary exacerbation risk score among CF patients not receiving recommended therapies for pulmonary care.


Effect of tobramycin inhalation solution on mortality in subgroups of patients with cystic fibrosis.

*Authors*: Latremouille-Viau D, Zhang J, Von Wartburg M, Signorovitch J, Wu EQ, Shi L.

Prevalence of pseudomonas aeruginosa infection and antibiotic resistance by age group in the CFF patient registry in 2003 and 2008.

*Authors*: Latremouille-Viau D, Zhang J, DeBonnett L, Signorovitch J, Von Wartbu M, Wu EQ, Shi L.

Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD.

*Authors*: Yu AP, Guerin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J.

Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.

*Authors*: Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Swensen A, Lefebvre P.

Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.

*Authors*: Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.

*Authors*: Sun SX, Marynchenko M, Banerjee R, Cheng D, Mocarski M, Yin D, Yu AP, Wu EQ.

Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.

*Authors*: Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.

*Authors*: Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.

*Authors*: Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J.
Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis.


Authors: Signorovitch J, Sawicki G, Zhang J, Latremouille-Viau D, Wu E, von Wartburg M, Lzheng S.

Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.


Authors: Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S.

Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs.


Authors: Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS.

Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.


Authors: Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.

Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.


Authors: Lafeuille M, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Swensen A, Stanley EL, Lefebvre P.

Cost-effectiveness analysis of roflumilast/tiotropium combination therapy vs. tiotropium monotherapy in patients with severe to very severe COPD.


Authors: Yu AP, Sun S, Marynchenko M, Banerjee R, Mocarski M, Yin D, Wu E.

Comparison of drug costs & clinical outcomes with tobramycin solution for inhalation & aztreonam lysine for inhalation in cystic fibrosis.


Authors: Signorovitch J, Latremouille-Viau D, Dea K, Wu E, Zhang J.

Cost comparison among moderate or severe persistent asthma patients with and without asthma exacerbations Respiratory Disease.


Authors: Ivanova JI, Bergman RE, Birnbaum HG, Colice GL, Silverman R, McLaurin KK.

Economic burden of exacerbations in chronic obstructive pulmonary disease.


Authors: Yu A, Yang H, Wu EQ, Dembiski M, Blum S, Setyawan J.

Persistence and adherence in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.


Authors: Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum S.

Relationship between daily dosing frequency, compliance, health care resource use, and costs: Evidence from the treatment of chronic obstructive pulmonary disease (COPD).


Authors: Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat C, Swensen A, Duh MS.
Resource utilization and costs in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.

Authors: Yu AP, Guérin A, De Leon Barido DP, Ramakrishnan K, Xie J, Wu EQ, Setyawan J, Dembiski M, Blum SI.

Risk of exacerbations among patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.

Authors: Yu AP, Guérin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis.

Authors: Sawicki GS, Signorovitch J, Latremouille-Viau D, Von Wartburg M, Wu E, Zhang J, Shi L.

Association between private-to-Medicaid change in health insurance & healthcare utilization & outcomes among children with cystic fibrosis.

Authors: Zhivan N, Campbell CR, Signorovitch J, Zhang J, Shi L.

The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.

Authors: Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS.

Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.

Authors: Signorovitch JE, Sheng Duh M, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D.

Persistence and Adherence in Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Multiple vs Single Long-Acting Inhalers.

Authors: Yu AP, Guérin A, de Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.

Abstract: Chest 2010 Meeting
Authors: Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

Chronic thromboembolic pulmonary hypertension (CTEPH) cost of illness in the privately-insured population in the United States.

Abstract: Chest 2010 Meeting
Authors: Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

The direct economic impact of exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A review of the literature.

Authors: Toy EL, Gallagher KF, Stanley EL, Duh MS.
The risk of hospitalization or emergency care following outpatient treatment of community-acquired pneumonia (CAP) with levofloxacin versus moxifloxacin.


*Authors:* Signorovitch JE, Gu A, Sengupta A, Raut M, Mody SH, Grant R, Schein J, Fisher AC, Ng D, Duh MS.

Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.


*Authors:* Frois C, Wu EQ, Ray S, Colice GL.

Comparability of the Asthma Control Test telephone interview administration format with self-administered mail-out mail-back format.


*Authors:* Kosinski M, Kite A, Yang M, Rosenzweig JC, Williams A.

Asthma severity categorization using a claims-based algorithm or pulmonary function testing.


*Authors:* Birnbaum HG, Ivanova JI, Yu AP, Hsieh M, Seal B, Emani S, Rosiello R, Colice GL.

Chronic thromboembolic pulmonary hypertension (CTEPH) cost of illness in the privately-insured population in the United States.


*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

The direct economic impact of exacerbations of chronic obstructive pulmonary disease (COPD): A review of the literature.


*Authors:* Toy EL, Gallagher KF, Stanley EL, Duh MS.

Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.


*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

Adherence to inhaled corticosteroid use and local adverse events in persistent asthma.

*Publication:* American Journal of Managed Care 2008 12; 14(12): 801-809.

*Authors:* Ivanova JI, Birnbaum HG, Hsieh M, Yu AP, Seal B, van der Molen T, Emani S, Rosiello RA, Colice GL.

Costs and resource use of mild persistent asthma patients initiated on controller therapy.


*Authors:* Colice GL, Yu AP, Ivanova JI, Hsieh M, Birnbaum HG, Lage MJ, Brewster C.

Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature.


*Authors:* Weiner JR, Toy EL, Sacco P, Duh MS.

Use of inhaled corticosteroids and healthcare costs in mild persistent asthma.


*Authors:* Colice G, Wu EQ, Birnbaum H, Daher M, Maryna BM.
Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.
Authors: Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF.

Development of a COPD severity score.
Authors: Wu EQ, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G.

Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population.
Authors: Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S.

Inpatient and Emergency Department Utilization of Persistent Asthma Patients.
Authors: Colice G, Crivera C, Wu EQ, Birnbaum HG, Daher M, Marynchenko MB, Faruqi R, Varghese ST.

PRS3 Acute exacerbation of chronic bronchitis (AECB) treatment effectiveness: Comparison of macrolides to fluoroquinolones.
Authors: Wu E, Birnbaum H, Cifaldi M, Kang Y, Colice G.

Development of a COPD Severity Score in ClaimsDatabase.
Authors: Wu EQ, Birnbaum H, Cifaldi M, Colice G, Kang Y.

Healthcare Costs of Patients with Persistent Asthma.
Abstract: AMCP.

Treatment costs of community-acquired pneumonia in an employed population.
Publication: Chest 2004 06; 125(6): 2140-2145.
Authors: Colice GL, Morley MA, Asche C, Birnbaum HG.

Red blood cell transfusion and ventilator-associated pneumonia: A potential link?
Authors: Shorr AF, Duh MS, Kelly KM, Kollef MH.

Lower respiratory tract infections: impact on the workplace.
Publication: Pharmacoeconomics 2003 06; 21(10): 749-759.
Authors: Birnbaum H, Morley M, Leong S, Greenberg P, Colice G.

PRP13: Assessing the cost implications of combined pharmacotherapy in the long term management of asthma.
Authors: Wu E, Johnson K, Nichol M.

Assessing the Cost Implication of Combined Pharmacotherapy in the Long Term Management of Asthma.
Abstract: International Society for Pharmacoeconomics & Outcomes Research (ISPOR).
Authors: Wu EQ, Johnson KA, Nichol MB.
Economic burden of respiratory infections in an employed population.
Publication: Chest 2002 08; 122(2): 603-611.
Authors: Birnbaum HG, Morley M, Greenberg PE, Colice GL.

Direct and indirect costs of asthma to an employer.
Publication: Journal of Allergy and Clinical Immunology 2002 02; 109(2): 264-270.
Authors: Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, Wanke LA.

Economic burden of pneumonia in an employed population.
Authors: Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL.

Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients.
Authors: Duh MS, Walker AM, Lindmark B, Laties AM.

Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis.
Publication: Clinical Therapeutics 2000 01; 22(1): 140-151.
Authors: LeLorier J, Perreault S, Birnbaum H, Greenberg P, Sheehy O.

Lack of Intraocular Pressure Effect of Budesonide Inhalation Therapy in a Mixed Asthmatic Population.
Authors: Duh M, Walker A, Lindmark B, Laties A.

Substance Abuse
PAINWeek Abstract Book 2018.
Authors: White AG, Spittle T, Fernan C, Marrett E, Kwong WJ, Rossiter LF.

Authors: Reinhart M, Scarpati LM, Kirson NY, Patton C, Shak N, Erensen JG.

Assessment of work loss and costs associated with opioid abuse: A retrospective claims analysis.
Abstract: ISPOR 23rd Annual International Meeting
Baltimore, MD May 19-23, 2018.
Authors: White AG, Spittle T, Fernan C, Marrett E, Kwong J, Rossiter LF.

Opioid Abuse: A Detailed Examination of Cost Drivers over a 24-Month Follow-up Period.
Authors: Scarpati LM, Kirson NY, Jia ZB, Wen J, Howard J.
Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
Authors: Yenikomshian MA, White AG, Carson ME, Garrison LP, Oderda GM, Biskupiak JE, Hlavacek PR, Roland CL.

Drivers of excess costs of opioid abuse among a commercially insured population.
Authors: Scarpati LM, Kirson NY, Zichlin ML, Jia ZB, Birnbaum HG, Howard JC.

The Economic Burden of Opioid Abuse: Updated Findings.
Authors: Kirson NY, Scarpati LM, Enloe CJ, Dincer AP, Birnbaum HG, Mayne TJ.

A harm reduction model to quantify potential misuse/abuse reduction and misuse/abuse-related events avoided from extended-release abuse deterrent opioids.
Abstract: 36th Annual Scientific Meeting of the American Pain Society, Pittsburgh, PA.
Authors: White A, Spittle T, Niebler W, Brown C, Dayno J, Katz N.

A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids.
Abstract: Annual Scientific Meeting of the American Pain Society, Austin, TX May 11-14, 2016.
Authors: White AG, Yenikomshian M, Carson M, Masters ET, Roland CL.

A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids.
Authors: White A, Yenikomshian M, Carson M, Masters E, Roland C.

The costs and cost drivers of opioid misuse by diagnosis: Abuse, dependence, and overdose/poisoning.
Authors: Howard J, Kirson N, Scarpati L, Dincer A, Hanway J, Zichlin M, Birnbaum H.

The economic burden of opioid abuse and its drivers: Evidence from a payer perspective.
Authors: Howard J, Kirson N, Scarpati L, Dincer A, Hanway J, Zichlin M, Birnbaum H.

Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.

The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals.
Authors: Kirson NY, Shei A, Rice JB, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs.
Authors: White AG, LeCates J, Birnbaum HG, Cheng W, Roland CL, Mardekian J.
Sources of prescription opioids among diagnosed opioid abusers.
Authors: Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

The burden of opioid abuse among commercially-insured patients.
Authors: Rice JB, Kirson NY, Shei A, Enloe C, Cummings AK, Birnbaum HG, Ben-Joseph R.

Characteristics of high-cost patients diagnosed with opioid abuse.
Authors: Birnbaum H, Kirson N, Shei A.

Comparing the prevalence and healthcare costs of opioid abuse using two commercial claims databases.
Authors: Rice B, Kirson NY, Shei A, Enloe CJ, Cummings AK, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

Differences between high-cost and low-cost patients diagnosed with opioid abuse.
Authors: Rice JB, Kirson NY, Bodnar K, Shei A, Birnbaum HG, Holly P, Ben-Joseph R.

Estimating the prevalence and healthcare costs of diagnosed opioid abuse in a large commercial claims database.
Authors: Birnbaum H, Kirson N, Shei A.

Examining the use of ICD-9-CM diagnosis codes for opioid abuse and opioid dependence in commercial claims data.
Authors: Shei A, Rice B, Kirson NY, Bodnar K, Cummings AKG, Birnbaum HG, Holly P, Ben-Joseph R.

Medical resource use and costs among pain patients with potential opioid tolerability issues.
Authors: Birnbaum H, Kirson N, Shei A.

Methods to estimate the prevalence and healthcare costs of undiagnosed opioid abuse among commercially-insured individuals.
Authors: Shei A, Rice B, Kirson NY, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

A model to estimate the health system burden of prescription opioid abuse in Europe.
Authors: Shei A, Hirst M, Kirson NY, Enloe CJ, Birnbaum HG, Dunlop W.

Opioid utilization and abuse rates following the introduction of an abuse-deterrent formulation.
Authors: Birnbaum H, Kirson N, Shei A.

The relationship between positive subjective measures in abuse liability studies and real-world non-medical use: potential impact of abuse deterrent opioids on rates of non-medical use and associated healthcare costs.
Authors: White AG, LeCates J, Cheng W, Roland CL, Schaaf D, Mardekian J.
Medical resource use and costs among pain patients with potential opioid-tolerability issues.
*Authors:* Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R, Michna E.

Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
*Authors:* Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Rossiter LF, Michna E.

Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data.
*Authors:* Rice JB, Kirson NY, Shei A, Cummings AK, Bodnar K, Birnbaum HG, Ben-Joseph R.

Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
*Authors:* Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.

The economic burden of diagnosed opioid abuse among commercially insured individuals.

Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
*Authors:* Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Michna E.

Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management.
*Authors:* Michna E, Cheng WY, Korves C, Birnbaum H, Andrews R, Zhou Z, Joshi AV, Schaaf D, Mardekian J, Sheng M.

Estimating the payer-specific excess medical costs of opioid abuse in the United States.
*Authors:* Michna E, Kirson NH, Shei A, White A, Birnbaum HG, Ben-Joseph R, Rossiter LF.

The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain.
*Authors:* Ivanova JI, Birnbaum HG, Yushkina Y, Sorg RA, Reed J, Merchant S.

Prescription opioid abuse: challenges and opportunities for payers.
*Authors:* Katz NP, Birnbaum H, Brennan MJ, Freedman JD, Gilmore GP, Jay D, Kenna GA, Madras BK, McElhaney L, Weiss RD, White AG.

A model to identify patients at risk for prescription opioid abuse, dependence, and misuse.
*Authors:* Rice JB, White AG, Birnbaum HG, Schiller M, Brown DA, Roland CL.
Characteristics and use patterns of chronic hydrocodone users.
Authors: Rice J, Samuelson T, Birnbaum H, Katz N.

Identifying predictors of chronic hydrocodone use.
Authors: Rice JB, Samuelson TM, Birnbaum HG, Katz N.

A systematic literature review of the efficacy and safety of abuse-deterrent formulation and non-abuse-deterrent formulation prescription opioids in non-cancer pain management.

Economic impact of opioid abuse, dependence, and misuse.
Authors: White AG, Birnbaum HG, Schiller M, Waldman T, Cleveland JM, Roland CL.

Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
Authors: Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL.

Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications.
Authors: Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE.

Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States.
Authors: Birnbaum H, White A, Schiller M, Waldman T, Cleveland JM, Setnik BS, Pixton GC, Roland CL.

Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications.
Authors: Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE.

Analytic models to identify patients at risk for prescription opioid abuse.
Authors: White AG, Birnbaum HG, Schiller M, Tang J, Katz NP.

Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.
Authors: White AG, Birnbaum HG, Rothman DB, Katz N.

Health care and work loss burden of prescription opioid abuse, dependence, and misuse.
Authors: White AG, Birnbaum H, Schiller M, Waldman T, Cleveland JM, Setnik B, Roland CL.
Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective.


**Authors:** Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, Schein JR, Katz NP.

Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States.


**Authors:** Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, Wright A, Woosley RL, Schulman KA.

Direct costs of opioid abuse in an insured population in the United States.


**Authors:** White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N.

Other Diseases & Conditions

Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study.


**Authors:** Dana R, Bradley JL, Guerin A, Pivneva I, Evans AM, Stillman IO.

The burden of non-infectious intraocular inflammatory eye diseases: a systematic literature review.


**Authors:** Rice JB, White AG, Scarpati LM, Wan GJ, Nelson WW.

Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication.


Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication.


Burden of illness associated with generalised lipodystrophy (GL) in leptin replacement therapy-naive patients: A longitudinal medical chart review study.

**Abstract:** 54th Annual Meeting of the European Association for the Study Diabetes, EASD 2018, Berlin, Germany  Oct 1-5, 2018.


Number Needed to Treat in Patients with Spinal Muscular Atrophy Type 1.

**Abstract:** 23rd International Annual Congress of the World Muscle Society Mendoza, Argentina  Oct 2-6, 2018

**Authors:** Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Sproule DM.
Number needed to treat in patients with spinal muscular atrophy type 1 treated with AVXS-101 relative to nusinersen.
Abstract: ISPOR 23rd Annual International Meeting
Baltimore, MD  May 19-23, 2018.
Authors: Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Sproule DM.

Number Needed to Treat in Patients with Spinal Muscular Atrophy Type 1 Treated with AVXS-101 Relative to Nusinersen.
Abstract: International Congress on Nueromuscular Diseases Vienna, Austria Jul 6-10, 2018
Authors: Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu E, Sproul D.

Number needed to treat in patients with spinal muscular atrophy type 1 with AVXS-101 relative to nusinersen
Authors: Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Droge M, Sproule DM.

Number needed to treat in spinal muscular atrophy type 1 with AVXS-101 relative to nusinersen.
Authors: Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Sproule DM.

Tuberous Sclerosis Complex (TSC) and epilepsy manifestations: The impact of refractory epilepsy on health-related quality of life (HRQoL).
Authors: Vergeer M, De Ranitz-Greven WL, Neary MP, Ionescu-Ittu R, Emond B, Duh MS, Zonnenberg B.

Out-of-pocket medical costs and third-party healthcare costs for children with Down syndrome.
Authors: Kageleiry A, Samuelson D, Duh MS, Lefebvre P, Campbell J, Skotko BG.

Treatment Patterns, Complications, and Health Care Utilization Among Endometriosis Patients Undergoing a Laparoscopy or a Hysterectomy: A Retrospective Claims Analysis.
Authors: Surrey ES, Soliman AM, Yang H, Du EX, Su B.

Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests.
Authors: Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ.

Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
Authors: Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, Bao Y, Joshi A.

Effect of Adalimumab on Visual Functioning in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
Authors: Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD.
Engagement in health and wellness: An online incentive-based program.
Authors: Gibson TB, Maclean JR, Carls GS, Moore BJ, Ehrlich ED, Fener V, Goldberg J, Mechanic E, Baigel C.

Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy.
Authors: Soliman AM, Du EX, Yang H, Wu EQ, Haley JC.

Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas.

Comorbidities among patients with dry eye disease in a large US healthcare system.
Authors: Dana R, Bradley JL, Guerin A, Pivneva I, Dea K, Evans AM, Özer-Stillman I.

A comparison of comorbidities among patients with and without dry eye disease in a large US healthcare system.
Authors: Dana R, Bradley JL, Guerin A, Pivneva I, Dea K, Evans AM, Özer-Stillman I.

Dry eye disease ranking among common reasons for seeking eye care in a United States claims database.
Authors: Bradley JL, Özer-Stillman I, Pivneva I, Guerin A, Evans AM, Dana R.

Dry eye symptoms and treatment satisfaction with ophthalmic cyclosporine: results of a claims database survey.
Authors: Bradley JL, Özer-Stillman I, Pivneva I, Guerin A, Evans AM, Dana R.

HPR predicting the future development of spondyloarthritis among patients with idiopathic acute anterior uveitis using real-world data.
Abstract: Annual European Congress of Rheumatology, Madrid, Spain June 14-17, 2017.
Authors: Haroon M, Betts KA, Mu F, Skup M, Anderson JK, Joshi AD.

Incidence and prevalence of dry eye disease: Estimates from claims database analysis in a large United States health care system.
Authors: Özer-Stillman I, Bradley JL, Guerin A, Pivneva I, Evans AM, Dana R, Schaumberg DA.

Liver damage in lipodystrophy and impact of metreleptin: Experience from a large retrospective review.

Ranking of dry eye disease among common reasons for seeking eye care in a United States claims database.
Authors: Özer-Stillman I, Bradley JL, Pivneva I, Guerin A, Evans AM, Dana R.
Treatment patterns and clinical characteristics among patients with tuberous sclerosis complex related angiomyolipomas.


Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis.
Authors: Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J, Ganguli A.

Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population.

The direct and indirect costs associated with endometriosis: a systematic literature review.
Authors: Soliman AM, Yang H, Du EX, Kelley C, Winkel C.

Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis.
Authors: Thorne JE, Skup M, Tundia N, Macaulay D, Revol C, Chao J, Joshi A, Dick AD.

Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Authors: Dick AD, Tundia N, Sorg R, Zhao C, Chao J, Joshi A, Skup M.

Adherence and persistence with cyclosporine ophthalmic emulsion for treatment of dry eye disease in a large US healthcare System.
Authors: Schaumberg DA, Bradley J, Guerin A, Pivneva I, Evans A, Stillman IO, Dana R.

Comorbidities and symptoms among endometriosis patients: A systematic literature review.
Authors: Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C.

Comparison of Annual Treatment Costs for Patients Treated with Infusion versus Injectable Biologics.
Authors: Skup M, Macaulay D, Wei J, Terasawa E, Chao J.

Development of a Risk Score for Fluconazole Failure among Patients with Invasive Candidiasis.
Epilepsy treatment patterns among patients with tuberous sclerosis complex.


Estimates of incidence and prevalence of dry eye disease across age groups in the US using data from a large healthcare system.

Authors: Bradley JL, Guerin A, Pivneva I, Evans AM, Özer-Stillman I, Dana R, Schaumberg DA.

Impact of the introduction of newer long acting reversible contraceptive (LARC) methods on LARC use in a commercially insured population.


Income growth trajectory for parents of children with down syndrome in the United States.

Authors: Samuelson D, Kageleiry A, Duh MS, Lefebvre P, Campbell JY, DerSarkissian M, Haider BA, Skotko BG.

Measuring opportunities to improve health outcomes via individualized treatment assignment.

Authors: Patterson-Lomba O, Signorovitch J.

Rates of subsequent endometriosis-related surgeries following an initial laparoscopy or hysterectomy: A longitudinal analysis of commercially insured endometriosis patient in the united states.

Authors: Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C.

Subependymal giant cell astrocytoma treatment patterns among patients with tuberous sclerosis complex.


A systematic literature review of comorbidities and symptoms among uterine fibroids patients between 2000 and 2013.

Authors: Soliman AM, Yang H, Du EX, Kelkar S, Winkel C.

The Economic Burden Associated with Zygomycosis-Related Hospitalizations in the U.S.

Abstract: IDSA IDWeek annual meeting, San Diego, CA  Oct 7-11, 2015.
The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013.
Authors: Soliman AM, Yang H, Du EX, Kelkar SS, Winkel C.

Incremental direct and indirect costs of untreated vasomotor symptoms.
Authors: Sarrel P, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM.

Healthcare utilization and costs among women diagnosed with uterine fibroids: A longitudinal evaluation for 5 years pre and post diagnosis.
Publication: Current Medical Research and Opinion 2015 01; (0): 1-38.
Authors: Fuldeore M, Yang H, Soliman AM, Winkel C.

Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases.
Authors: Fuldeore M, Yang H, Du EX, Soliman AM, Wu EQ, Winkel C.

Cellular rejuvenation and ageing-proteome by Ginsenoside 20(S)-Rg3.
Authors: Kim YR, Baek SJ, Kang YM, Oh KS, Kwon J, Choi JS.

The Clinical Burden Associated With Zygomycosis-Related Hospitalizations in the United States.

Demographic and Clinical Characteristics of Patients with Tuberous Sclerosis Complex in a TSC Patient Database.

Kidney involvement in tuberous sclerosis complex: The impact on health care resource use and costs in The Netherlands.
Authors: Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Zonnenberg BA.

Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs.
Authors: Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

Monitoring testing patterns among patients with tuberous sclerosis complex-related angiomyolipomas.

Out-of-pocket medical costs for parents with children with down syndrome in the united states.
Authors: Kageleiry A, Samuelson D, Duh MS, Lefebvre P, DerSarkissian M, Campbell JY, Skotko BG.
Treatment patterns of women diagnosed with uterine fibroids 5 years pre and post diagnosis: A longitudinal retrospective claims analysis of a commercially insured population in the US.

Authors: Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

Using ClinicalTrials.gov to supplement information in ophthalmology conference abstracts about trial outcomes: A comparison study.
Authors: Scherer RW, Huynh L, Ervin AM, Dickersin K.

Clinical and economic burden of vasomotor symptoms among untreated menopausal women.
Authors: Sarrel P, Lefebvre P, Lafauille M, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM, Portman D.

Clinical and economic burden of vasomotor symptoms among untreated menopausal women.
Authors: Sarrel P, Lefebvre P, Lafauille M, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM, Portman D.

Diagnosis and treatment patterns among patients with tuberous sclerosis complex-related angiomyolipomas.

Kidney dysfunction and healthcare resource utilization in tuberous sclerosis complex patients in the Netherlands.
Authors: Magestro M, Vekeman F, Nichols T, Karner P, Duh MS, Srivastava B, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

Risk of leaving the workforce in non-infectious uveitis.
Abstract: Association for Research in Vision and Ophthalmology, Orlando, FL May 4-8, 2014.
Authors: Tundia N, Skup M, Sorg R, Macaulay D, Chao J, Mulani P, Thorne JE.

Risk of ocular complications in non-infectious uveitis.
Abstract: Association for Research in Vision and Ophthalmology, Orlando, FL May 4-8, 2014.
Authors: Skup M, Tundia N, Sorg R, Chao J, Mulani P, Dick AD.

Duloxetine use in employees with low back pain: treatment patterns and direct and indirect costs.
Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

Burden of venous leg ulcers in the United States.
Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

Medicaid spending on contraceptive coverage and pregnancy-related care.
Authors: Laliberte F, Lefebvre P, Law A, Duh MS, Pocoski J, Lynen R, Darney P.

Direct and indirect resource use and costs associated with non-infectious non-anterior uveitis.
Authors: Thorne JE, Tundia N, Skup M, Macaulay D, Revol C, Chao J, Mulani P, Dick AD.
Incremental direct and indirect cost of untreated vasomotor symptoms (VMS).
Authors: Sarrel P, Lefebvre P, Lafeuille MH, Gravel J, Sheng Duh M, Aupperle PM, Portman D.

A longitudinal retrospective claims analysis of healthcare costs incurred by uterine fibroids patients.
Abstract: 70th Annual Meeting of the American Society for Reproductive Medicine, Honolulu, HI Oct 18-22, 2014.
Authors: Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

Significant Economic Burden Among Endometriosis Patients before and after Diagnosis: A Retrospective Claims Database Analysis.
Authors: Soliman AM, Fuldeore MJ, Yang H, Du EX, Wu EQ, Winkel CA.

Treatment patterns among US women diagnosed with endometriosis: A retrospective claims analyses pre-and post-diagnosis.
Abstract: 70th Annual Meeting of the American Society for Reproductive Medicine, Honolulu, HI Oct 18-22, 2014.
Authors: Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

Actuarial analysis of Medicaid spending for contraception and pregnancy care.
Abstract: 1st Global Conference on Contraception, Reproductive and Sexual Health, Copenhagen, Denmark May 22-25, 2013.
Authors: Laliberte F, Lefebvre P, Law A, Sheng Duh M, Lynen R, Darney P.

Medicaid spending for users of contraceptives and pregnancy-related care.
Abstract: 1st Global Conference on Contraception, Reproductive and Sexual Health, Copenhagen, Denmark May 22-25, 2013.
Authors: Laliberte F, Lefebvre P, Law A, Sheng Duh M, Lynen R, Darney P.

Medical, drug, and work-loss costs of venous leg ulcers.
Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

Actuarial analysis of Medicaid spending for contraception and pregnancy care.
Authors: Laliberte F, Lefebvre P, Law A, Duh MS, Lynen R, Darney P.

Direct and indirect costs for women with vasomotor symptoms (VMS) receiving lower-versus higher-dose paroxetine.
Authors: Portman D, Lafeuille MH, Lefebvre P, Gravel J, Duh MS, Aupperle PM, Sarrel P.

Incremental direct and indirect cost of untreated vasomotor symptoms (VMS).
Authors: Sarrel P, Lefebvre P, Lafeuille MH, Gravel J, Sheng Duh M, Aupperle PM, Portman D.

Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies.
Authors: Kaltenboeck A, Long G, Hayes-Larson E, Lopes Gde L.
Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA.
Publication: Journal of ophthalmic inflammation and infection 2013 11; 3(1): 64.
Authors: Chu DS, Johnson SJ, Mallya UG, Davis MR, Sorg RA, Duh MS.

Systematic literature review of the costs of pregnancy in the US.
Authors: Huynh L, McCoy M, Law A, Tran KN, Knuth S, Lefebvre P, Sullivan S, Duh MS.

Medical resource use and costs associated with chylomicronemia.
Authors: Gaudet D, Signorovitch J, Swallow E, Fan L, Tremblay K, Brisson D, Meyers C, Gruenberger JB.

Health care costs and utilization for privately insured patients treated for non-infectious uveitis in the United States.
Authors: Johnson S, Duh MS, Mallya U, Diener M, Sorg R, Chu D.

Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.
Authors: Kavanagh S, Kwong W, Hammond G, Nelson W, Upmalis D, Yang M.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.
Authors: Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

Duloxetine use in chronic low back pain: treatment patterns and costs.
Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

Cost burden and treatment patterns associated with management of heavy menstrual bleeding.
Authors: Jensen JT, Lefebvre P, Laliberte F, Sarda SP, Law A, Pocoski J, Duh MS.

Economic burden and quality of life of vulvodynia in the United States.
Authors: Xie Y, Shi L, Xiong X, Wu E, Veasley C, Dade C.

Effects of quinestrol and levonorgestrel on populations of plateau pikas, Ochotona curzoniae, in the Qinghai-Tibetan Plateau.

Direct and indirect costs associated with Dupuytren’s contracture.
Authors: Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P.

Direct and indirect costs associated with dupuytren’s contracture.
Authors: Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P.
Health care resource utilization and costs in females with newly diagnosed heavy menstrual bleeding: An employer's perspective.
Authors: Jensen JT, Lefebvre P, Laliberte F, Sarda SP, Law A, Pocoski J, MS. D.

New methods to adjust for selective crossover in survival analysis: In assessments of costeffectiveness of cancer therapies.
Authors: Delea TE, Duh MS, Wei LJ, Robins J.

Prevalence and costs of osteoporotic patients with subsequent non-vertebral fractures in the US.
Authors: Pike CT, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET.

A qualitative study on feasibility of a web-based Women’s Health Portal and Information System.
Authors: Yang M, Kosinski M, Boulanger R.

Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
Authors: Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

Analysis of genetic diversity of gemplasm of Pinellia ternata based on SRAP.
Authors: Yang M, Chen K.

Economic burden of privately insured non-vertebral fracture patients with osteoporosis over a 2-year period in the US.
Authors: Pike C, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET.

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.
Abstract: 30th Annual Scientific Meeting of the American Pain Society, Austin, TX May 19-21, 2011.
Authors: Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

Real-world use of duloxetine for low back pain and chronic low back pain: Treatment pattern, direct and indirect costs.
Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Johnstone B, Faries D, Risser R, Swindle R.

Evaluation of cardiovascular diseases (CVDs) risk for patients with fibromyalgia syndrome in the United States.
Authors: Mease PJ, Duh MS, Vekeman F, Lefebvre P, Laliberte F, Boerstoel-Streefland M, Jiang W, Zimetbaum PJ.

Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.
Authors: Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET.

Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder.
Authors: Rendas-Baum R, Yang M, Gricar J, Wallenstein GV.
Real-world use of duloxetine for chronic low back pain: Treatment pattern and costs.
Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle R.

Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference.
Authors: Yang M, Morin CM, Schaefer K, Wallenstein GV.

Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia.
Authors: White LA, Robinson RL, Yu AP, Kaltenboeck A, Samuels S, Mallett D, Birnbaum HG.

The costs of non-vertebral osteoporotic fractures in the United States.
Authors: Birnbaum HG, Pike C, Schiller M, Sharma H, Gu A, Burge RT, Edgell ET.

Real-world use of duloxetine for low back pain.

Burden of premenstrual dysphoric disorder on health-related quality of life.

Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss.
Authors: White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL.

Authors: Yu A, Wu EQ, Perrson B, Chang J, Costales C, Gricar J.

WH3 Clinical and economic outcomes among women using levonorgestrel-releasing intrauterine system (LNG-IUS).

Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance.
Authors: Meadows ES, Rousculp M, Sassar AC, Birnbaum HG, Moynier E, Mallet D, Johnston JA.

Mapping MOS Sleep Scale scores to SF-6D utility index.
Authors: Yang M, Dubois D, Kosinski M, Sun X, Gajria K.

The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids.
Authors: Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA.
Hemodynamic changes induced by positive pressure capnothorax during thoracoscopic thymectomy.

Publication: Chirurgia 2007 05; 102(3): 263-270.
Authors: Tomescu D, Grigorescu B, Nitulescu R, Tomulescu V, Popescu I, Tulbure D.

Annual costs associated with diagnosis of uterine leiomyomata.
Authors: Hartmann KE, Birnbaum H, Ben-Hamadi R, Wu EQ, Farrell MH, Spalding J, Stang P.

Annual Costs Associated with Diagnosis of Uterine Fibroids.
Abstract: The American College of Obstetricians and Gynecologists
Authors: Hartmann KE, Birnbaum H, Wu EQ, Ben-Hamadi R, Spalding J, Stang P.

Lifetime Costs of Patients with Clinically Detected Uterine Fibroids: An Employer’s Perspective.
Authors: Wu E, Ben-Hamadi R, Birnbaum H, Farrell M, Spalding J, Stang P, Hartmann K.

Lifetime Costs of Patients with Clinically-Detected Uterine Fibroids: An Employer Perspective.
Abstract: The American College of Obstetricians and Gynecologists.
Authors: Wu EQ, Birnbaum H, Farrell MH, Spalding J, Stang P, Hartmann KE.

Assessing the economic impact of chronic conditions in postmenopausal women.
Authors: Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M.

Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.
Authors: Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

POS1 Using a budget impact model to predict first-year use of a new osteoporosis therapy.
Authors: Sasser A, Rousculp M, Birnbaum H, Moynier E, Wu E, Marcus R.

Validation of a Budget Impact Model in Predicting First-Year Use of a New Osteoporosis Therapy.
Authors: Rousculp MD, Sasser AC, Birnbaum HG, Moynier E, Wu EQ, Mallet D, Marcus R.

Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently.
Authors: Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F.

Authors: Baker L, Deal B.

Economic cost and epidemiological characteristics of patients with fibromyalgia claims.
Authors: Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ.

The effects of chronic medical conditions on work loss and work cutback.
Authors: Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS.
Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts.


*Authors:* Duh MS, Walker AM, Kronlund KH, Jr.

Calculating the workplace cost of chronic disease.


*Authors:* Greenberg PE, Finkelstein SN, Berndt ER.

An alternative in terminal care: results of the National Hospice Study.


*Authors:* Greer DS, Mor V, Morris JN, Sherwood S, Kidder D, H. B.

An Alternative in Terminal Care: Results of the National Advice on Hospice Care for Benefits Design.

*Publication:* Business and Health 1985.

*Authors:* Birnbaum H.

Disability burden in patients with tenosynovial giant cell tumors in the United States from employer perspective.


*Authors:* Lin FI-I, Pivneva, I; Wynant, W; Shi, S; Shohudi Mojdehi, A; Wu, E.Q; Kwong, J; Abraham, J.A.

Other (Health Policy, Market Access, and other topics)

CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge.


*Authors:* Laliberte F, Coleman CI, Bookhart B, Schein J, Martin S, Wynant W, Xiao Y, Lefebvre P, Kaatz S.

Examining a Statewide Educational Consulting Program for Pediatric Brain Injury.


*Authors:* Myers RK, Eagan-Brown BL, Conway AT, Nagele DA, Vaccaro MJ, Kendi S, Zonfrillo MR.

Removal of ineligible outcome cases reduces confounding.


*Authors:* Walker AM, Schneeweiss S, DerSarkissian M, Duh MS.

One-Year Effect of the Medicare Annual Wellness Visit on Detection of Cognitive Impairment: A Cohort Study.


*Authors:* Fowler NR, Campbell NL, Pohl GM, Munsie LM, Kirson NY, Desai U, Trieschman EJ, Meiselbach MK, Andrews JS, Boustani MA.

Community health workers improve disease control and medication adherence among patients with diabetes and/or hypertension in Chiapas, Mexico: an observational stepped-wedge study.


Activity-based costing of health-care delivery, Haiti.


Economic impact of non-medical switching from originator biologics to biosimilars-a systematic literature review.


Authors: Liu Y, Garg V, Yang M, Wu EQ, Skup M.

Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?


Authors: Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders.


Authors: Nazareth T, Ko JJ, Sasane R, Frois C, Carpenter S, Demean S, Vegesna A, Wu E, Navarro RP.


Publication: Law360 2017 09.

Authors: Kirson N.

Insurer And Provider Market Share.


Authors: Dyckman Z.

Tracing the Path to Health Care Investigation Settlements.

Publication: Law360 2017 04.

Authors: Weinstein KA, Pike CT, Greenberg PE.

Matching-adjusted indirect comparison (MAIC): Sensitivity analyses and graphical diagnostics.

Abstract: ISPOR 20th Annual European Congress, Glasgow, UK.

Authors: Signorovitch J, Gao W, Rybkin V, Yao Z, Hellstern M.

Can social media data lead to earlier detection of drug-related adverse events?


Authors: Duh MS, Cremieux P, Audenrode MV, Vekeman F, Karner P, Zhang H, Greenberg P.

Reliable Analysis Is Key To Addressing Ascertainability.

Publication: Law360 2016 12.

Authors: Cacciola S, Fink S.

Rethinking the cost of healthcare in low-resource settings: the value of time-driven activity-based costing.


Following Recent Trends in Affordable Care Act Insurance.
Publication: Law360 2016 09.
Authors: Chawla A, Cook K.

The Potential for Litigation in New Era of Biosimilars.
Publication: Law360 2016 09.
Authors: Frois C, R M, White A.

Practical Uses For Machine Learning In Health Care Cases.
Publication: Law360 2016 09.
Authors: Yenikomshian M, Pinheiro LB, Royer J, Greenberg PE.

Publication: Law360 2016 06.
Authors: Pinheiro L, Royer J, Dadson N, Greenberg P.

The Myth of 'Price Disconnects' In US Pharma Markets.
Publication: Law360 2016 05.
Authors: Fink S, Lewis M.

Can The Life Sciences Industry Bank On Biosimilars?
Publication: Law360 2016 04.
Authors: Greenberg P, Sisitsky T, Mortimer R.

Updated trends in US brand-name and generic drug competition.
Authors: Grabowski H, Long G, Mortimer R, Boyo A.

Viewing Recent Opioid Regulations In Context.
Publication: Law360 2016 04.
Authors: Pike C, Weinstein K, Darling P, Greenberg P.

Correlation Or Cause: Brand-Name Drug Prescription Rates.
Publication: Law360 2016 03.
Authors: Greenbert P, Sisitsky T, R M.

Care pathways in US healthcare settings: current successes and limitations, and future challenges.
Authors: Chawla A, Westrich K, Matter S, Kaltenboeck A, Dubois R.

Retention of clinically stable art patients in a rapid model of care in Haiti.
Authors: Moise CG, Bellot C, Hennessey KA, Rivera VR, Severe P, Aubin D, Homeus F, Saint-Vil A, Koenig SP, Pape JW.

Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in the U.S. and EU-5: Payer and manufacturer experience and outlook.
Authors: Ko J, Nazareth T, Carpenter S, Demean S, Wu E, Sasane R, Navarro R.
Economists' Perspective on the Efficiency Defense in Provider Consolidations: What Works, What Doesn't Work, and What We Still Don't Know.
Publication: AHLA Connections 2015 09.
Authors: Chipty T, Sendonaris A.

Authors: Chawla A, Carls G, Deng E, Tuttle E.

Authors: Chawla AS, Hsiao CW, Romney MC, Cohen R, Rubino F, Schauer P, Cremieux P.

The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.
Authors: Cockburn I, Long G.

Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.
Authors: Chao J, Skup M, Alexander E, Tundia N, Macaulay D, Wu E, Mulani P.

The roles of patents and research and development incentives in biopharmaceutical innovation.
Authors: Grabowski HG, DiMasi JA, Long G.

Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in The US and EU-5: Payer and manufacturer experience and outlook.
Authors: Nazareth T, Ko JJ, Frois C, Carpenter S, Demean S, Wu EQ, Sasane R, Navarro R.

Statistical identification of potential selection bias in retrospective chart reviews.
Authors: Signorovitch JE, Reichmann WM, Li N, Liu Z, Hao Y, Perez JR.

Identifying high-value treatment populations in clinical trials and real-world data.
Authors: Signorovitch J, Shaw J, Betts K, Wu EQ.

Outcomes-based contracting for pharmaceutical products in the United States: payer and manufacturer experience and outlook.
Authors: Frois C, Carpenter S, Demean S, Wu E, Navarro R.

Cost of illness: an ongoing battle worth fighting.
Authors: Greenberg PE.

Evolving provider payment models and patient access to innovative medical technology.
Authors: Long G, Mortimer R, Sanzenbacher G.
Advanced Diagnostics: Innovation, Reimbursement, and Coverage Challenges.
*Publication:* In Vivo 2014 10.
*Authors:* Gorin B, Tuttle E.

Cost-effectiveness of health research study participant recruitment strategies: a systematic review.
*Authors:* Huynh L, Johns B, Liu SH, Vedula SS, Li T, Puhan MA.

Random Selection Is Best For MDL Bellwether Trials.
*Authors:* Brown L, Holian M, Rothman D.

Big Data Can Yield Big Insights on Promotional Practices.
*Publication:* Law360 2014 08.
*Authors:* Greenberg P, Sisitsky T.

The impact of Brazil’s Bolsa Familia conditional cash transfer program on children’s health care utilization and health outcomes.
*Authors:* Shei A, Costa F, Reis MG, Ko AI.

Recent trends in brand-name and generic drug competition.
*Authors:* Grabowski H, Long G, Mortimer R.

The role of health economics and outcomes research in health care reform in China.
*Authors:* Liang W, Xie J, Fu H, Wu EQ.

What Attorneys Should Know about FDA’s MedWatch Data.
*Publication:* Law360 2014 01.
*Authors:* Duh MS CP, Greenberg P, Ellman B.

Biosimilars.
*Authors:* Grabowski H, Long G, Mortimer R.

Evaluation of the value of webdata for detecting drug adverse events.

The randomized blind start trial: Evaluation of a new study design for assessing clinical outcomes in rare and heterogeneous patient populations.
*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.
*Authors:* Signorovitch J, Ayyagari R, Kakkis E.

Beyond average adherence: Temporal patterns of medication adherence predict hospitalization risk more accurately than the medication possession ratio.
*Authors:* Signorovitch J, Chopra P, Cheng D, Ayyagari R, Wu EQ.
Investigator-initiated approach to address an optimization problem in designing cost-efficient studies.  
**Abstract:** ISPOR 18th Annual International Meeting, New Orleans, LA  May 18-22, 2013.  
**Authors:** Huynh L, Clark M, Frick KD.

Effects of care management and telehealth: a longitudinal analysis using Medicare data.  
**Authors:** Baker LC, Macaulay DS, Sorg RA, Diener MD, Johnson SJ, Birnbaum HG.

Recent Average Price Trends for Implantable Medical Devices, 2007-2011.  
**Publication:** White paper 2013 09.  
**Authors:** Long G, Mortimer R, Sanzenbalcher G.

**Publication:** Today’s General Council 2013 08; 10(4).  
**Authors:** John L, Leckerman J, Greenberg P.

Brazil’s conditional cash transfer program associated with declines in infant mortality rates.  
**Authors:** Shei A.

On-Market Pricing Strategies.  
**Publication:** Pharmaceutical Executive 2013 06.  
**Authors:** Works J, Parece A.

**Abstract:** International Society for Pharmacoeconomics and Outcomes Research 2013,  May 18-22, 2013.  
**Authors:** Signorovitch J, Ayyagari R, Cheng D, Wu E.

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication.  
**Publication:** JHEOR 2013 01: 54-61.  
**Authors:** C CF, Tl OC, Pesa J, Fastenau J, Doshi D.

Innovation in the Biopharmaceutical Pipeline: A Multidimensional View.  
**Publication:** White paper 2013 01.  
**Authors:** Long G, Works J.

Estimating chronic disease prevalence from claims data: Reducing bias by accounting for diseased individuals who do not generate claims.  
**Abstract:** ISPOR 16th Annual European Congress, Dublin, Ireland  Nov 2-6, 2011.  
**Authors:** Signorovitch J, De G, Drabo E, Guerin A.

Impact of Medicare part D coverage gap on beneficiaries' adherence to prescription medications.  
**Abstract:** ISPOR 17th Annual International Meeting, Washington, DC  Jun 2-6, 2012.  
**Authors:** Desai U, Carroll NV.

Modeling the progression of chronic diseases in a dynamic market: Implications for budget impact analysis.  
**Abstract:** ISPOR 17th Annual International Meeting, Washington, DC  Jun 2-6, 2012.  
**Authors:** Eldar-Lissai A, Banerjee R, McBride S, Leaf-Herrmann W.

How to use Clinical-Trial Data in Court.  
**Publication:** Law360 2012 07.  
**Authors:** Cremieux P GA, Pinheiro L.
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.
Authors: Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ.

Authors: Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ.

Prioritizing Safety versus Budget: FDA and CMS Adopt Different Stances.
Publication: FDLI Update 2012 05.
Authors: Sisitsky T, Greenberg P.

Recently Released FDA Guidance and Biosimilar Development: Implications for the Litigation Environment.
Authors: Long G, Mulhern C.

Confounding factors in off-label drug use.
Authors: Greenberg PE, Pike C, Sisitsky T.

Comparative effectiveness research using matching-adjusted indirect comparison – A method for improving the reliability and interpretability of indirect comparisons by incorporating individual patient data.
Abstract: 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, Baltimore, MD Jun 6-7, 2011.
Authors: Signorovitch JE, Wu EQ, Xie J, Lu M, Sikirica V, Hodgkins P, Erder MH.

Improved indirect treatment comparisons for comparative effectiveness research.
Authors: Signorovitch J, Navarro R, Betts K, Wu EQ.

Utilizing rich data sources to identify patients’ subgroups that can benefit most from a treatment.
Abstract: 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, Baltimore, MD Jun 6-7, 2011.
Authors: Wei LJ, Signorovitch JE, Wu EQ, Betts K, Yang H, Xie J, Setyawan J, Hodgkins P, Erder MH.

Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
Authors: Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N.

Interprofessional education about decision support for patients across cultures.
Authors: Hagoel L, Volz S, Palileo LM, Eldar-Lissai A, Kamath CC, Cox ED.

Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings.
Authors: Baker LC, Johnson SJ, Macaulay D, Birnbaum H.

Implementation of the biosimilar pathway: economic and policy issues.
Authors: Grabowski H, Long G, Mortimer R.
Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care.
Authors: Ivanova JI, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW.

Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.

Publication: CPI Antitrust Chronicle 2011 05.
Authors: Chipty T.

Authors: Danzon PM, Johnson SJ, Long G, Furukawa MF.

President Reignites Biologics Exclusivity Battle with Proposal for Seven Years.
Publication: Specialty Pharmacy News 2011 03.
Authors: Long G.

Budget Proposals on Biosimilars, "Pay for Delay" Spark Controversy.
Publication: AIS's Health Reform Week 2011 02; 2(6).
Authors: Long G.

Reading of Biosimilar Law Could Mean One Day or Years Until Competitors on Market.
Publication: Specialty Pharmacy News 2011 02; 8(2).
Authors: Long G.

The role of public-sector research in the discovery of drugs and vaccines.
Authors: Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML.

Data exclusivity for biologics.
Authors: Grabowski H, Long G, Mortimer R.

An Effective Way to Quantify the Safety Profile of a Drug or Device When Background Toxicity Rates Are Low.
Publication: FDLI Update 2011 01; Jan/Feb.
Authors: Wei E, Claggett B, Greenberg P, Wei LJ.

Panel discussion: New imperatives for evidence to support successful licensing, reimbursement, and commercial strategy.
Authors: Chawla A (moderator), Szela M, Blansett L, Garrison L, Schroeder T.

The role of compliance in telehealth adoption.
Authors: Newell D, Johnson S, Rutherford P, Welte I.
Selecting the optimal target population for formulary coverage.
Authors: Wu EQ, Yu D, Xie J, Gu.

CER The Fruits of Comparative Effectiveness Sometimes it’s necessary to compare apples to oranges, as well as to other apples. New tools and a commitment to managing the impact of comparative effectiveness research grants payers the evidence they need to control drug costs.
Publication: Pharmaceutical Executive 2010 11: 78.
Authors: Tuttle E, Chawla A, Nellesen D, Works J.

Introducing perspectives on comparative effectiveness research.
Authors: Birnbaum HG, Greenberg PE.

Perspectives on comparative effectiveness research: views from diverse constituencies.
Authors: Nellesen D, Birnbaum HG, Greenberg PE.

Methodological issues in a meta-analysis.
Authors: Cremieux P.

ICONS: Managing Care and Costs: The Sustained Cost Impact of Reduced Hospitalizations in a Partnership- Measurement Model of Disease Management.
Authors: Paradis PE, Nemis-White J, Meilleur MC, Ginn M, Cox J, Montague T.

Comparative Effectiveness Research for Personalized Medicine.
Authors: Signorovitch J, Wu EQ, We LJ.

The Growing Role of Economic Analysis in Off-Label Promotion Cases.
Authors: Greenberg P, Sisitsky T.

The impact of drug vintage on patient survival: a patient-level analysis using Quebec’s provincial health plan data.
Authors: Lichtenberg FR, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P.

A comparative analysis of Medicaid long-term care policies and their effects on elderly dual enrollees.
Authors: Rice JB, Kasper JD, Pezzin LE.

Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.
Authors: Tian L, Cai T, Pfeffer MA, Piankov N, Cremieux PY, Wei LJ.

Economic Analysis in Off-Label Promotion Cases.
Publication: Law360 2009 02.
Authors: Greenberg P, Sisitsky T.
Comparative Effectiveness without Head-To-Head Trials: Indirect Comparisons Using Primary and Published Clinical Trial Data.

Authors: Wu EQ, Signorovitch J, Yu A.

Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.

Authors: Kalb PE, Greenberg PE.

Personalized medicine: trends in clinical studies based on national registry data.

Authors: Nellesen D, Person A, Yee K, Chawla A.

Societal cost of rheumatoid arthritis (RA) in the United States: Methodology for incorporating intangible costs.

Authors: Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.


Publication: FDLI Update 2008 05; (3).
Authors: Duh MS, Greenberg P, Antras L.

Does generic substitution always make sense?

Authors: Greenberg PE.

The Role of Epidemiology in Drug Safety Litigations.

Authors: Duh MS, Greenberg PE, Weiner JR.

The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.

Authors: Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY.

The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions.

Publication: White paper 2007 08.
Authors: Grabowski H, Cockburn I, Long G, Mortimer R, Johnson S.

Retrospective economic and outcomes analyses using non-US databases: a review.

Authors: Shi L, Wu EQ, Hodges M, Yu A, Birnbaum H.

Authorized generic drugs, price competition, and consumers' welfare.

Authors: Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E.

Do drugs reduce utilization of other healthcare resources?

Authors: Cremieux PY, Ouellette P, Petit P.
The value of antihypertensive drugs: a perspective on medical innovation.

Authors: Wu EQ, Greenberg P, Erder MH.

Competition between Generic and Branded Drugs.
Authors: Grabowski H.

The Drug Delivery Delimma.
Authors: Gorin B, Tuttle E.

Pharmaceutical spending and health outcomes.
Authors: Cremieux P-Y, Jarvinen D, Long G, Merrigan P.

Publication: Analysis Group Forum 2006 11.
Authors: Greenberg P, Sisitsky T.

A Roundtable Discussion: The Importance of Causation Analysis in Mass Tort Cases.
Publication: Food and Drug Law Institute Update 2006 11.
Authors: Greenberg PE, Lykos G, Gourley S, Davies C.

The market for follow-on biologics: how it will evolve?
Authors: Grabowski H, Cockburn I, Long G.

Retirement patterns from career employment.
Publication: Gerontologist 2006 08; 46(4): 514-523.
Authors: Cahill KE, Giandrea MD, Quinn JF.

A Regulatory Perspective on Productivity Claims: Implications for Future Productivity Research.
Publication: Health and Work Productivity: Emerging Issues in Research and Policy. 2006 04; (Spring).
Authors: Greenberg PE, Birnbaum HG.

Generic competition in the U.S. pharmaceutical industry.
Authors: Saha A, Grabowski H, Birnbaum H, Greenberg P.

Hospital cost flexibility in the presence of many outputs: a public-private comparison.
Authors: Cremieux PY, Ouellette P, Rimbaud F, Vigeant S.
Public and private pharmaceutical spending as determinants of health outcomes in Canada.
Authors: Cremieux PY, Meilleur MC, Ouellette P, Petit P, Zelder M, Potvin K.

Systematic Differences in Subjective vs. Societal Preferences.
Abstract: International Society for Quality of Life Research.
Authors: Sullivan PW, Ghushchyan V, Wu EQ.

Your patent is about to expire: what now.
Authors: Parece A, Tuttle E, Hector A.

Money can't buy happiness.
Publication: Business and Health 2004 04; 2004.
Authors: Greenberg PE BH, Kessler RC.

Authors: Cremieux P, Greenberg PE.

Administrative Claims Data: A Valuable Tool in Pharmaceutical Litigation.
Publication: FDLI Update 2004 01.
Authors: Birnbaum HG, Greenberg PE.

Authors: Baker L, Deal B.

Measuring hospital performance in the presence of quasi-fixed inputs: an analysis of Québec hospitals.
Authors: Bilodeau D, Crémieux P-Y, Jaumard B, Ouellette P, Vovor T.

The relationship between technology availability and health care spending.
Publication: Health Affairs 2003 07; Suppl Web Exclusives: W3-537-551.
Authors: Baker L, Birnbaum H, Geppert J, Mishol D, Moyneur E.

PMD3: Instrument strength and performance of a parametric latent index model in estimating average treatment effect (ate).
Authors: Wu E, Johnson K, Nichol M.

PMD4: Performance of two conditional expectation methods under unobserved selection bias.
Authors: Wu E, Nichol M, Johnson K.

Provision of pharmacy services in community health centers and migrant health centers.
Authors: Barner JC, Brown CM, Shepherd MD, Chou JY, Yang M.

Switching costs, price sensitivity and health plan choice.
Authors: Strombom BA, Buchmueller TC, Feldstein PJ.
Hospital technology in a nonmarket health care system.
*Authors:* Bilodeau D, Cremieux P-Y, Ouellette P.

Actual and perceived impacts of tobacco regulation on restaurants and firms.
*Authors:* Cremieux PY, Ouellette P.

Omitted variable bias and hospital costs.
*Authors:* Cremieux PY, Ouellette P.

Impact of illness and its treatment on workplace costs: regulatory and measurement issues.
*Authors:* Greenberg PE, Birnbaum HG, Kessler RC, Morgan M, Stang P.

Évaluation de l’efficience budgétaire des CLSC au Québec à partir de la méthode DEA.
*Authors:* Crémieux P-Y, Gadbois D, Jaumard B, Ouellette P, Vovor T.

Modeling for health care and other policy decisions: uses, roles, and validity.
*Authors:* Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK.

Pharmaceutical spending and health outcomes in the United States.
*Publication:* RESEARCH IN HUMAN CAPITAL AND DEVELOPMENT 2001: 59-76.
*Authors:* Cremieux P-Y, Ouellette P, Meilleur M-C, Leong S, Greenberg P, Birnbaum H.

Comparative Econometric Models of Medical Costs.
*Authors:* Wu EQ, Hay JW.

Diagnosing the illness.
*Authors:* Cremieux P-Y, Ouellette P.

Hospital cost function in a non-market health care system.
*Authors:* Bilodeau D, Cremieux P-Y, Ouellette P.

Health care spending as determinants of health outcomes.
*Authors:* Cremieux PY, Ouellette P, Pilon C.

Pharmacoconomics and health policy. Current applications and prospects for the future.
*Publication:* Pharmacoeconomics 1999 11; 16(5 Pt 1): 425-432.
*Authors:* Greenberg PE, Arcelus A, Birnbaum HG, Cremieux PY, LeLorier J, Ouellette P, Slavin MB.

Using healthcare claims data for outcomes research and pharmaecoeconomic analyses.
*Authors:* Birnbaum HG, Cremieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L.
Tackling costs one disease at a time.
Publication: Business and Health 1999 05; 17(5): 31-32, 37.
Authors: Greenberg P.

Epidemiologic interpretation of artificial neural networks.
Authors: Duh MS, Walker AM, Ayanian JZ.

The Home Infusion Therapy/Relative Benefit Index: summary of an analysis using insurance claims data.
Publication: Medical Care 1998 05; 36(5): 757-765.
Authors: Birnbaum HG, Tang M.

Calculating Return on Investment from Reducing Workplace Costs of Illness.
Publication: Drug Benefit Trends 1998 03.
Authors: Greenberg PE, Baker A, Berndt E, Finkelstein S, Russell J.

Prediction and cross-validation of neural networks versus logistic regression: using hepatic disorders as an example.
Authors: Duh MS, Walker AM, Pagano M, Kronlund K.

Interpretation of the Weight Matrix in an Artificial Neural Network.
Authors: Duh MS, Walker Am, Ayanian JZ.

Prediction and cross-validation in modeling incident cases of hepatic disorders using automated medical data.
Authors: Duh M, Walker A, Pagano M, Kronlund K.

Une analyse de la performance des CLSC au Québec.
Authors: Crémieux P-Y, Gadbois D, Ouellette P.

The Next Phase of Managed Care: Targeting Investments in Employee Health.
Publication: On Managed Care 1997 09.
Authors: Greenberg PE, Berndt E, Finkelstein S.

Une analyse du contexte budgetaire de l’activité medicale au Quebec (An analysis of the budgetary context of medical activity in Quebec).
Publication: Le Medecin du Quebec 1997 08.
Authors: Cremieux PY, Ouellette P.

Etude d’impact du projet de loi sur le tabac (Impact report on the proposed tobacco law).
Publication: Ministry of Health and Social Services 1997.
Authors: Cremieux PY FP, Lavoie F, Ouellette P, St Pierre Y.

Hospital Consolidation: Optimal Strategy for a Two-Hospital Town.
Publication: Ambulatory Health Care 1996.
Authors: Deal B, Tiscornia JF.

Price Growth of prescription pharmaceutical preparations: an update and extension.
Publication: Competitive Strategies in the Pharmaceutical Industry 1996.
Authors: Berndt E, Greenberg P.
Consolidation and restructuring: the next step in managed care.
*Authors:* Danzon PM, Boothman LG, Greenberg PE.

Consolidation is a Tonic for Health Care Providers: Trend Toward Managed Care and Ascent of Information Technology Fuel Restructuring of an Industry.
*Authors:* Danzon P, Stamm L, Greenberg P.

Economic consequences of illness in the workplace.
*Authors:* Greenberg PE, Finkelstein SN, Berndt ER.

The Health Care System in Canada.
*Authors:* Mulhern C, Rozek R.

Navigating the Changing Tides of Managed Care and Health Reform.
*Authors:* Sherwin R.

When can a Medicare Insured Group (MIG) Succeed?
*Authors:* Birnbaum HG CN, Lang K.

Savings estimate for a Medicare insured group.
*Authors:* Birnbaum H, Holland SK, Lenhart G, Reilly HL, Hoffman K, Pardo DP.

Impacts of the New York long-term home health care program.
*Publication:* Medical Care 1986 24(7).
*Authors:* Birnbaum HG, Gaumer G, Pratter F, Burke R, Franklin S, Ellingon-Otto K.

*Publication:* Gerontologist 1984 08; 24(4): 380-386.
*Authors:* Birnbaum H, Burke R, Swearingen C, Dunlop B.

What does hospice cost?
*Authors:* Birnbaum HG, Kidder D.

The determinants of nursing home operating costs in New York State.
*Authors:* Lee AJ, Birnbaum H.

Medicare legislation for hospice care: implications of national hospice study data.
*Publication:* Health Affairs 1983 08; 2(2): 80-90.
*Authors:* Mor V, Birnbaum H.

Home care in hospices.
*Publication:* Caring 1983 06; 2(6): 40-44.
*Authors:* Birnbaum H, Mor V, Greer DS.
Managing programs for the elderly: design of a social information systems.
Authors: Birnbaum H, Burke R, Pratter F.

National hospice study analysis plan.
Publication: Journal of Chronic Diseases 1983 01; 36(11): 737-780.
Authors: Greer DS, Mor V, Sherwood S, Morris JN, Birnbaum H.

How nursing homes behave: a multi-equation model of nursing home behavior.
Authors: Birnbaum HG, Lee AJ, Bishop C.

Why do nursing home costs vary? The determinants of nursing home costs.
Authors: Birnbaum H, Bishop C, Lee AJ, Jensen G.
About Analysis Group’s HEOR Practice

Founded in 1981, Analysis Group is one of the largest economics consulting firms, with more than 900 professionals across 14 offices. Analysis Group’s health care experts apply analytical expertise to health economics and outcomes research, clinical research, market access and commercial strategy, and health care policy engagements, as well as drug-safety related engagements in epidemiology. Analysis Group’s internal experts, together with its network of affiliated experts from academia, industry, and government, provide our clients with exceptional breadth and depth of expertise and end-to-end consulting services globally.

www.analysisgroup.com